Effects of candesartan in patients with chronic heart fai systolic function taking angiotensin-converting-enzym

Lancet, The

362, 767-771

DOI: 10.1016/s0140-6736(03)14283-3

Citation Report

#	Article	IF	Citations
1	Chick-Embryo Deaths Traced to Tincture of Iodine. Journal of Infectious Diseases, 1973, 127, 581-581.	1.9	0
3	What's new inâ€¦ Heart failure. Medicine, 2002, 30, 1-4.	0.2	0
4	More evidence on blocking the reninâ€“angiotensinâ€“aldosterone system in cardiovascular disease and the long-term treatment of hypertension: data from recent clinical trials (CHARM, EUROPA, ValHEFT,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.9	20
5	Combination Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Therapy: Its Role in Clinical Practice. Journal of Clinical Hypertension, 2003, 5, 414-420.	1.0	20
6	Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both. New England Journal of Medicine, 2003, 349, 1893-1906.	13.9	2,240
7	Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet, The, 2003, 362, 759-766.	6.3	1,752
8	Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet, The, 2003, 362, 777-781.	6.3	2,584
9	The CHARM programme. Lancet, The, 2003, 362, 1675-1676.	6.3	1
10	The CHARM programme. Lancet, The, 2003, 362, 1677.	6.3	0
11	Interaction of -blockers and angiotensin receptor blockers/ACE inhibitors in heart failure. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2003, 4, 137-139.	1.0	9
12	Angiotensin receptor blockers in heart failure. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2003, 4, 171-175.	1.0	5
13	Novel pharmacological treatments for heart failure. Expert Opinion on Investigational Drugs, 2003, 12, 1791-1801.	1.9	12
14	Management of Glomerular Proteinuria: A Commentary. Journal of the American Society of Nephrology: JASN, 2003, 14, 3217-3232.	3.0	194
15	Clinical trials update from the European Society of Cardiology: CHARM, BASEL, EUROPA and ESTEEM. European Journal of Heart Failure, 2003, 5, 697-704.	2.9	16
16	Angiotensin-Receptor Blockade in Acute Myocardial Infarction â€" A Matter of Dose. New England Journal of Medicine, 2003, 349, 1963-1965.	13.9	46
17	Growth hormone and proinflammatory cytokine activation in heart failure Just a new verse to an old sirens' song?. European Heart Journal, 2003, 24, 2164-2165.	1.0	6
18	Combined treatment with angiotensinâ€converting enzyme inhibitors and angiotensinâ€receptor blockers to prevent endâ€stage kidney disease in patients who do not have diabetes. Medical Journal of Australia, 2004, 181, 450-451.	0.8	4
19	ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. Circulation, 2004, 110, .	1.6	99

#	Article	IF	Citations
20	Angiotensin receptor blockers and heart failure: still CHARMing after VALIANT?. European Heart Journal, 2004, 25, 357-358.	1.0	7
21	Cardiac angiotensin II receptors as predictors of transplant coronary artery disease following heart transplantation. European Heart Journal, 2004, 25, 377-385.	1.0	18
22	Effect of candesartan on New York Heart Association functional classResults of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal, 2004, 25, 1920-1926.	1.0	43
23	Novel antihypertensive agents. Expert Opinion on Investigational Drugs, 2004, 13, 987-998.	1.9	1
24	Angiotensin receptor blockers in acute myocardial infarction. Expert Opinion on Investigational Drugs, 2004, 13, 427-430.	1.9	0
25	Challenges in improving prognosis and therapy: The Ongoing Telmisartan Alone and in Combination with Ramipril Global End point Trial Programme. Expert Opinion on Pharmacotherapy, 2004, 5, 1201-1208.	0.9	22
26	AII antagonists in hypertension, heart failure, and diabetic nephropathy: focus on losartan. Current Medical Research and Opinion, 2004, 20, 279-293.	0.9	18
27	Therapeutic patents for chronic heart failure: a review of patent applications from 1996 to 2002. Expert Opinion on Therapeutic Patents, 2004, 14, 639-654.	2.4	3
28	Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular diseaseThe Task Force on ACE-inhibitors of the European Society of Cardiology. European Heart Journal, 2004, 25, 1454-1470.	1.0	249
30	Effect of Candesartan on Cause-Specific Mortality in Heart Failure Patients. Circulation, 2004, 110, 2180-2183.	1.6	241
31	Combined Blockade of the Renin-Angiotensin System With Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Type 1 Receptor Antagonists. Circulation, 2004, 109, 2492-2499.	1.6	184
32	Conclusions on the management of heart failure.. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2004, 5, S34.	1.0	0
33	Cellular Basis for Therapeutic Choices in Heart Failure. Circulation, 2004, 110, 2559-2561.	1.6	17
34	AT1 Receptor Blocker Added to ACE Inhibitor Provides Benefits at Advanced Stage of Hypertensive Diastolic Heart Failure. Hypertension, 2004, 43, 686-691.	1.3	109
35	Aldosterone and cardiovascular remodelling: focus on myocardial failure. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2004, 5, 3-13.	1.0	12
36	Which Inhibitor of the Reninâ€“Angiotensin System Should Be Used in Chronic Heart Failure and Acute Myocardial Infarction?. Circulation, 2004, 110, 3281-3288.	1.6	73
37	Bradykinin Contributes to the Systemic Hemodynamic Effects of Chronic Angiotensin-Converting Enzyme Inhibition in Patients With Heart Failure. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 1043-1048.	1.1	45
38	Reassessing guidelines for heart failure.. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2004, 5, S28.	1.0	0

#	Article	IF	Citations
39	Current guidelines in the pharmacological management of chronic heart failure.. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2004, 5, S11.	1.0	3
40	ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarctionâ€"Executive Summary. Circulation, 2004, 110, 588-636.	1.6	3,307
41	Effect of candesartan and lisinopril alone and in combination on blood pressure and microalbuminuria. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2004, 5, 64-71.	1.0	35
42	The Top 10 Hot Topics in Aging. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2004, 59, M24-M33.	1.7	56
43	Clinical Trial in Nephrology at Hard End Point?. Journal of the American Society of Nephrology: JASN, 2004, 15, 506-508.	3.0	9
44	TGF-?1 and angiotensin networking in cardiac remodeling. Cardiovascular Research, 2004, 63, 423-432.	1.8	605
46	DIAGNOSIS AND MANAGEMENT OF CHRONIC HEART FAILURE: HOW TO REESTABLISH A KEY ROLE FOR THE PRIMARY CARE PHYSICIAN?. Acta Clinica Belgica, 2004, 59, 300-303.	0.5	0
47	Angiotensin receptor blockers and myocardial infarction. BMJ: British Medical Journal, 2004, 329, 1248-1249.	2.4	182
48	Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. European Heart Journal, 2004, 25, 1214-1220.	1.0	315
49	Heart failure clinics and outpatient management: review of the evidence and call for quality assurance. European Heart Journal, 2004, 25, 1596-1604.	1.0	86
50	Candesartan Prevents Myocardial Fibrosis during Progression of Congestive Heart Failure. Journal of Cardiovascular Pharmacology, 2004, 43, 860-867.	0.8	9
51	The Use of Angiotensin Receptor Blockers in the Treatment of Chronic Heart Failure. Journal of Cardiovascular Pharmacology, 2004, 44, 718-724.	0.8	2
52	Identification of Telmisartan as a Unique Angiotensin II Receptor Antagonist With Selective PPARÎ³â€"Modulating Activity. Hypertension, 2004, 43, 993-1002.	1.3	1,009
53	Angiotensin inhibition in heart failure.. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2004, 5, S17.	1.0	14
54	Candesartan for the treatment of hypertension and heart failure. Expert Opinion on Pharmacotherapy, 2004, 5, 1589-1597.	0.9	14
55	Angiotensin II Receptor Blockers in Older Patients. The American Journal of Geriatric Cardiology, 2004, 13, 197-205.	0.7	7
56	Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction. Circulation, 2004, 110, 2618-2626.	1.6	347
57	Clinical trials update from the American Heart Association meeting: Î©-3 fatty acids and arrhythmia risk in patients with an implantable defibrillator, ACTIV in CHF, VALIANT, the Hanover autologous bone marrow transplantation study, SPORTIF V, ORBIT and PA. European Journal of Heart Failure, 2004, 6, 109-115.	2.9	29

#	Article	IF	Citations
58	Combined angiotensin receptor blocker and ACE inhibitor on myocardial fibrosis and left ventricular stiffness in dogs with heart failure. American Journal of Physiology - Heart and Circulatory Physiology, 2004, 287, H2487-H2492.	1.5	24
59	Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT. European Journal of Heart Failure, 2004, 6, 937-945.	2.9	87
60	Changes in endothelium-derived hyperpolarizing factor in hypertension and ageing: response to chronic treatment with renin-angiotensin system inhibitors. Clinical and Experimental Pharmacology and Physiology, 2004, 31, 650-655.	0.9	55
61	Beneficial impact on cardiovascular risk factors by dual blockade of the renin-angiotensin system in diabetic nephropathy. Kidney International, 2004, 66, S108-S110.	2.6	13
62	Effects of Candesartan on Mortality and Morbidity in Patients With Chronic Heart Failure: The CHARM-Overall Programme. Congestive Heart Failure, 2004, 10, 114-116.	2.0	2
63	The clinical use of angiotensin-converting enzyme inhibitors. Progress in Cardiovascular Diseases, 2004, 47, 116-130.	1.6	80
64	Angiotensin II receptor antagonists: Role in hypertension, cardiovascular disease, and renoprotection. Progress in Cardiovascular Diseases, 2004, 47, 105-115.	1.6	22
65	Elevations in Serum Creatinine Concentration: Concerning or Reassuring?. Pharmacotherapy, 2004, 24, 697-703.	1.2	22
66	Remodeling as an End-Point in Heart Failure Therapy. Cardiovascular Drugs and Therapy, 2004, 18, 7-8.	1.3	11
67	Use of angiotensin receptor antagonists in patients with ACE inhibitor induced angioedema. International Journal of Clinical Pharmacy, 2004, 26, 191-192.	1.4	27
68	Treatment strategies in patients with chronic renal disease: ACE inhibitors, angiotensin receptor antagonists, or both?. Pediatric Nephrology, 2004, 19, 956-61.	0.9	39
69	Dual blockade of the renin-angiotensin system in chronic renal disease: to do or not to do. Clinical and Experimental Nephrology, 2004, 8, 183-187.	0.7	3
70	New Pharmacological Strategies in Chronic Heart Failure. Cardiovascular Drugs and Therapy, 2004, 18, 491-501.	1.3	4
73	Is too much neurohormonal blockade harmful?. Current Cardiology Reports, 2004, 6, 169-175.	1.3	4
74	Is heart failure different on the two continents (North America and Europe)?. Current Cardiology Reports, 2004, 6, 182-188.	1.3	1
75	Current concepts for the neurohormonal management of left ventricular dysfunction after myocardial infarction. Current Heart Failure Reports, 2004, 1, 161-167.	1.3	1
76	Anemia and heart failure. Current Heart Failure Reports, 2004, 1, 176-182.	1.3	30
77	Pharmacologic effects on cardiac remodeling. Current Heart Failure Reports, 2004, 1, 9-13.	1.3	5

#	Article	IF	Citations
78	Inhibition of RAASâ€"When is it too much?. Current Heart Failure Reports, 2004, 1, 57-64.	1.3	1
80	Dual blockade of the renin angiotensin system in diabetic and nondiabetic kidney disease. Current Hypertension Reports, 2004, 6, 369-376.	1.5	12
81	Is proteinuria a plausible target of therapy?. Current Hypertension Reports, 2004, 6, 177-181.	1.5	23
82	The tissue renin-angiotensin-aldosterone system in diabetes mellitus. Current Hypertension Reports, 2004, 6, 98-105.	1.5	22
83	Neurohormonal therapy for congestive heart failure. Current Treatment Options in Cardiovascular Medicine, 2004, 6, 499-507.	0.4	1
84	Diastolic dysfunction. Current Treatment Options in Cardiovascular Medicine, 2004, 6, 61-68.	0.4	4
85	Managing Hyperkalemia Caused by Inhibitors of the Reninâ€"Angiotensinâ€"Aldosterone System. New England Journal of Medicine, 2004, 351, 585-592.	13.9	519
86	Valsartan for the treatment of heart failure. Expert Opinion on Pharmacotherapy, 2004, 5, 181-193.	0.9	4
87	Angiotensin Receptor Blockers and Target-Organ Protection Beyond Blood Pressure Control. High Blood Pressure and Cardiovascular Prevention, 2004, 11, 65-73.	1.0	4
88	Angiotensin Antagonism in Patients with Heart Failure. American Journal of Cardiovascular Drugs, 2004, 4, 345-353.	1.0	9
89	Valsartan. American Journal of Cardiovascular Drugs, 2004, 4, 395-404.	1.0	45
90	Mechanisms and management of hypertensive heart disease: from left ventricular hypertrophy to heart failure. Medical Clinics of North America, 2004, 88, 1257-1271.	1.1	93
92	IntervenciÃ³n sobre el sistema renina-angiotensina para la protecciÃ³n vascular del paciente hipertenso y en la nefropatÃa diabÃ©tica. Revista Clinica Espanola, 2004, 204, 596-600.	0.2	0
93	Ischemic heart disease and congestive heart failure in diabetic patients. Medical Clinics of North America, 2004, 88, 1037-1061.	1.1	24
94	Los antagonistas de los receptores de angiotensina II tienen ventajas sobre los inhibidores de la enzima de conversiÃ³n de la angiotensina. Hipertension Y Riesgo Vascular, 2004, 21, 78-83.	0.3	0
95	Documento de Consenso de Expertos sobre el uso de inhibidores de la enzima de conversiÃ³n de la angiotensina en la enfermedad cardiovascular. Revista Espanola De Cardiologia, 2004, 57, 1213-1232.	0.6	8
96	Bases y evidencias clÃnicas de los efectos de los nuevos tratamientos farmacolÃ³gicos en la insuficiencia cardÃaca. Revista Espanola De Cardiologia, 2004, 57, 447-464.	0.6	12
97	Rationale and Clinical Evidence for the Effects of New Pharmacological Treatments for Heart Failure. Revista Espanola De Cardiologia (English Ed), 2004, 57, 447-464.	0.4	2

#	Article	IF	Citations
98	The role of G-protein-coupled receptors in heart failure. Drug Discovery Today Disease Mechanisms, 2004, 1, 37-43.	0.8	1
100	Angiotensin II receptors from peritransplantation through first-year post-transplantation and the risk of transplant coronary artery disease. Journal of the American College of Cardiology, 2004, 43, 1565-1573.	1.2	14
101	Angiotensin-converting enzyme inhibitors, beta-blockers, and mortality in systolic heart failure. Journal of the American College of Cardiology, 2004, 43, 1333.	1.2	2
103	ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2004, 44, E1-E211.	1.2	1,028
104	A hard look at angiotensin receptor blockers in heart failure. Journal of the American College of Cardiology, 2004, 44, 1841-1846.	1.2	28
105	Dismantling mandates in the treatment of heart failure**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.. Journal of the American College of Cardiology, 2004, 44, 1831-1833.	1.2	9
106	The year in heart failure. Journal of the American College of Cardiology, 2004, 44, 2398-2405.	1.2	11
107	2003: The year in heart failure. Journal of Cardiac Failure, 2004, 10, 1-3.	0.7	3
108	Consistency of the beneficial effect of metoprolol succinate extended release across a wide range dose of angiotensin-converting enzyme inhibitors and digitalis. Journal of Cardiac Failure, 2004, 10, 452-459.	0.7	6
109	Key issues in trial design for ventricular assist devices: a position statement of the heart failure society of America. Journal of Cardiac Failure, 2004, 10, 91-100.	0.7	2
110	Diabetic cardiomyopathy: mechanisms, diagnosis and treatment. Clinical Science, 2004, 107, 539-557.	1.8	291
111	Slowing the Progression of Adult Chronic Kidney Disease. Drugs, 2004, 64, 2273-2289.	4.9	27
112	Pharmacologic Demonstration of the Synergistic Effects of a Combination of the Renin Inhibitor Aliskiren and the AT1 Receptor Antagonist Valsartan on the Angiotensin II-Renin Feedback Interruption. Journal of the American Society of Nephrology: JASN, 2004, 15, 3126-3133.	3.0	234
113	Angiotensin Vol. II. Handbook of Experimental Pharmacology, 2004, , .	0.9	1
114	Antihypertensive efficacy of olmesartan medoxomil alone and in combination with hydrochlorothiazide. Expert Opinion on Pharmacotherapy, 2004, 5, 657-667.	0.9	21
115	Documentation forms for patients with asthma: an evaluation. Annals of Pharmacotherapy, 2004, 38, 2170-2171.	0.9	1
116	Candesartan cilexetil in cardiovascular disease. Expert Review of Cardiovascular Therapy, 2004, 2, 829-835.	0.6	14
117	AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction. Expert Review of Cardiovascular Therapy, 2004, 2, 891-902.	0.6	3

#	Article	IF	Citations
120	ThÃ©rapeutique diurÃ©tique. EMC - Nephrologie, 2004, 1, 73-111.	0.0	0
121	The role of the AT1 angiotensin receptor in cardiac hypertrophy: angiotensin II receptor or stretch sensor?. Trends in Endocrinology and Metabolism, 2004, 15, 405-408.	3.1	26
122	Meta-analyses of mortality and morbidity effects of an angiotensin receptor blocker in patients with chronic heart failure already receiving an ACE inhibitor (alone or with a Î²-blocker). International Journal of Cardiology, 2004, 93, 105-111.	0.8	43
123	From CONSENSUS to CHARMâ€"how do ACEI and ARB produce clinical benefits in CHF?. International Journal of Cardiology, 2004, 94, 137-141.	0.8	17
124	Role of angiotensin receptor blockers in patients with left ventricular dysfunction: lessons from CHARM and VALIANT. International Journal of Cardiology, 2004, 97, 345-348.	0.8	9
125	Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). American Heart Journal, 2004, 148, 122-128.	1.2	44
126	Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. American Heart Journal, 2004, 148, 52-61.	1.2	388
127	Impact of angiotensin-converting enzyme gene polymorphism on neurohormonal responses to high- versus low-dose enalapril in advanced heart failure. American Heart Journal, 2004, 148, 889-894.	1.2	18
128	Pharmacological and Clinical Profile of Moexipril: A Concise Review. Journal of Clinical Pharmacology, 2004, 44, 827-836.	1.0	9
129	Effect of Drug Therapy for Heart Failure on Quality of Life. Journal of Clinical Hypertension, 2004, 6, 256-261.	1.0	5
130	Blood Pressure Goal Attainment: Meeting the Challenge of the JNC 7's Blood Pressure Goals and the Role of Reninâ€Angiotensinâ€Aldosterone System Blockade. Journal of Clinical Hypertension, 2004, 6, 699-705.	1.0	4
131	Update on the Management of Hypertension: Recent Clinical Trials and the JNC 7. Journal of Clinical Hypertension, 2004, 6, 4-13.	1.0	30
132	Angiotensin II Receptor Blockers: The Importance of Dose in Cardiovascular and Renal Risk Reduction. Journal of Clinical Hypertension, 2004, 6, 315-325.	1.0	5
133	ActualitÃ©s sur les grands essais cliniques en cardiologie. Presse Medicale, 2004, 33, 1064-1072.	0.8	0
135	Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Diabetes and Metabolism, 2004, 30, 487-496.	1.4	238
136	ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarctionâ€"Executive Summary. Journal of the American College of Cardiology, 2004, 44, 671-719.	1.2	1,084
137	Assessment of the optimal daily dose of valsartan in patients with hypertension, heart failure, or both. Clinical Therapeutics, 2004, 26, 460-472.	1.1	17
138	ARBs and target organ protection. Postgraduate Medicine, 2004, 116, 31-41.	0.9	31

#	Article	IF	Citations
139	Guidelines for the Diagnosis and Management of Heart Failure. American Journal of Therapeutics, 2004, 11, 467-472.	0.5	11
141	Developments in Cardiologyâ€"2004. Journal of Pharmacy Practice and Research, 2004, 34, 234-236.	0.5	0
142	The treatment of chronic heart failure due to left ventricular systolic dysfunction. Clinical Medicine, 2004, 4, 18-22.	0.8	7
143	European Society of Cardiology Congress 2003. Journal of Pharmacy Practice and Research, 2004, 34, 39-40.	0.5	0
144	Haemodynamic and neurohormonal effects of AT1-receptor blockers. European Heart Journal Supplements, 2004, 6, h49-h54.	0.0	0
145	Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T Nephrology and Hypertension, 2004, 13, 319-324.	1.0	23
146	Renin???angiotensin system blockade. Journal of Hypertension, 2004, 22, 459-462.	0.3	1
147	Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists. Journal of Hypertension, 2004, 22, 2253-2261.	0.3	172
148	Angiotensin in atherosclerosis. Current Opinion in Nephrology and Hypertension, 2004, 13, 291-297.	1.0	36
149	2003: The year in heart failure*1. Journal of Cardiac Failure, 2004, 10, 1-3.	0.7	30
150	The role of the AT1 receptor in the cardiovascular continuum. European Heart Journal Supplements, 2004, 6, h3-h9.	0.0	8
151	Importance of CHARM in relation to other heart failure trials with ARBs. European Heart Journal Supplements, 2004, 6, h55-h60.	0.0	0
153	Meta-Analysis: Angiotensin-Receptor Blockers in Chronic Heart Failure and High-Risk Acute Myocardial Infarction. Annals of Internal Medicine, 2004, 141, 693.	2.0	180
154	Rationale for the Use of Combination Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Therapy in Heart Failure. Circulation Journal, 2004, 68, 361-366.	0.7	25
156	A Practical and Evidence-Based Approach to Cardiovascular Disease Risk Reduction. Archives of Internal Medicine, 2004, 164, 1490.	4.3	54
157	The role of the AT1 angiotensin receptor in cardiac hypertrophy: angiotensin II receptor or stretch sensor?. Trends in Endocrinology and Metabolism, 2004, 15, 405-408.	3.1	21
158	The Role of Aldosterone Blockers in the Management of Chronic Heart Failure. American Journal of the Medical Sciences, 2005, 330, 176-183.	0.4	6
160	Current guidelines in the management of chronic heart failure: Practical issues in their application to the community population. European Journal of Heart Failure, 2005, 7, 317-321.	2.9	10

#	Article	IF	Citations
161	Review: Optimising the use of Angiotensin Receptor Blockers in the Management of Chronic Heart Failure. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2005, 6, S2-S5.	1.0	0
162	Review: Effective Implementation of the New ESC Guidelines for the Management of Chronic Heart Failure in Routine Clinical Practice. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2005, 6, S6-S10.	1.0	1
163	Diabetic Nephropathy. Diabetes Care, 2005, 28, 745-751.	4.3	36
164	Angiotensin Receptor Blockers in Congestive Heart Failure. Cardiology in Review, 2005, 13, 297-303.	0.6	12
165	Optimizing therapeutic strategies to achieve renal and cardiovascular risk reduction in diabetic patients with angiotensin receptor blockers. Journal of Hypertension, 2005, 23, 905-911.	0.3	17
166	Levosimendan: A New Inodilatory Drug for the Treatment of Decompensated Heart Failure. Current Pharmaceutical Design, 2005, 11, 435-455.	0.9	43
167	Antihypertensive, cardiovascular, and pleiotropic effects of angiotensin-receptor blockers. Current Opinion in Nephrology and Hypertension, 2005, 14, 435-441.	1.0	32
169	Long-term combined therapy with losartan and an angiotensin-converting enzyme inhibitor improves functional capacity in patients with left ventricular dysfunction. Acta Cardiologica, 2005, 60, 373-377.	0.3	8
170	The cardiovascular continuum and reninâ€“angiotensinâ€“aldosterone system blockade. Journal of Hypertension, 2005, 23, S9-S17.	0.3	159
171	Recent advances in hypertension, stroke, and cardiorenal disease. Current Opinion in Cardiology, 2005, 20, 258-263.	0.8	8
172	Angiotensin-Converting Enzyme Inhibitors, AG Receptor Blockers, and Aldosterone Receptor Antagonists. International Anesthesiology Clinics, 2005, 43, 23-37.	0.3	4
173	Why blockade of the reninâ€“angiotensin system reduces the incidence of new-onset diabetes. Journal of Hypertension, 2005, 23, 463-473.	0.3	259
175	Angiotensin-converting enzyme inhibitors and angiotensin II type I receptor blockers in the management of congestive heart failure patients: what have we learned from recent clinical trials?. Current Opinion in Internal Medicine, 2005, 4, 529-534.	1.5	13
176	Managing the patient at risk for a second stroke. Journal of Hypertension, 2005, 23, S41-S47.	0.3	7
177	Angiotensin II receptor blockers and myocardial infarction: deeds and misdeeds. Journal of Hypertension, 2005, 23, 2113-2118.	0.3	46
178	Pathway for the Management of Acute Heart Failure. Critical Pathways in Cardiology, 2005, 4, 37-42.	0.2	16
179	Narrative Review: Pharmacotherapy for Chronic Heart Failure: Evidence from Recent Clinical Trials. Annals of Internal Medicine, 2005, 142, 132.	2.0	40
181	Beneficial Effect of Candesartan on Rat Diastolic Heart Failure. Journal of Pharmacological Sciences, 2005, 98, 372-379.	1.1	17

#	Article	IF	Citations
184	Mechanisms of Combined Treatment With Celiprolol and Candesartan for Ventricular Remodeling in Experimental Heart Failure. Circulation Journal, 2005, 69, 596-602.	0.7	22
185	Effects of Candesartan on Cardiovascular Outcomes in Japanese Hypertensive Patients. Hypertension Research, 2005, 28, 307-314.	1.5	77
186	An Angiotensin Receptor Blocker Reduces the Risk of Congestive Heart Failure in Elderly Hypertensive Patients with Renal Insufficiency. Hypertension Research, 2005, 28, 415-423.	1.5	27
188	Clinical update: The role of angiotensin II receptor blockers in patients with left ventricular dysfunction (Part II of II). Clinical Cardiology, 2005, 28, 277-280.	0.7	2
189	Chronic kidney disease in patients with cardiac disease: A review of evidence-based treatment. Kidney International, 2005, 68, 1419-1426.	2.6	12
190	A review of the current evidence for the use of angiotensin-receptor blockers in chronic heart failure. International Journal of Clinical Practice, 2005, 59, 571-578.	0.8	17
191	Activation of calcineurin in human failing heart ventricle by endothelin-1, angiotensin II and urotensin II. British Journal of Pharmacology, 2005, 145, 432-440.	2.7	13
192	Current status of angiotensin receptor blockers for the treatment of cardiovascular diseases: focus on telmisartan. Journal of Human Hypertension, 2005, 19, 173-183.	1.0	24
193	Angiotensin-II receptor blockers: benefits beyond blood pressure reduction?. Journal of Human Hypertension, 2005, 19, 331-339.	1.0	45
194	Impact of nonfatal myocardial infarction on outcomes in patients with advanced heart failure and the effect of bucindolol therapy. American Journal of Cardiology, 2005, 95, 558-564.	0.7	13
195	Reliability of Ventricular Remodeling as a Surrogate for Use in Conjunction With Clinical Outcomes in Heart Failure. American Journal of Cardiology, 2005, 96, 867-871.	0.7	49
196	Drugs for Left Ventricular Remodeling in Heart Failure. American Journal of Cardiology, 2005, 96, 10-18.	0.7	123
197	Protective Effects of Angiotensin II Interruption: Evidence for Antiinflammatory Actions. Pharmacotherapy, 2005, 25, 1213-1229.	1.2	83
198	Heart Failure and its Treatment in Women. Herz, 2005, 30, 356-367.	0.4	40
200	Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator. Acta Diabetologica, 2005, 42, s9-s16.	1.2	88
201	The ONTARGET/TRANSCEND Trial Programme: baseline data. Acta Diabetologica, 2005, 42, s50-s56.	1.2	43
202	Heart failure and shock complicating acute coronary syndromes. Current Cardiology Reports, 2005, 7, 276-282.	1.3	0
203	The addition of angiotensin receptor blockers to angiotens-inconverting enzyme inhibitorsâ€"What has time told us?. Current Heart Failure Reports, 2005, 2, 59-64.	1.3	1

#	Article	IF	Citations
204	Angiotensin II-receptor antagonist in the treatment of hypertension. Current Hypertension Reports, 2005, 7, 287-293.	1.5	7
205	Effects of angiotensin-II receptor blocker candesartan cilexetil in rats with dilated cardiomyopathy. Molecular and Cellular Biochemistry, 2005, 269, 137-142.	1.4	13
206	Eliciting and using expert opinions about influence of patient characteristics on treatment effects: a Bayesian analysis of the CHARM trials. Statistics in Medicine, 2005, 24, 3805-3821.	0.8	25
207	Demarcated Truncal Jaundice: A Sign of Retroperitoneal Bile Leakage. Annals of Internal Medicine, 2005, 142, 389.	2.0	5
208	Angiotensin II Receptor Antagonists. , 2005, , 705-724.		4
209	Chronic Heart Failure: Developments and Perspectives. The Consultant Pharmacist, 2005, 20, 751-765.	0.4	4
210	EXPERT CONSENSUS DOCUMENT ON ANGIOTENSIN CONVERTING ENZYME INHIBITORS IN CARDIOVASCULAR DISEASE. Rational Pharmacotherapy in Cardiology, 2005, 1, 49-69.	0.3	5
211	Chronische Herzinsuffizienz. , 2005, , 97-121.		0
213	Inhibition of the Renin-Angiotensin System and Atrial Fibrillation in Heart Failure. Cardiology, 2005, 5, 214-219.	0.3	2
215	Hypertension in Patients With Diabetes. , 2005, , 171-190.		0
216	Risk Reduction in Patients With Diabetes. , 2005, , 205-223.		1
217	The Future of Angiotensin II Inhibition in Cardiovascular Medicine. Current Drug Targets Cardiovascular & Haematological Disorders, 2005, 5, 15-30.	2.0	19
218	Care Management for Heart Failure. Annals of Internal Medicine, 2005, 142, 386.	2.0	0
219	Assessment of Cardiac Sympathetic Innervation in Heart Failure and Lethal Arrhythmias: Therapeutic and Prognostic Implications. Current Cardiology Reviews, 2005, 1, 29-36.	0.6	5
221	The diagnosis and management of chronic heart failure in the older patient. British Medical Bulletin, 2005, 75-76, 49-62.	2.7	12
222	Patient perception of the effect of treatment with candesartan in heart failure. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure, 2005, 7, 650-656.	2.9	24
223	Angiotensin receptor blockers: Therapeutic targets and cardiovascular protection. Blood Pressure, 2005, 14, 196-209.	0.7	67
224	Influence of Ejection Fraction on Cardiovascular Outcomes in a Broad Spectrum of Heart Failure Patients. Circulation, 2005, 112, 3738-3744.	1.6	678

#	Article	IF	Citations
225	Angiotensin converting enzyme inhibitor prevents left ventricular remodelling after myocardial infarction in angiotensin II type 1 receptor knockout mice. Heart, 2005, 91, 1080-1085.	1.2	22
226	Sex Differences in Cardiovascular Disease and Hypertension. Hypertension, 2005, 46, 475-476.	1.3	28
227	Effects of Candesartan on the Development of a New Diagnosis of Diabetes Mellitus in Patients With Heart Failure. Circulation, 2005, 112, 48-53.	1.6	211
228	Angiotensin II, but not aldosterone and renin, correlates positively with increased concentrations of N-terminal pro-brain natriuretic peptide in patients with chronic heart failure. Heart, 2005, 91, 1223-1224.	1.2	0
229	Changes in Ventricular Size and Function in Patients Treated With Valsartan, Captopril, or Both After Myocardial Infarction. Circulation, 2005, 111, 3411-3419.	1.6	251
230	Impaired glucose tolerance and impaired fasting glucose â€" a review of diagnosis, clinical implications and management. Diabetes and Vascular Disease Research, 2005, 2, 9-15.	0.9	128
231	Mortality and Morbidity Remain High Despite Captopril and/or Valsartan Therapy in Elderly Patients With Left Ventricular Systolic Dysfunction, Heart Failure, or Both After Acute Myocardial Infarction. Circulation, 2005, 112, 3391-3399.	1.6	101
232	A Simplified Approach to the Management of Nonâ€"ST-Segment Elevation Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 2005, 293, 349.	3.8	54
233	Losartan in cardiovascular disease. Future Cardiology, 2005, 1, 433-446.	0.5	4
234	Epidemiology, treatment, and guidelines for the treatment of heart failure in Europe. Country Review Ukraine, 2005, 7, J5-J9.	0.8	41
235	Combination of antihypertensive drugs from a historical perspective. Blood Pressure, 2005, 14, 72-79.	0.7	5
236	ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adultâ€"Summary Article. Circulation, 2005, 112, 1825-1852.	1.6	402
237	Valsartan in Chronic Heart Failure. Annals of Pharmacotherapy, 2005, 39, 460-469.	0.9	8
238	Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). European Heart Journal, 2005, 26, 1115-1140.	1.0	1,986
239	Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: Putting guidelines into practice. European Journal of Heart Failure, 2005, 7, 710-721.	2.9	111
240	Review: Preventing End-Stage Renal Disease in Diabetic Patients â€" Dual Blockade of the Renin-Angiotensin System (Part II). JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2005, 6, 55-68.	1.0	9
241	Diabetes and cardiovascular disease: the road to cardioprotection. Heart, 2005, 91, 1621-1625.	1.2	24
242	Mechanisms and Models in Heart Failure. Circulation, 2005, 111, 2837-2849.	1.6	740

#	Article	IF	Citations
243	Targeting the reninâ€“angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Expert Opinion on Emerging Drugs, 2005, 10, 729-745.	1.0	8
244	Angiotensin II in the Failing Heart. Kidney and Blood Pressure Research, 2005, 28, 349-352.	0.9	3
245	Pharmacotherapy of Congestive Heart Failure in Elderly Patients. Journal of Cardiovascular Pharmacology and Therapeutics, 2005, 10, 85-94.	1.0	5
246	Val-HeFT: do angiotensin-receptor blockers benefit heart failure patients already receiving ACE inhibitor therapy?. Nature Clinical Practice Cardiovascular Medicine, 2005, 2, 128-129.	3.3	5
247	Diabetic Nephropathy: The Proteinuria Hypothesis. American Journal of Nephrology, 2005, 25, 77-94.	1.4	88
248	Effects of Optimized Heart Failure Therapy and Anemia Correction with Epoetin Î² on Left Ventricular Mass in Hemodialysis Patients. American Journal of Nephrology, 2005, 25, 211-220.	1.4	41
249	Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal, 2005, 27, 1447-1458.	1.0	35
250	Treatment for heart failure: good news and bad. British Journal of Hospital Medicine (London,) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.2	0
251	Angiotensin receptor blockers and risk of myocardial infarction: systematic review. BMJ: British Medical Journal, 2005, 331, 873.	2.4	67
252	The death rate among hospitalized heart failure patients with normal and depressed left ventricular ejection fraction in the year following discharge: evolution over a 10-year period. European Heart Journal, 2005, 26, 2251-2258.	1.0	43
253	Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense?The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.. European Heart Journal, 2005, 26, 2361-2367.	1.0	31
254	The Task Force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: full text (update) Tj ETQq1 1 0.784314 rgBT /Overlock 10	3.4	49
255	Review of the new ESC guidelines for the pharmacological management of chronic heart failure. Country Review Ukraine, 2005, 7, J15-J20.	0.8	1
256	The role of angiotensin II receptor blockers in the management of heart failure. Country Review Ukraine, 2005, 7, J10-J14.	0.8	2
257	Heart failure. Lancet, The, 2005, 365, 1877-1889.	6.3	756
258	Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet, The, 2005, 366, 2005-2011.	6.3	410
260	Indicaciones y uso clÃnico de los antagonistas de los receptores de la angiotensina II en la insuficiencia cardÃaca. FMC Formacion Medica Continuada En Atencion Primaria, 2005, 12, 103-112.	0.0	0
261	New Directions in the Medical Management of Heart Failure. Seminars in Thoracic and Cardiovascular Surgery, 2005, 17, 334-342.	0.4	3

#	Article	IF	Citations
265	Neurohormonal Upregulation in Heart Failure. Heart Failure Clinics, 2005, 1, 1-9.	1.0	8
266	Therapeutic Controversies in Hypertension. Seminars in Nephrology, 2005, 25, 227-235.	0.6	7
267	The renin angiotensin system as a therapeutic target to prevent diabetes and its complications. Cardiology Clinics, 2005, 23, 165-183.	0.9	23
268	Management of Cardiovascular Disease in the Renal Transplant Recipient. Cardiology Clinics, 2005, 23, 331-342.	0.9	11
269	Angiotensin-Converting Enzyme Inhibitors, Angiotensin-Receptor Blockers, or Both in Chronic Heart Failure. Heart Failure Clinics, 2005, 1, 39-47.	1.0	0
270	CHARMed â€“ the effects of candesartan in heart failure. Expert Opinion on Pharmacotherapy, 2005, 6, 513-516.	0.9	2
271	Drug and Drug-Device Therapy in Heart Failure Patients in the Post-COMET and SCD-HeFT Era. Journal of Cardiovascular Pharmacology and Therapeutics, 2005, 10, S45-S58.	1.0	9
272	Out-patient management of chronic heart failure. Expert Opinion on Pharmacotherapy, 2005, 6, 1857-1881.	0.9	1
273	Insights into the emerging cardiometabolic prevention and management of diabetes mellitus. Expert Opinion on Pharmacotherapy, 2005, 6, 2209-2221.	0.9	16
274	Chronic heart failure: an overview of conventional treatment versus novel approaches. Nature Clinical Practice Cardiovascular Medicine, 2005, 2, 628-638.	3.3	38
275	Angiotensin II Receptor Antagonists Alone and Combined with Hydrochlorothiazide. American Journal of Cardiovascular Drugs, 2005, 5, 171-183.	1.0	38
276	ACE Inhibitors in Heart Failure. American Journal of Cardiovascular Drugs, 2005, 5, 351-359.	1.0	23
277	Treating Hypertension with Angiotensin II Receptor Blockers. High Blood Pressure and Cardiovascular Prevention, 2005, 12, 9-15.	1.0	2
278	ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult. Circulation, 2005, 112, e154-235.	1.6	2,179
279	Diuretics Should Continue to Be One of the Preferred Initial Therapies in the Management of Hypertension. Journal of Clinical Hypertension, 2005, 7, 111-116.	1.0	7
280	Hypertension and the Cardiometabolic Syndrome. Journal of Clinical Hypertension, 2005, 7, 471-476.	1.0	56
281	Heart failure due to left ventricular systolic dysfunction: Treatment at discharge from hospital and at one year. International Journal of Cardiology, 2005, 103, 286-292.	0.8	14
282	The prognostic use of right heart catheterization data in patients with advanced heart failure: How relevant are invasive procedures in the risk stratification of advanced heart failure in the era of neurohormones?. Journal of Heart and Lung Transplantation, 2005, 24, 303-309.	0.3	29

#	Article	IF	Citations
283	Effects of oral fixed-dose combinations of telmisartan plus ramipril and losartan plus ramipril in hypertension: A multicenter, prospective, randomized, double-blind, phase iii trial in adult indian patients. Current Therapeutic Research, 2005, 66, 630-642.	0.5	2
284	Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Failure Trial (Val-HeFT). American Heart Journal, 2005, 149, 548-557.	1.2	401
285	Comparison of losartan and captopril on heart failureâ€"related outcomes and symptoms from the losartan heart failure survival study (ELITE II). American Heart Journal, 2005, 150, 123-131.	1.2	34
286	The data monitoring experience in the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) program. American Heart Journal, 2005, 149, 939-943.	1.2	28
287	Effects of angiotensin-converting enzyme inhibitor plus irbesartan on maximal and submaximal exercise capacity and neurohumoral activation in patients with congestive heart failure. American Heart Journal, 2005, 149, 938.e1-938.e7.	1.2	14
288	Role of angiotensin receptor blockers as monotherapy in reaching blood pressure goals. American Journal of Hypertension, 2005, 18, 287-294.	1.0	46
289	Mechanisms for the Clinical Benefits of Angiotensin II Receptor Blockers. American Journal of Hypertension, 2005, 18, 720-730.	1.0	105
290	Renin-Angiotensin System Modulation: The Weight of Evidence. American Journal of Hypertension, 2005, 18, 127-133.	1.0	27
292	Blood Pressure Reduction and Cardiovascular Prevention: An Update Including the 2003-2004 Secondary Prevention Trials. Hypertension Research, 2005, 28, 385-407.	1.5	229
293	Candesartan Cilexetil. Drugs, 2005, 65, 537-558.	4.9	15
294	Angiotensin Antagonism in Coronary Artery Disease. Drugs, 2005, 65, 1073-1096.	4.9	14
295	Candesartan Treatment for Peripheral Occlusive Arterial Disease after Stent Angioplasty. Clinical Drug Investigation, 2005, 25, 89-97.	1.1	2
297	Long-Term Trends in Drug Prescription for Hospitalized Patients With Congestive Heart Failure. Influence of Type of Dysfunction. Revista Espanola De Cardiologia (English Ed), 2005, 58, 381-388.	0.4	1
298	Rationale and Design of a Randomized Trial to Assess the Effects of Î²-blocker in Diastolic Heart Failure; Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiac Failure, 2005, 11, 542-547.	0.7	35
299	ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult. Journal of the American College of Cardiology, 2005, 46, e1-e82.	1.2	1,860
300	ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adultâ€"Summary Article. Journal of the American College of Cardiology, 2005, 46, 1116-1143.	1.2	373
301	Renin inhibitors: An antihypertensive strategy on the verge of reality. Drug Discovery Today: Therapeutic Strategies, 2005, 2, 181-185.	0.5	11
302	Cardiovascular Drug Therapy in Elderly Patients. Drugs and Aging, 2005, 22, 913-941.	1.3	35

#	Article	IF	Citations
303	Hypertension in the Elderly. Drugs and Aging, 2005, 22, 297-314.	1.3	11
304	The Role of Angiotensin II Type 1 Receptor Antagonists in Elderly Patients with Hypertension. Drugs and Aging, 2006, 23, 131-155.	1.3	32
305	2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal, 2006, 28, 1462-1536.	1.0	1,617
306	The Rationale and Indications for Angiotensin Receptor Blockers in Heart Failure. Heart Failure Clinics, 2006, 2, 81-88.	1.0	2
307	Candesartan Cilexetil. Pharmacoeconomics, 2006, 24, 1249-1272.	1.7	3
308	Candesartan for the management of heart failure: more than an alternative. Expert Opinion on Pharmacotherapy, 2006, 7, 1945-1956.	0.9	4
309	Angiotensin II antagonists â€“ therapeutic benefits spanning the cardiovascular disease continuum from hypertension to heart failure and diabetic nephropathy. Current Medical Research and Opinion, 2006, 22, 1-16.	0.9	26
310	Outcome of Heart Failure with Preserved Ejection Fraction in a Population-Based Study. New England Journal of Medicine, 2006, 355, 260-269.	13.9	1,710
311	Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: Diagnosis and management. Canadian Journal of Cardiology, 2006, 22, 23-45.	0.8	378
312	The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II â€“ Therapy. Canadian Journal of Cardiology, 2006, 22, 583-593.	0.8	113
313	Antihypertensive medications and blood sugar: Theories and implications. Canadian Journal of Cardiology, 2006, 22, 229-233.	0.8	37
314	Influencia de la prediabetes en el pronÃ³stico cardiovascular del paciente hipertenso. Hipertension, 2006, 23, 86-92.	0.0	0
316	AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update. Journal of the American College of Cardiology, 2006, 47, 2130-2139.	1.2	526
318	Heart Failure in Older Adults. Medical Clinics of North America, 2006, 90, 863-885.	1.1	35
320	ACE Inhibitors and Angiotensin Receptor Antagonists and the Incidence of New-Onset Diabetes Mellitus. Drugs, 2006, 66, 1169-1177.	4.9	20
321	Effects of Candesartan for Middle-Aged and Elderly Women with Hypertension and Menopausal-Like Symptoms. Hypertension Research, 2006, 29, 1007-1012.	1.5	24
322	The Effect of Valsartan, Captopril, or Both on Atherosclerotic Events After Acute Myocardial Infarction. Journal of the American College of Cardiology, 2006, 47, 726-733.	1.2	149
323	Diagnosis and Management of Chronic Heart Failure. Journal of the American College of Cardiology, 2006, 48, 223.	1.2	0

#	Article	IF	Citations
325	Chinaâ€™s Role in International Cardiology. Journal of the American College of Cardiology, 2006, 48, 224-225.	1.2	7
327	Section 7: Heart Failure in Patients With Left Ventricular Systolic Dysfunction. Journal of Cardiac Failure, 2006, 12, e38-e57.	0.7	21
328	What Is the Economic Value of Digoxin Therapy in Congestive Heart Failure Patients? Results From the DIG Trial. Journal of Cardiac Failure, 2006, 12, 336-342.	0.7	8
329	Carvedilol Reduces Aldosterone Release in Systolic Heart Failure. Heart Lung and Circulation, 2006, 15, 306-309.	0.2	7
330	Use of valsartan in post-myocardial infarction and heart failure patients.. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2006, 7, S19.	1.0	3
331	Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). European Heart Journal, 2006, 28, 88-136.	1.0	1,144
332	Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction. American Heart Journal, 2006, 152, 705-712.	1.2	60
333	Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. American Heart Journal, 2006, 152, 86-92.	1.2	275
334	Meta-analysis: Inhibition of renin-angiotensin system prevents new-onset atrial fibrillation. American Heart Journal, 2006, 152, 217-222.	1.2	158
335	Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)â€“Added trial. American Heart Journal, 2006, 151, 985-991.	1.2	102
336	Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-Î³. International Journal of Biochemistry and Cell Biology, 2006, 38, 766-781.	1.2	56
337	The Pleiotropic Effects of Angiotensin Receptor Blockers. Journal of Clinical Hypertension, 2006, 8, 261-268.	1.0	46
338	Optimal Pharmacologic and Non-pharmacologic Management of Cardiac Transplant Candidates: Approaches to Be Considered Prior to Transplant Evaluation: International Society for Heart and Lung Transplantation Guidelines for the Care of Cardiac Transplant Candidatesâ€”2006. Journal of Heart and Lung Transplantation, 2006, 25, 1003-1023.	0.3	61
339	Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. International Journal of Cardiology, 2006, 106, 367-372.	0.8	120
340	Cheyneâ€“Stokes respiration with central sleep apnoea in chronic heart failure: Proposals for a diagnostic and therapeutic strategy. Sleep Medicine Reviews, 2006, 10, 33-47.	3.8	66
341	Pharmacotherapy Implications of Revised Chronic Heart Failure Guidelines. The Consultant Pharmacist, 2006, 21, 576-582.	0.4	2
342	Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers. , 2006, , 61-67.		1
343	Tratamento atual da insuficiÃªncia cardÃaca descompensada. Arquivos Brasileiros De Cardiologia, 2006, 87, 369-377.	0.3	6

#	Article	IF	Citations
344	Guidelines for the prevention, detection and management of people with chronic heart failure in Australia 2006. Medical Journal of Australia, 2006, 185, 549-556.	0.8	122
346	Aldosterone Antagonism in the Pharmacological Management of Chronic Heart Failure. , 0, , 82-103.		0
347	Angiotensin Receptor Blockers in the Treatment of Heart Failure. , 0, , 44-56.		0
349	Proposed New Score to Rate the Strength of Evidence and Its Application to Large-Scale Clinical Trials of Angiotensin-Receptor Blockers. Circulation Journal, 2006, 70, 1155-1158.	0.7	3
350	Managing heart failure in the very old. Aging Health, 2006, 2, 253-275.	0.3	0
352	Lack of effect on coronary atherosclerotic disease biomarkers with modest dosing of an angiotensin-converting enzyme inhibitor, angiotensin II type-1 receptor blocker, and the combination. Coronary Artery Disease, 2006, 17, 439-445.	0.3	1
353	Review: Dual blockade of renin-angiotensin system in diabetic nephropathy: review of literature and local experience. British Journal of Diabetes and Vascular Disease, 2006, 6, 23-28.	0.6	4
354	Suppression of the Reninâ€“Angiotensinâ€“Aldosterone System in Chronic Heart Failure. Cardiology in Review, 2006, 14, 81-87.	0.6	19
355	Effects of selective angiotensin II and Î²1-receptor blockade on renal haemodynamics and sodium handling during orthostatic stress in healthy individuals. Journal of Hypertension, 2006, 24, S89-S93.	0.3	8
357	Angiotensin II Receptor Blockers in Congestive Heart Failure. Cardiology in Review, 2006, 14, 26-34.	0.6	16
358	Drug therapy of chronic heart failure in the elderly: the current state of clinical-trial evidence. Current Opinion in Cardiology, 2006, 21, 393-399.	0.8	16
359	Renin inhibition with aliskiren: where are we now, and where are we going?. Journal of Hypertension, 2006, 24, 243-256.	0.3	229
360	Inhibiting the reninâ€“angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials. Current Opinion in Cardiology, 2006, 21, 268-272.	0.8	19
361	Pathophysiological regulation of the AT1-receptor and implications for vascular disease. Journal of Hypertension, 2006, 24, S15-S21.	0.3	103
362	Epidemiology, Pathophysiology, Prognosis, and Treatment of Systolic and Diastolic Heart Failure. Cardiology in Review, 2006, 14, 108-124.	0.6	100
363	Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure â€" Assessment of Reduction in Mortality and morbidity (CHARM) programme. Journal of Hypertension, 2006, 24, S3-S7.	0.3	13
364	Long-term safety of high-dose angiotensin receptor blocker therapy in hypertensive patients with chronic kidney disease. Journal of Hypertension, 2006, 24, S95-S99.	0.3	13
365	Perioperative Management of Chronic Heart Failure. Anesthesia and Analgesia, 2006, 103, 557-575.	1.1	156

#	Article	IF	Citations
366	Targeting effective blood pressure control with angiotensin receptor blockers. International Journal of Clinical Practice, 2006, 60, 315-320.	0.8	23
367	A review of the management of patients after percutaneous coronary intervention. International Journal of Clinical Practice, 2006, 60, 582-589.	0.8	10
368	Angiotensin inhibition after myocardial infarction: Does drug class matter?. Journal of General Internal Medicine, 2006, 21, 1242-1247.	1.3	9
369	Candesartan. Cardiovascular Drug Reviews, 2004, 22, 263-284.	4.4	40
370	Angiotensin II-receptor blocker dosages: How high should we go?. International Journal of Clinical Practice, 2006, 60, 179-183.	0.8	6
371	Effects of Angiotensin Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker on Ventricular Defibrillation Threshold. PACE - Pacing and Clinical Electrophysiology, 2006, 29, 747-752.	0.5	3
372	The implications of a growing evidence base for drug use in elderly patients Part 2 - ACE inhibitors and angiotensin receptor blockers in heart failure and high cardiovascular risk patients. British Journal of Clinical Pharmacology, 2006, 61, 502-512.	1.1	24
373	Difficulties in maintaining potassium homeostasis in patients with heart failure. Clinical Cardiology, 2006, 29, 388-392.	0.7	13
374	Pharmacological treatment of chronic heart failure. Heart Failure Reviews, 2006, 11, 109-123.	1.7	29
375	Efficacy of Angiotensin Receptor Blockers in Cardiovascular Disease. Cardiovascular Drugs and Therapy, 2006, 20, 295-308.	1.3	25
377	The influence of cardiovascular and antiinflammatory drugs on thiazide-induced hemodynamic and saluretic effects. European Journal of Clinical Pharmacology, 2006, 62, 885-892.	0.8	11
378	Future Pharmacologic Agents for Treatment of Heart Failure in Children. Pediatric Cardiology, 2006, 27, 533-551.	0.6	23
379	Diagnostic and Therapeutic Algorithms in Chronic Heart Failure. Herz, 2006, 31, 877-880.	0.4	2
381	Interference with the renin-angiotensin system in heart failure. Naunyn-Schmiedeberg's Archives of Pharmacology, 2006, 372, 331-334.	1.4	1
382	The problem of polypharmacy in heart failure. Current Cardiology Reports, 2006, 8, 217-225.	1.3	28
383	The renin-angiotensin system and its blockade in diabetic renal and cardiovascular disease. Current Diabetes Reports, 2006, 6, 8-16.	1.7	13
384	Should we employ combination ACEI and ARB therapy in primary hypertension?. Current Hypertension Reports, 2006, 8, 101-102.	1.5	2
385	Hypertension and heart failure: Diagnosis and management. Current Hypertension Reports, 2006, 8, 185-190.	1.5	5

#	Article	IF	Citations
386	Metabolic safety of antihypertensive drugs: Myth versus reality. Current Hypertension Reports, 2006, 8, 403-408.	1.5	16
387	What is the Optimal Angiotensinâ€Converting Enzyme Inhibitor Dose in Heart Failure?. Congestive Heart Failure, 2006, 12, 213-218.	2.0	4
388	Prognosis and Mechanism of Death in Treated Heart Failure: Data From the Placebo Arm of Val-HeFT. Congestive Heart Failure, 2006, 12, 127-131.	2.0	0
389	Management of Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus as a Component of the Cardiometabolic Syndrome. Journal of the Cardiometabolic Syndrome, 2006, 1, 133-140.	1.7	10
391	Tratamiento mÃ©dico de la insuficiencia cardiaca por disfunciÃ³n diastÃ³lica. Revista Espanola De Cardiologia Suplementos, 2006, 6, 46F-52F.	0.2	0
393	CaracterÃsticas farmacolÃ³gicas de los ARA-II. Â¿Son todos iguales?. Revista Espanola De Cardiologia Suplementos, 2006, 6, 10C-24C.	0.2	2
394	Â¿Se necesitan mÃ¡s fÃ¡rmacos para el tratamiento de la insuficiencia cardiaca? Diferencias entre los ensayos clÃnicos y la prÃ¡ctica clÃnica. Revista Espanola De Cardiologia Suplementos, 2006, 6, 25C-28C.	0.2	2
395	Â¿CuÃ¡l deberÃa ser el fÃ¡rmaco que se aÃ±adiera a un IECA y un bloqueador beta en la insuficiencia cardiaca por disfunciÃ³n sistÃ³lica: un antagonista de la aldosterona o un ARA-II? Evidencias clÃnicas con ambos. Revista Espanola De Cardiologia Suplementos, 2006, 6, 29C-36C.	0.2	0
397	Papel de los ARA-II en el tratamiento de la insuficiencia cardiaca: Â¿quÃ© dicen las guÃas de prÃ¡ctica clÃnica?. Revista Espanola De Cardiologia Suplementos, 2006, 6, 58C-72C.	0.2	0
398	Hypertension and the Cardiometabolic Syndrome?Is It the Blood Pressure Lowering or the Blood Pressure Medication That Is Important?. Journal of the Cardiometabolic Syndrome, 2006, 1, 72-73.	1.7	0
399	Optimal Medical Therapy for Heart Failure. Progress in Cardiovascular Diseases, 2006, 48, 372-385.	1.6	17
400	Long-term safety of antihypertensive therapy. Progress in Cardiovascular Diseases, 2006, 49, 16-25.	1.6	25
401	The investigation and treatment of chronic heart failure. Medicine, 2006, 34, 215-219.	0.2	0
402	Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Type 1 Receptor Blockers on the Rate of New-Onset Diabetes Mellitus: A Review and Pooled Analysis. Pharmacotherapy, 2006, 26, 1297-1306.	1.2	22
403	Optimizationvia experimental design of an SPE-HPLC-UV-fluorescence method for the determination of valsartan and its metabolite in human plasma samples. Journal of Separation Science, 2006, 29, 2265-2283.	1.3	28
404	Who needs a heart transplant?The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.. European Heart Journal, 2006, 27, 770-772.	1.0	16
405	The evolution of heart failure management over recent decades: from CONSENSUS to CIBIS. Country Review Ukraine, 2006, 8, C5-C12.	0.8	3
406	From coronary artery disease to heart failure: potential benefits of ivabradine. Country Review Ukraine, 2006, 8, D24-D29.	0.8	4

#	Article	IF	Citations
407	Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. European Heart Journal, 2006, 27, 178-186.	1.0	344
408	Chronic Obstructive Pulmonary Disease, Risk Factors, and Outcome Trials: Comparisons with Cardiovascular Disease. Proceedings of the American Thoracic Society, 2006, 3, 635-640.	3.5	34
409	Treatment of chronic heart failure: a comparison between the major guidelines. European Heart Journal, 2006, 27, 1773-1777.	1.0	46
410	Combined Treatment With Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers: A Review of the Current Evidence. Journal of Cardiovascular Pharmacology and Therapeutics, 2006, 11, 1-15.	1.0	31
412	Current and future uses of candesartan in the treatment of heart failure. Future Cardiology, 2006, 2, 391-402.	0.5	0
413	Telmisartan, its Potential Therapeutic Implications in Cardiometabolic Disorders. Recent Patents on Cardiovascular Drug Discovery, 2006, 1, 79-83.	1.5	2
414	Therapeutic potential of angiotensin receptor blockers in hypertension. Expert Opinion on Investigational Drugs, 2006, 15, 625-635.	1.9	6
415	The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes. Circulation, 2006, 114, 2871-2891.	1.6	109
416	Angiotensin Receptor Blockers May Increase Risk of Myocardial Infarction. Circulation, 2006, 114, 838-854.	1.6	226
417	Review: From Hypertension to Heart Failure â€" Are There Better Primary Prevention Strategies?. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2006, 7, 64-73.	1.0	33
418	Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure. Circulation, 2006, 113, 671-678.	1.6	817
419	The diagnosis and management of chronic heart failure in the older patient. Reviews in Clinical Gerontology, 2006, 16, 199.	0.5	0
420	Heart Failure and Nephropathy: Catastrophic and Interrelated Complications of Diabetes. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 193-208.	2.2	58
421	Lack of Deleterious Interaction Between Angiotensin Receptor Blockers and Î²-Blockers in the Treatment of Patients With Heart Failure. Journal of Cardiovascular Pharmacology and Therapeutics, 2006, 11, 149-152.	1.0	2
422	Angiotensin blockade or aldosterone blockade as the third neuroendocrine-blocking drug in mild but symptomatic heart failure patients. Heart, 2006, 92, 1728-1731.	1.2	4
423	Angiotensin Receptor Blockers Do Not Increase Risk ofMyocardial Infarction. Circulation, 2006, 114, 855-860.	1.6	54
424	Clinical evidence for the cardiovascular benefits of angiotensin receptor blockers.. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2006, 7, S1.	1.0	24
425	Drug Therapy Recommendations from the 2005 ACC/AHA Guidelines for Treatment of Chronic Heart Failure. Annals of Pharmacotherapy, 2006, 40, 1607-1617.	0.9	17

#	Article	IF	Citations
426	Variable Impact of Combining Fatal and Nonfatal End Points in Heart Failure Trials. Circulation, 2006, 114, 2298-2303.	1.6	34
427	Underrepresentation of Renal Disease in Randomized Controlled Trials of Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2006, 296, 1377.	3.8	353
429	AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update. Circulation, 2006, 113, 2363-2372.	1.6	1,742
430	The Diabetic Kidney. , 2006, , .		1
431	Canadian Cardiovascular Society Consensus Conference Recommendations on Heart Failure 2006. Canadian Pharmacists Journal, 2006, 139, 34-36.	0.4	6
432	Cardiology in Family Practice. , 2006, , .		0
433	Contemporary Use of Digoxin in the Management of Cardiovascular Disorders. Circulation, 2006, 113, 2556-2564.	1.6	164
434	Advanced Glycation End Products Activate a Chymase-Dependent Angiotensin Iiâ€“Generating Pathway in Diabetic Complications. Circulation, 2006, 113, 1353-1360.	1.6	77
435	Aldosterone antagonists in the treatment of heart failure. American Journal of Health-System Pharmacy, 2006, 63, 49-58.	0.5	20
436	Best practice in primary care pathology: review 6. Journal of Clinical Pathology, 2006, 60, 225-234.	1.0	23
437	Role of Angiotensin II in Cardiovascular Disease â€" Therapeutic Implications of More Than a Century of Research. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2006, 7, 3-14.	1.0	188
439	Hypertension and antihypertensive treatment of diabetic nephropathy. Nature Clinical Practice Nephrology, 2006, 2, 562-567.	2.0	40
440	Diet, Metabolic Syndrome, and Obesity. Fundamental and Clinical Cardiology, 2006, , 37-58.	0.0	0
441	Standards of Medical Care in Diabetes--2007. Diabetes Care, 2007, 30, S4-S41.	4.3	1,296
442	Candesartan: from left ventricular hypertrophy to heart failure, a global approach. Expert Review of Cardiovascular Therapy, 2007, 5, 825-834.	0.6	2
443	Role of Renin Angiotensin System Inhibitors in Cardiovascular and Renal Protection: A Lesson from Clinical Trials. Current Pharmaceutical Design, 2007, 13, 1335-1345.	0.9	42
444	Anaemia and renal function in heart failure due to idiopathic dilated cardiomyopathy. European Journal of Heart Failure, 2007, 9, 384-390.	2.9	14
445	Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2007, 9, 684-694.	2.9	335

#	Article	IF	Citations
446	Atenolol: Differences in Mode of Action Compared with other Antihypertensives.An Opportunity to Identify Features that Influence Outcome?. Current Pharmaceutical Design, 2007, 13, 229-239.	0.9	11
447	Management of patients with non-ischaemic cardiomyopathy. Heart, 2007, 93, 403-408.	1.2	30
448	Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM. European Journal of Heart Failure, 2007, 9, 83-91.	2.9	188
449	Sex differences in the effectiveness of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in patients with congestive heart failure - A population study. European Journal of Heart Failure, 2007, 9, 602-609.	2.9	91
450	Is the gap between guidelines and clinical practice in heart failure treatment being filled? Insights from the IMPACT RECO survey. European Journal of Heart Failure, 2007, 9, 1205-1211.	2.9	109
451	Angiotensin-converting enzyme inhibitors and survival in women and men with heart failure. European Journal of Heart Failure, 2007, 9, 594-601.	2.9	23
452	Adverse Effects of Combination Angiotensin II Receptor Blockers Plus Angiotensin-Converting Enzyme Inhibitors for Left Ventricular Dysfunction. Archives of Internal Medicine, 2007, 167, 1930.	4.3	170
453	The role of reninâ€“angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal?. Expert Opinion on Therapeutic Targets, 2007, 11, 191-205.	1.5	24
454	Drug Insight: aldosterone-receptor antagonists in heart failureâ€"the journey continues. Nature Clinical Practice Cardiovascular Medicine, 2007, 4, 368-378.	3.3	17
456	Management of acute decompensated heart failure. Cmaj, 2007, 176, 797-805.	0.9	71
457	Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). European Heart Journal Supplements, 2007, 9, C3-C74.	0.0	40
458	Antihypertensive strategy based on angiotensin II receptor blockers: a new gateway to reduce risk in hypertension. Expert Review of Cardiovascular Therapy, 2007, 5, 767-776.	0.6	14
459	Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease. Circulation, 2007, 115, 2761-2788.	1.6	694
460	Prevalence and prognostic impact of bundle branch block in patients with heart failure: Evidence from the CHARM programme. European Journal of Heart Failure, 2007, 9, 510-517.	2.9	47
461	The CHARM Program: Study Design Leads to Findings of Clinical and Public Health Importance. Journal of Cardiovascular Pharmacology and Therapeutics, 2007, 12, 124-126.	1.0	0
462	2007 Guidelines for the Management of Arterial Hypertension. Journal of Hypertension, 2007, 25, 1105-1187.	0.3	4,778
463	Blood pressure-dependent and independent effects of agents that inhibit the reninâ€“angiotensin system. Journal of Hypertension, 2007, 25, 951-958.	0.3	372
464	REPRINT Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease. Hypertension, 2007, 50, .	1.3	14

#	Article	IF	Citations
465	Management of end stage cardiac failure. Postgraduate Medical Journal, 2007, 83, 395-401.	0.9	35
466	Current News in Cardiology. , 2007, , .		0
467	Insights into the Relationship Between Hypertension and Albuminuria. Current Hypertension Reviews, 2007, 3, 29-37.	0.5	7
468	Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure. Circulation, 2007, 116, 1482-1487.	1.6	528
469	Renin Inhibition as a New Strategy to Combat Cardiovascular Disease. Current Hypertension Reviews, 2007, 3, 39-43.	0.5	1
470	MANAGEMENT OF END STAGE HEART FAILURE. Heart, 2007, 93, 626-631.	1.2	74
471	Therapeutic effects of angiotensin II type 1 receptor blocker at an advanced stage of hypertensive diastolic heart failure. Journal of Hypertension, 2007, 25, 455-461.	0.3	36
472	Reducing diabetes incidence through the inhibition of the reninâ€“angiotensin system: a strategy for reducing cardiovascular mortality and morbidity?. Journal of Cardiovascular Medicine, 2007, 8, 473-482.	0.6	3
473	Angiotensin Receptor Blockers in Chronic Heart Failure: Clinical Implications and Molecular Mechanisms. Current Cardiology Reviews, 2007, 3, 296-303.	0.6	0
475	Role of AT1 receptor in isoproterenol-induced cardiac hypertrophy and oxidative stress in mice. Journal of Molecular and Cellular Cardiology, 2007, 42, 804-811.	0.9	73
476	Treating Patients for Cardiovascular Protection: Combination Therapy to Achieve Complete Renin-Angiotensin System Blockade. Preventive Cardiology, 2007, 10, 147-155.	1.1	0
477	Antihypertensive Combination Therapy: Optimizing Blood Pressure Control and Cardiovascular Risk Reduction. Journal of Clinical Hypertension, 2007, 9, 26-32.	1.0	20
478	Combination ACE Inhibitor and Angiotensin Receptor Blocker Therapyâ€"Future Considerations. Journal of Clinical Hypertension, 2007, 9, 78-86.	1.0	12
479	Combining Neuroendocrine Inhibitors in Heart Failure: Reflections on Safety and Efficacy. American Journal of Medicine, 2007, 120, 1090.e1-1090.e8.	0.6	11
480	Effects of renin-angiotensin system inhibition end-organ protection: Can we do better?. Clinical Therapeutics, 2007, 29, 1803-1824.	1.1	152
481	The Incidence of Ischemic Stroke in Chronic Heart Failure: A Meta-Analysis. Journal of Cardiac Failure, 2007, 13, 489-496.	0.7	100
482	Heart Failure in Diabetes and Related Conditions. Journal of Cardiac Failure, 2007, 13, 861-873.	0.7	31
483	Losartan Improves Heart Rate Variability and Heart Rate Turbulence in Heart Failure Due to Ischemic Cardiomyopathy. Journal of Cardiac Failure, 2007, 13, 812-817.	0.7	20

#	Article	IF	Citations
484	Telmisartan ramipril combination therapy reduces strokes and improves cardiac and renal protection in stroke prone spontaneously hypertensive rats. Journal of the American Society of Hypertension, 2007, 1, 423-432.	2.3	3
486	Dual inhibition of the renin system by aliskiren and valsartan. Lancet, The, 2007, 370, 195-196.	6.3	35
487	Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet, The, 2007, 370, 221-229.	6.3	432
488	GuÃas de prÃ¡ctica clÃnica sobre diabetes, prediabetes y enfermedades cardiovasculares: versiÃ³n resumida. Revista Espanola De Cardiologia, 2007, 60, 525.e1-525.e64.	0.6	13
490	Beneficios adicionales del tratamiento con candesartÃ¡n en la insuficiencia cardÃaca. Programa CHARM. Hipertension, 2007, 24, 34-42.	0.0	0
491	Perspectivas futuras del tratamiento con antagonistas de los recepetores de la angiotensina. Hipertension, 2007, 24, 43-50.	0.0	0
492	Heart-Failureâ€“Complicating Acute Myocardial Infarction. Clinics in Geriatric Medicine, 2007, 23, 123-139.	1.0	1
493	Rationale for Combining Blockers of the Renin-Angiotensin System. Seminars in Nephrology, 2007, 27, 544-554.	0.6	10
494	Inotropic Drugs and Neurohormonal Antagonists in the Treatment of HF in the Elderly. Heart Failure Clinics, 2007, 3, 477-484.	1.0	0
495	Treatment of Heart Failure with Abnormal Left Ventricular Systolic Function in the Elderly. Heart Failure Clinics, 2007, 3, 423-436.	1.0	2
496	Spotlight on the Pharmacoeconomics of Candesartan Cilexetil in Chronic Heart Failure and Hypertension1. Disease Management and Health Outcomes, 2007, 15, 57-63.	0.3	1
497	2007 ESHâ€ESC Guidelines for the management of arterial hypertension. Blood Pressure, 2007, 16, 135-232.	0.7	292
498	Drug Treatment of Chronic Heart Failure in the Elderly. Drugs and Aging, 2007, 24, 991-1006.	1.3	14
499	Direct renin inhibitors: the dawn of a new era, or just a variation on a theme?. Nephrology Dialysis Transplantation, 2007, 22, 2435-2439.	0.4	30
500	Heart failure: metabolic derangements and therapeutic rationale. Expert Review of Cardiovascular Therapy, 2007, 5, 331-343.	0.6	0
501	Angiotensin II reactivation and aldosterone escape phenomena in reninâ€“angiotensinâ€“aldosterone system blockade: is oral renin inhibition the solution?. Expert Opinion on Pharmacotherapy, 2007, 8, 529-535.	0.9	68
502	Candesartan cilexetil â€“ a review of effects on cardiovascular complications in hypertension and chronic heart failure. Current Medical Research and Opinion, 2007, 23, 1693-1705.	0.9	20
503	Renin: friend or foe?. Heart, 2007, 93, 1026-1033.	1.2	74

#	Article	IF	Citations
504	Inotropic Drugs and Neurohormonal Antagonists in the Treatment of HF in the Elderly. Clinics in Geriatric Medicine, 2007, 23, 141-153.	1.0	1
505	Treatment of Heart Failure with Abnormal Left Ventricular Systolic Function in the Elderly. Clinics in Geriatric Medicine, 2007, 23, 61-81.	1.0	2
507	Anti-angiotensin Therapy: New Perspectives. Cardiology Clinics, 2007, 25, 573-580.	0.9	11
508	Heart Failure in the Diabetic Patient. Cardiology Clinics, 2007, 25, 523-538.	0.9	13
509	Cardiac Transplantation: Any Role Left?. Heart Failure Clinics, 2007, 3, 321-347.	1.0	10
510	Heart Failureâ€“Complicating Acute Myocardial Infarction. Heart Failure Clinics, 2007, 3, 465-475.	1.0	6
512	Dihydropyridine Calcium Channel Antagonists in the Management of Hypertension. Drugs, 2007, 67, 1309-1327.	4.9	86
513	Perindopril versus Angiotensin II Receptor Blockade in Hypertension and Coronary Artery Disease. Clinical Drug Investigation, 2007, 27, 149-161.	1.1	6
514	Incidence and Predictors of Hyperkalemia in Patients With Heart Failure. Journal of the American College of Cardiology, 2007, 50, 1959-1966.	1.2	153
516	Effects of Combined Candesartan and ACE Inhibitors on BNP, Markers of Inflammation and Oxidative Stress, and Glucose Regulation in Patients With Symptomatic Heart Failure. Journal of Cardiac Failure, 2007, 13, 86-94.	0.7	42
517	Pharmacologic Therapy of Chronic Heart Failure. American Journal of Cardiovascular Drugs, 2007, 7, 235-248.	1.0	22
519	Rationale for Combination Therapy in Hypertension Management: Focus on Angiotensin Receptor Blockers and Thiazide Diuretics. Southern Medical Journal, 2007, 100, 386-392.	0.3	11
520	Interactions Between Antihypertensive Drugs and Other Medications. , 2007, , 1075-1086.		0
521	Hypertension in Patients with Concomitant Cardiac Disorders. , 2007, , 753-759.		0
522	Angiotensin II Receptor Blockers. , 2007, , 1003-1017.		3
523	Angiotensin Receptor Blockers. , 2007, , 254-267.		0
525	Diabetes, Left Ventricular Systolic Dysfunction and Chronic Heart Failure. , 0, , 93-134.		0
526	Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Pharmacoepidemiology and Drug Safety, 2007, 16, 55-64.	0.9	75

#	Article	IF	Citations
527	The role of angiotensin II type 1 receptor blockers in the prevention and management of diabetes mellitus. Diabetes, Obesity and Metabolism, 2007, 9, 617-629.	2.2	10
528	Maximising antihypertensive effects of angiotensin II receptor blockers with thiazide diuretic combination therapy: focus on irbesartan/hydrochlorothiazide. International Journal of Clinical Practice, 2007, 61, 2093-2102.	0.8	17
529	Angiotensin II Receptor Blockers for the Treatment of Heart Failure: A Class Effect?. Pharmacotherapy, 2007, 27, 526-534.	1.2	20
530	Current Guidelines for Treatment of Heart Failure: 2006 Update. Pharmacotherapy, 2007, 27, 12S-17S.	1.2	15
531	Clinical and Economic Implications of New Strategies for Heart Failure Management in the Managed Care Setting. Pharmacotherapy, 2007, 27, 29S-32S.	1.2	3
532	New Studies Influencing Treatment of Heart Failure: 2006 Update. Pharmacotherapy, 2007, 27, 3S-11S.	1.2	5
533	Association of Î²-Blocker Dose with Serum Procollagen Concentrations and Cardiac Response to Spironolactone in Patients with Heart Failure. Pharmacotherapy, 2007, 27, 801-812.	1.2	5
534	New Opportunities in Cardiovascular Patient Management: A Survey of Clinical Data on the Combination of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers. American Journal of Cardiology, 2007, 100, S45-S52.	0.7	12
536	Reducing cardiovascular risk by blockade of the renin-angiotensin-aldosterone system. Advances in Therapy, 2007, 24, 1290-1304.	1.3	20
537	Adverse events of blood-pressure-lowering drugs: evidence of high incidence in a clinical setting. European Journal of Clinical Pharmacology, 2007, 63, 973-978.	0.8	26
540	Gradual reactivation of vascular angiotensin I to angiotensin II conversion during chronic ACE inhibitor therapy in patients with diabetes mellitus. Diabetologia, 2007, 50, 2061-2066.	2.9	9
541	Treatment of heart failure with ACE inhibitors and beta-blockers. Clinical Research in Cardiology, 2007, 96, 196-198.	1.5	18
542	The renin-angiotensin system and insulin resistance. Current Diabetes Reports, 2007, 7, 34-42.	1.7	50
543	Inhibiting the renin-angiotensin system with ACE inhibitors or ARBs after MI. Current Heart Failure Reports, 2007, 4, 190-197.	1.3	8
544	Evidence-based Treatment of Chronic Heart Failure. Comprehensive Therapy, 2007, 33, 2-17.	0.2	1
545	Selective type 1 angiotensin II receptor blockade attenuates oxidative stress and regulates angiotensin II receptors in the canine failing heart. Molecular and Cellular Biochemistry, 2008, 317, 97-104.	1.4	13
546	Pleiotropic effects of cardiac drugs on healing post-MI. The good, bad, and ugly. Heart Failure Reviews, 2008, 13, 439-452.	1.7	25
550	Direct renin inhibition: An analysis of possible benefits. Current Hypertension Reports, 2008, 10, 313-318.	1.5	6

#	Article	IF	Citations
551	New guidelines of the European society of hypertension. Current Hypertension Reports, 2008, 10, 337-338.	1.5	3
552	ONTARGET study of telmisartan, ramipril, or both in high-risk patients. Current Hypertension Reports, 2008, 10, 345-348.	1.5	2
553	Management of hypertension in patients with coronary artery disease. Current Hypertension Reports, 2008, 10, 349-354.	1.5	4
554	Single and dual blockade of the renin-angiotensin system in high-risk patients without heart failure: Lessons from ONTARGET. Current Cardiovascular Risk Reports, 2008, 2, 417-419.	0.8	0
555	RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection. Clinical Research in Cardiology, 2008, 97, 418-431.	1.5	135
557	Exposure of the elderly to potential nephrotoxic drug combinations in Belgium. Pharmacoepidemiology and Drug Safety, 2008, 17, 1014-1019.	0.9	18
558	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). European Heart Journal, 2008, 29, 2388-2442.	1.0	2,656
559	Neurohormones and heart failure: the importance of aldosterone. International Journal of Clinical Practice, 2008, 60, 835-846.	0.8	10
560	Dual renin-angiotensin system blockade: on the target. International Journal of Clinical Practice, 2008, 62, 1134-1136.	0.8	0
561	The effects of angiotensin-receptor blockers on mortality and morbidity in heart failure: a systematic review. International Journal of Clinical Practice, 2008, 62, 1397-1402.	0.8	20
562	Type 2 Diabetes Mellitus and Heart Failure. Pharmacotherapy, 2008, 28, 170-192.	1.2	29
563	Pharmacotherapy for Heart Failure with Left Ventricular Dysfunction: Beyond Angiotensin-Converting Enzyme Inhibitors and Î²-Blockers. Pharmacotherapy, 2008, 28, 920-931.	1.2	3
564	Effect of Combination Angiotensin-Converting Enzyme and Angiotensin Receptor Blocker Therapy on Heart Failure Mortality and Morbidity. American Journal of Cardiology, 2008, 101, 744-745.	0.7	1
565	Angiotensin Receptor Blockers and Cardiovascular Protection: Are We ONTARGET?. American Journal of Cardiology, 2008, 102, 1281-1283.	0.7	0
566	The apelinâ€“APJ system in heart failure. Biochemical Pharmacology, 2008, 75, 1882-1892.	2.0	149
567	Adverse Drug Reactions in Patients with Cardiovascular Disease. Current Problems in Cardiology, 2008, 33, 703-768.	1.1	30
569	Implicaciones del estudio ONTARGET en hipertensiÃ³n arterial y diabetes tipo 2. Revista Espanola De Cardiologia Suplementos, 2008, 8, 56E-62E.	0.2	0
570	Implicaciones clÃnicas del programa ONTARGET en pacientes con cardiopatÃa isquÃ©mica crÃ³nica. Revista Espanola De Cardiologia Suplementos, 2008, 8, 63E-72E.	0.2	1

#	Article	IF	Citations
571	Â¿Inhibidores de la enzima conversiva de la angiotensina o antagonistas de los receptores de la angiotensina II en pacientes de alto riesgo? Resultados del estudio ONTARGET. FMC Formacion Medica Continuada En Atencion Primaria, 2008, 15, 622.	0.0	0
572	Use of Angiotensinâ€Converting Enzyme Inhibitor/Angiotensin II Receptor Blocker Therapy to Reduce Cardiovascular Events in Highâ€Risk Patients: Part 1. Preventive Cardiology, 2008, 11, 148-154.	1.1	7
573	ONTARGET: Questions Asked, Questions Answered. Journal of Clinical Hypertension, 2008, 10, 427-430.	1.0	0
574	Beneficial effects of Waon therapy on patients with chronic heart failure: Results of a prospective multicenter study. Journal of Cardiology, 2008, 52, 79-85.	0.8	70
582	Molecular Imaging of Interstitial Alterations in Remodeling Myocardium After Myocardial Infarction. Journal of the American College of Cardiology, 2008, 52, 2017-2028.	1.2	138
583	Clinical Outcomes According to Baseline Blood Pressure in Patients With a Low Ejection Fraction in the CHARM (Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity) Program. Journal of the American College of Cardiology, 2008, 52, 2000-2007.	1.2	42
584	Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. New England Journal of Medicine, 2008, 358, 1547-1559.	13.9	3,155
586	Management of Heart Failure: a Brief Review and Selected Update. Cardiology Clinics, 2008, 26, 561-571.	0.9	2
587	Survival and Quality of Life in Patients With Cardiac Resynchronization Therapy for Severe Heart Failure and in Heart Transplant Recipients Within a Contemporary Heart Failure Management Program. Journal of Heart and Lung Transplantation, 2008, 27, 746-752.	0.3	6
588	Diastolic heart failure. Heart and Lung: Journal of Acute and Critical Care, 2008, 37, 405-416.	0.8	33
589	Effects of ICD implantation on quality-adjusted life years in patients with congestive heart failure. International Journal of Cardiology, 2008, 123, 213-216.	0.8	4
590	Comparison of angiotensin-converting enzyme inhibitor alone and in combination with irbesartan for the treatment of heart failure. International Journal of Cardiology, 2008, 125, 16-21.	0.8	45
591	The pathophysiology of acute heart failureâ€"Is it all about fluid accumulation?. American Heart Journal, 2008, 155, 9-18.	1.2	179
592	Why and when do patients with heart failure and normal left ventricular ejection fraction die? Analysis of >600 deaths in a community long-term study. American Heart Journal, 2008, 156, 1184-1190.	1.2	46
593	Stretch-induced regulation of angiotensinogen gene expression in cardiac myocytes and fibroblasts: Opposing roles of JNK1/2 and p38Î± MAP kinases. Journal of Molecular and Cellular Cardiology, 2008, 45, 770-778.	0.9	33
594	Safety and Tolerability of Angiotensin-Converting Enzyme Inhibitor Versus the Combination of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker in Patients With Left Ventricular Dysfunction: A Systematic Review andÂMeta-Analysis of Randomized Controlled Trials. Journal of Cardiac Failure, 2008, 14, 181-188.	0.7	115
595	Consultation between specialists in Internal Medicine and Family Medicine improves management and prognosis of heart failure. European Journal of Internal Medicine, 2008, 19, 548-554.	1.0	13
598	Multiple Neurohumoral Modulating Agents in Systolic Dysfunction Heart Failure: Are We Lowering Blood Pressure Too Much?. Journal of Cardiac Failure, 2008, 14, 555-560.	0.7	19

#	Article	IF	Citations
599	De la evidencia a la prÃ¡ctica clÃnica. El ejemplo del estudio ONTARGET. Hipertension, 2008, 25, 44-54.	0.0	0
600	The power to TRANSCEND. Lancet, The, 2008, 372, 1128-1130.	6.3	15
601	GuÃa de prÃ¡ctica clÃnica de la Sociedad Europea de CardiologÃa (ESC) para el diagnÃ³stico y tratamiento de la insuficiencia cardiaca aguda y crÃ³nica (2008). Revista Espanola De Cardiologia, 2008, 61, 1329.e1-1329.e70.	0.6	36
602	Angiotensin Receptor Blockers: Novel Role in High-Risk Patients. Cardiology Clinics, 2008, 26, 507-526.	0.9	7
603	Gestione dellâ€™insufficienza cardiaca delle persone anziane. EMC - AKOS - Trattato Di Medicina, 2008, 10, 1-10.	0.0	0
604	Traditional and Novel Approaches to Management of Heart Failure: Successes and Failures. Cardiology Clinics, 2008, 26, 59-72.	0.9	17
606	Changes in Kidney Function Following Heart Failure Treatment: Focus on Renin-Angiotensin System Blockade. Heart Failure Clinics, 2008, 4, 425-438.	1.0	10
607	Hyperkalemia Risk and Treatment of Heart Failure. Heart Failure Clinics, 2008, 4, 455-464.	1.0	3
608	A New Option for Therapeutic Management of Patients with Cardiovascular Disease. High Blood Pressure and Cardiovascular Prevention, 2008, 15, 47-51.	1.0	4
609	Angiotensin II Blockade and Total Cardiovascular Risk. High Blood Pressure and Cardiovascular Prevention, 2008, 15, 245-253.	1.0	1
610	Which Strategy Is More Effective for the Treatment of Cardiovascular Disease. American Journal of Cardiovascular Drugs, 2008, 8, 88-90.	1.0	1
611	Economic Burden of Heart Failure in??the Elderly. Pharmacoeconomics, 2008, 26, 447-462.	1.7	175
612	Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis. Current Medical Research and Opinion, 2008, 24, 1039-1047.	0.9	40
613	Hypertension and Diabetes. , 2008, 45, 82-106.		48
614	Angiotensin-Converting Enzyme Inhibitor and/or Angiotensin Receptor Antagonist for the Postmyocardial Infarction Patient. Cardiology Clinics, 2008, 26, 73-77.	0.9	2
615	Comparative Effectiveness of Different Î²-Adrenergic Antagonists on Mortality Among Adults With Heart Failure in Clinical Practice. Archives of Internal Medicine, 2008, 168, 2415.	4.3	68
616	Role of renin in heart failure and therapeutic potential of direct renin inhibition. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2008, 9, 177-180.	1.0	13
617	Short-term effects of angiotensin receptor blockers on blood pressure control, and plasma inflammatory and fibrinolytic parameters in patients taking angiotensin-converting enzyme inhibitors. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2008, 9, 22-26.	1.0	6

#	Article	IF	Citations
618	Letter to the Editor * Authors' Response. American Journal of Sports Medicine, 2008, 36, e5-e7.	1.9	0
619	Partial Peroxisome Proliferator-Activated Receptor Agonist Angiotensin Receptor Blockers. Cerebrovascular Diseases, 2008, 26, 106-112.	0.8	19
620	Influence of drugs and comorbidity on serum potassium in 15 000 consecutive hospital admissions. Nephrology Dialysis Transplantation, 2008, 23, 3939-3945.	0.4	26
621	Awareness and perception of heart failure among European cardiologists, internists, geriatricians, and primary care physicians. European Heart Journal, 2008, 29, 1739-1752.	1.0	90
622	Current and Future Considerations in the Use of Mechanical Circulatory Support Devices. Annual Review of Biomedical Engineering, 2008, 10, 59-84.	5.7	17
623	Current possibilities of ACE inhibitor and ARB combination in arterial hypertension and its complications. Expert Review of Cardiovascular Therapy, 2008, 6, 759-771.	0.6	11
624	Effects of AGTR1 A1166C Gene Polymorphism in Patients with Heart Failure Treated with Candesartan. Annals of Pharmacotherapy, 2008, 42, 925-932.	0.9	33
625	Standards of Medical Care in Diabetesâ€”2008. Diabetes Care, 2008, 31, S12-S54.	4.3	1,509
626	ACE-inhibitor, AT₁-receptor-antagonist, or both? A clinical pharmacologist`s perspective after publication of the results of ONTARGET. Therapeutic Advances in Cardiovascular Disease, 2008, 2, 233-248.	1.0	19
627	Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. European Heart Journal, 2008, 30, 469-477.	1.0	145
628	Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensinâ€converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)â€Added trial. European Journal of Heart Failure, 2008, 10, 157-163.	2.9	30
629	Prevention of Macrovascular Disease in Type 2 Diabetic Patients: Blockade of the Renin-Angiotensin-Aldosterone System. Current Diabetes Reviews, 2008, 4, 63-78.	0.6	6
631	Management of Heart Failure. , 2008, , .		1
632	Prognostic impact of NTâ€proBNP and renal function in comparison to contemporary multiâ€marker risk scores in heart failure patients. European Journal of Heart Failure, 2008, 10, 315-320.	2.9	56
633	Chronic heart failure, selected risk factors and coâ€morbidities among adults treated for hypertension in a cardiac referral hospital in Cameroon. European Journal of Heart Failure, 2008, 10, 367-372.	2.9	32
634	Design of the Heart failure Endpoint evaluation of Allâ€Antagonist Losartan (HEAAL) study in patients intolerant to ACEâ€inhibitor. European Journal of Heart Failure, 2008, 10, 899-906.	2.9	18
636	Review: The therapeutic role of RAS blockade in chronic heart failure. Therapeutic Advances in Cardiovascular Disease, 2008, 2, 167-177.	1.0	36
637	Establishing A New Option for Target-organ Protection: Rationale for ARB Plus ACE Inhibitor Combination Therapy. American Journal of Hypertension, 2008, 21, 248-256.	1.0	14

#	Article	IF	Citations
638	Management of Coronary Artery Disease in Type 2 Diabetes Mellitus. , 2008, , 289-319.		1
639	The Hemoglobin A1c Level as a Progressive Risk Factor for Cardiovascular Death, Hospitalization for Heart Failure, or Death in Patients With Chronic Heart Failure. Archives of Internal Medicine, 2008, 168, 1699.	4.3	194
640	Which strategy in inhibition of the renin-angiotensin system is the most efficient for heart failure?. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2008, 9, 184-185.	1.0	0
641	Effects of the Oral Direct Renin Inhibitor Aliskiren in Patients With Symptomatic Heart Failure. Circulation: Heart Failure, 2008, 1, 17-24.	1.6	340
642	Does the angiotensin receptor blocker telmisartan prevent morbid atherosclerotic events?. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 526-527.	3.3	0
643	ACE Inhibitors in Cardiovascular Disease â€" Unbeatable?. New England Journal of Medicine, 2008, 358, 1615-1616.	13.9	37
645	Beneficial Effects of Combination Therapy with Angiotensin II Receptor Blocker and Angiotensin-Converting Enzyme Inhibitor on Vascular Endothelial Function. Hypertension Research, 2008, 31, 1603-1610.	1.5	17
646	Comparison of Dual RAAS Blockade and Higher-Dose RAAS Inhibition on Nephropathy Progression. Postgraduate Medicine, 2008, 120, 33-42.	0.9	15
647	Challenges in advanced chronic heart failure: drug therapy. Future Cardiology, 2008, 4, 517-525.	0.5	4
648	A stunning day in hypertension research â€" Results of ONTARGET, ACCOMPLISH and HYVET. Blood Pressure, 2008, 17, 68-69.	0.7	4
649	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008â€¡. European Journal of Heart Failure, 2008, 10, 933-989.	2.9	1,893
650	Prognostic value of blood pressure measured during hospitalization after acute myocardial infarction: an insight from survival trials. Yearbook of Cardiology, 2008, 2008, 81-82.	0.0	0
652	Medical management of advanced heart failure. Progress in Palliative Care, 2008, 16, 229-240.	0.7	0
653	LESSONS FROM ONTARGET. Acta Clinica Belgica, 2008, 63, 142-151.	0.5	3
654	A Comparative Literature Review Exploring Hypertension Drugs that Lower Target Organ Damage Above and Beyond Reducing Blood Pressure Based on Research Studies Between 1992 and 2006. Current Hypertension Reviews, 2008, 4, 167-176.	0.5	1
655	Does Body Mass Index Really Matter in the Management of Heart Failure?. Cardiology in Review, 2008, 16, 124-128.	0.6	9
656	Heart failure in the elderly. Aging Health, 2008, 4, 137-155.	0.3	1
657	Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP. Journal of Hypertension, 2008, 26, 322-333.	0.3	31

#	Article	IF	Citations
658	Integrated Heart Failure Management in the Patient with Heart Failure Caused by Left Ventricular Systolic Dysfunction. , 0, , 1-30.		0
659	Carvedilol in the treatment of elderly patients with chronic heart failure. Clinical Interventions in Aging, 2008, Volume 3, 55-70.	1.3	3
660	Severe Heart Failure. , 2008, , 559-587.		0
661	Is Combined Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Therapy Safe in Heart Failure Patients?. Hospital Pharmacy, 2008, 43, 362-367.	0.4	0
662	Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy. Vascular Health and Risk Management, 0, Volume 4, 223-234.	1.0	4
663	Efeito favorÃ¡vel da terapia farmacolÃ³gica otimizada da insuficiÃªncia cardÃaca sobre as arritmias ventriculares. Arquivos Brasileiros De Cardiologia, 2008, 91, 363-9.	0.3	0
664	Results of the ONTARGET and TRANSCEND studies: an update and discussion. Vascular Health and Risk Management, 2008, , 21.	1.0	7
665	Role of Neurohormones. , 2008, , 345-366.		0
666	General Treatment of Diastolic Heart Failure. , 2008, , 415-427.		0
667	Management Strategies for Patients not Responding to CRT. , 0, , 374-387.		0
668	Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utility. Vascular Health and Risk Management, 2009, 5, 1043.	1.0	12
670	Diagnosis and Management of Heart Disease in the Elderly. , 0, , 102-122.		0
671	Candesartan cilexetil in the treatment of chronic heart failure. Vascular Health and Risk Management, 2009, 5, 257.	1.0	5
672	Comparative assessment of angiotensin receptor blockers in different clinical settings. Vascular Health and Risk Management, 2009, 5, 939.	1.0	14
673	Current controversies in drug use. European Journal of Heart Failure, Supplement, 2009, 8, i15-i20.	0.2	0
674	Management of end-stage heart failure: a perspective on the Arab Gulf states. Annals of Saudi Medicine, 2009, 29, 460-466.	0.5	4
675	Benefits of ACE Inhibitors in Diabetes. Clinical Medicine Therapeutics, 2009, 1, CMT.S2027.	0.1	8
676	Angiotensin II receptor blockers in the prevention of atrial fibrillation. Expert Opinion on Pharmacotherapy, 2009, 10, 1395-1411.	0.9	2

#	Article	IF	Citations
677	Vascular and metabolic effects of angiotensin II receptor blockers. Expert Opinion on Pharmacotherapy, 2009, 10, 173-189.	0.9	18
678	RAAS inhibition/blockade in patients with cardiovascular disease: implications of recent large-scale randomised trials for clinical practice. Heart, 2009, 95, 1205-1208.	1.2	6
679	Conivaptan: promise of treatment in heart failure. Expert Opinion on Pharmacotherapy, 2009, 10, 2161-2169.	0.9	8
680	The CHARM program: the effects of candesartan for the management of patients with chronic heart failure. Expert Review of Cardiovascular Therapy, 2009, 7, 9-16.	0.6	6
681	Heart Failure in Women: Epidemiology, Biology and Treatment. Women's Health, 2009, 5, 517-527.	0.7	27
682	2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. Circulation, 2009, 119, e391-479.	1.6	2,001
683	Dual Blockade of the Renin-Angiotensin-Aldosterone System: Beyond the ACE Inhibitor and Angiotensin-II Receptor Blocker Combination. American Journal of Hypertension, 2009, 22, 1032-1040.	1.0	46
684	The Hazards of Dual Renin-Angiotensin Blockade in Chronic Kidney Disease. Archives of Internal Medicine, 2009, 169, 1015.	4.3	11
685	2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults. Circulation, 2009, 119, 1977-2016.	1.6	1,423
686	Vascular protection: telmisartan in the ONTARGET Trial Programme. European Heart Journal Supplements, 2009, 11, F47-F53.	0.0	2
687	Heart failure burden and therapy. Europace, 2009, 11, v1-v9.	0.7	86
688	Cardiovascular protection: a breakthrough for high-risk patients. European Heart Journal Supplements, 2009, 11, F19-F26.	0.0	1
689	Clinical evidence from ONTARGET: proven cardio- and vascular protection. European Heart Journal Supplements, 2009, 11, F9-F15.	0.0	3
690	Candesartan: widening indications for this angiotensin II receptor blocker?. Expert Opinion on Pharmacotherapy, 2009, 10, 1995-2007.	0.9	5
691	Review of ONTARGET: Treating Patients at High Risk for Vascular Events with Telmisartan, Ramipril, or Both. Postgraduate Medicine, 2009, 121, 202-204.	0.9	0
692	Dual ACE-inhibition and AT1 receptor antagonism improves ventricular lusitropy without affecting cardiac fibrosis in the congenic mRen2.Lewis rat. Therapeutic Advances in Cardiovascular Disease, 2009, 3, 245-257.	1.0	8
693	Design of Combination Angiotensin Receptor Blocker and Angiotensin-Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D). Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 361-368.	2.2	111
694	Mouse strain determines the outcome of wound healing after myocardial infarction. Cardiovascular Research, 2009, 84, 273-282.	1.8	137

#	Article	IF	Citations
695	Aliskiren and the Kidney: Beyond Hypertension. Nephrology Research & Reviews, 2009, 1, 1-4.	0.2	3
696	Improvement in the management of chronic heart failure since the publication of the updated guidelines of the European Society of Cardiology. European Journal of Heart Failure, 2009, 11, 85-91.	2.9	51
698	The Renin-Angiotensin System Modulates Inflammatory Processes in Atherosclerosis: Evidence from Basic Research and Clinical Studies. Mediators of Inflammation, 2009, 2009, 1-13.	1.4	85
699	Insuficiencia cardÃaca. , 2009, , 278-291.		0
700	Combination renin-angiotensin system blockade with the renin inhibitor aliskiren in hypertension. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2009, 10, 185-189.	1.0	5
701	Direct inhibition of renin: a physiological approach to treat hypertension and cardiovascular disease. Future Cardiology, 2009, 5, 453-465.	0.5	5
703	Effects of enalapril, candesartan or both on neurohumoral activation and LV volumes and function in patients with heart failure not treated with a beta-blocker. Therapeutic Advances in Cardiovascular Disease, 2009, 3, 113-121.	1.0	14
704	Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Journal of Hypertension, 2009, 27, 2121-2158.	0.3	1,236
705	Inhibition of Tumor Necrosis Factor-Î±â€“Induced Interleukin-6 Expression by Telmisartan Through Cross-Talk of Peroxisome Proliferator-Activated Receptor-Î³ With Nuclear Factor ÎºB and CCAAT/Enhancer-Binding Protein-Î². Hypertension, 2009, 53, 798-804.	1.3	47
706	Predictors of Development of Diabetes in Patients With Chronic Heart Failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Diabetes Care, 2009, 32, 915-920.	4.3	61
707	Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. European Journal of Heart Failure, 2009, 11, 170-177.	2.9	326
708	Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET): Implications for Reduced Cardiovascular Risk. Preventive Cardiology, 2009, 12, 43-50.	1.1	14
709	Reninâ€Angiotensinâ€Aldosterone System Inhibition and Improvement in Glucose Tolerance. Journal of Clinical Hypertension, 2009, 11, .	1.0	1
710	Is Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Combination Therapy Better Than Monotherapy and Safe in Patients With CKD?. American Journal of Kidney Diseases, 2009, 53, 192-196.	2.1	13
711	Dual Blockade of the Renin-Angiotensin System for Cardiorenal Protection: An Update. American Journal of Kidney Diseases, 2009, 53, 332-345.	2.1	32
712	Recent Advances in Cardiovascular Risk Reduction: Implications of ONTARGET. Clinical Cornerstone, 2009, 9, S18-S26.	1.0	4
713	Clinical assessment of atherosclerotic parameters and cardiac function in chronic hemodialysis patients. Clinical and Experimental Nephrology, 2009, 13, 651-658.	0.7	10
714	Effects of candesartan cilexetil â€œadd-onâ€•treatment in congestive heart failure outpatients in daily practice. Clinical Research in Cardiology, 2009, 98, 379-389.	1.5	7

#	Article	IF	Citations
715	Heart failure exacerbation leading to hospital admission: a cross-sectional study. International Journal of Clinical Pharmacy, 2009, 31, 572-579.	1.4	5
716	Renal effects of dual reninâ€“angiotensinâ€“aldosterone system blockade in patients with diabetic nephropathy. International Urology and Nephrology, 2009, 41, 119-126.	0.6	8
717	Lower extremity edema and pulmonary hypertension in morbidly obese patients with obstructive sleep apnea. Sleep and Breathing, 2009, 13, 25-34.	0.9	15
718	Update on renin-angiotensin-aldosterone blockade in heart failure. Current Treatment Options in Cardiovascular Medicine, 2009, 11, 455-466.	0.4	1
719	The role of ACE inhibitors and angiotensin receptor blockers in the treatment of hypertension and cardiovascular disease. Current Cardiovascular Risk Reports, 2009, 3, 255-263.	0.8	0
721	Herzinsuffizienztherapie im Lichte von ONTARGET und TRANSCEND. Clinical Research in Cardiology Supplements, 2009, 4, 192-195.	2.0	0
722	Lessons learned from the ONTARGET and TRANSCEND trials. Current Atherosclerosis Reports, 2009, 11, 371-376.	2.0	6
723	ONTARGET: Use of ramipril, telmisartan, or both in patients with high cardiovascular risks. Current Diabetes Reports, 2009, 9, 185-187.	1.7	1
724	Multiple renin-angiotensin-aldosterone-blocking agents in heart failure: How much is too much?. Current Heart Failure Reports, 2009, 6, 112-116.	1.3	2
725	Pharmacologic management of patients with both heart failure and diabetes. Current Heart Failure Reports, 2009, 6, 126-132.	1.3	3
726	Hyperkalemia in patients with heart failure: Incidence, prevalence, and management. Current Heart Failure Reports, 2009, 6, 272-280.	1.3	49
727	Outcomes of antiproteinuric RAAS blockade: High-dose compared with dual therapy. Current Hypertension Reports, 2009, 11, 345-353.	1.5	6
728	Dual renin-angiotensin system blockade in the ONTARGET study: Clinically relevant risk for the kidney?. Current Hypertension Reports, 2009, 11, 375-381.	1.5	2
729	Effects of AT1â€•and Î²â€•adrenergic receptor antagonists on TGFâ€Î²1â€•induced fibrosis in transgenic mice. European Journal of Clinical Investigation, 2009, 39, 851-859.	1.7	29
730	Inhibiting the reninâ€“angiotensin system: Why and in which patients. Journal of the American Academy of Nurse Practitioners, 2009, 21, 66-75.	1.4	2
731	Hypertension strategies in the third millennium: conservatism, evidence and the folly of speculation. International Journal of Clinical Practice, 2009, 63, 7-14.	0.8	1
732	Targetâ€•organ protection with combination reninâ€•angiotensinâ€•system blockade. Clinical Cardiology, 2009, 32, 4-12.	0.7	7
733	Angiotensin Receptor Blocker Therapy for Heart Failure Patients: Is Combination Treatment a Feasible Prospect?. Clinical Cardiology, 2009, 32, 513-518.	0.7	3

#	Article	IF	Citations
734	Reducing the risks of sudden death and heart failure post myocardial infarction: Utility of optimized pharmacotherapy. Clinical Cardiology, 2005, 28, 19-27.	0.7	7
735	Practical algorithms for pharmacologic management of the post myocardial infarction patient. Clinical Cardiology, 2009, 28, 28-37.	0.7	10
736	Reninâ€“Angiotensin Blockade: Therapeutic Agents. , 2009, , 189-201.		1
737	A Synthetic Non-degradable Polyethylene Glycol Hydrogel Retards Adverse Post-infarct Left Ventricular Remodeling. Journal of Cardiac Failure, 2009, 15, 629-636.	0.7	137
739	Evolving understanding of the renin-angiotensin-aldosterone system: Pathophysiology and targets for therapeutic intervention. American Heart Journal, 2009, 157, S1-S6.	1.2	23
740	Combined renin-angiotensin-aldosterone system inhibition in patients with chronic heart failure secondary to left ventricular systolic dysfunction. American Heart Journal, 2009, 157, S17-S23.	1.2	17
741	Management of ST-segment elevation myocardial infarction: Comparison of the updated guidelines from North America and Europe. American Heart Journal, 2009, 158, 695-705.	1.2	13
742	The Management of Hyperkalemia in Patients with Cardiovascular Disease. American Journal of Medicine, 2009, 122, 215-221.	0.6	43
743	A review of heart failure management in the elderly population. American Journal of Geriatric Pharmacotherapy, 2009, 7, 233-249.	3.0	62
744	Heart Failure Guidelines and Implications for Surgically Treating Heart Failure. AORN Journal, 2009, 90, 874-892.	0.2	2
747	Blocking the reninâ€“angiotensin system: dual- versus mono-therapy. Expert Review of Cardiovascular Therapy, 2009, 7, 667-674.	0.6	16
748	The Sudden Demise of Dual Renin-Angiotensin System Blockade or the Soft Science of the Surrogate End Point. Journal of the American College of Cardiology, 2009, 53, 468-470.	1.2	63
749	2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults. Journal of the American College of Cardiology, 2009, 53, 1343-1382.	1.2	212
750	Dual Renin-Angiotensin System Blockade in Heart Failure. Journal of the American College of Cardiology, 2009, 54, 278.	1.2	1
751	Molecular Imaging for Efficacy of Pharmacologic Intervention in Myocardial Remodeling. JACC: Cardiovascular Imaging, 2009, 2, 187-198.	2.3	59
753	Effect on the Atherogenic Marker Plasminogen Activator Inhibitor Type-1 of Addition of the ACE Inhibitor Imidapril to Angiotensin II Type 1 Receptor Antagonist Therapy in Hypertensive Patients with Abnormal Glucose Metabolism. Clinical Drug Investigation, 2009, 29, 811-819.	1.1	1
754	Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Pressure, 2009, 18, 308-347.	0.7	351
755	Left ventricular diastolic dysfunction of the cardiac surgery patient; a point of view for the cardiac surgeon and cardio-anesthesiologist. Journal of Cardiothoracic Surgery, 2009, 4, 67.	0.4	34

#	Article	IF	Citations
756	Cardiovascular Endocrinology. , 2009, , .		3
757	Telmisartan prevents cardiovascular events in a broad group of at-risk patients. Expert Opinion on Pharmacotherapy, 2009, 10, 3113-3117.	0.9	6
758	ACE inhibitors, angiotensin receptor blockers and direct renin inhibitors in combination: a review of their role after the ONTARGET trial. Current Medical Research and Opinion, 2009, 25, 2287-2301.	0.9	29
759	Standards of Medical Care in Diabetesâ€"2009. Diabetes Care, 2009, 32, S13-S61.	4.3	1,606
760	Efficacy in angiotensin receptor blockade: a comparative review of data with olmesartan. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2009, 10, 147-156.	1.0	18
761	ONTARGET, TRANSCEND and PROFESS â€“ Clarifying, confusing or misleading. Blood Pressure, 2009, 18, 4-6.	0.7	3
762	Management of hypertension in chronic heart failure. Expert Review of Cardiovascular Therapy, 2009, 7, 423-433.	0.6	11
763	Recent changes in the landscape of combination RAS blockade. Expert Review of Cardiovascular Therapy, 2009, 7, 1373-1384.	0.6	24
764	Cardiovascular Outcomes in High-Risk Patients without Heart Failure Treated with ARBs. American Journal of Cardiovascular Drugs, 2009, 9, 29-43.	1.0	16
765	On Target to Dual Block RAS?. Angiology, 2009, 60, 739-749.	0.8	2
766	Immunoadsorption in patients with dilated cardiomyopathy. Atherosclerosis Supplements, 2009, 10, 126-128.	1.2	3
767	2009 Canadian Hypertension Education Program recommendations: The scientific summary â€“ an annual update. Canadian Journal of Cardiology, 2009, 25, 271-277.	0.8	35
768	The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 â€“ therapy. Canadian Journal of Cardiology, 2009, 25, 287-298.	0.8	111
769	Heart failure. Lancet, The, 2009, 373, 941-955.	6.3	152
770	Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet, The, 2009, 374, 1840-1848.	6.3	548
771	Tratamiento de la insuficiencia cardiaca crÃ³nica. Medicine, 2009, 10, 2340-2348.	0.0	0
772	2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. Journal of the American College of Cardiology, 2009, 53, e1-e90.	1.2	1,386
773	Macrovascular Complications of Diabetes Mellitus. Journal of Pharmacy Practice, 2009, 22, 135-148.	0.5	10

#	Article	IF	Citations
774	OPTIMAL MANAGEMENT OF CHRONIC HEART FAILURE IN PATIENTS WITH CHRONIC KIDNEY DISEASE. Journal of Renal Care, 2009, 35, 2-10.	0.6	1
775	Pathway for the Management of Heart Failure Complicating Acute Coronary Syndrome. , 2009, , 365-376.		0
776	USE OF ANGIOTENSIN RECEPTOR BLOCKERS AFTER ANGIOEDEMA WITH AN ANGIOTENSIN-CONVERTING ENZYME INHIBITOR. Annals of Allergy, Asthma and Immunology, 2009, 103, 83-84.	0.5	15
777	Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials. Journal of Hypertension, 2009, 27, 941-946.	0.3	29
778	Dual blockade versus single blockade of the reninâ€“angiotensin system in the light of ONTARGET. Journal of Hypertension, 2009, 27, S11-S14.	0.3	5
779	Pharmacologic therapy in patients with chronic heart failure and chronic kidney disease: a complex issue. Journal of Cardiovascular Medicine, 2009, 10, 13-21.	0.6	6
780	Perioperative Optimization of the Heart Failure Patient. International Anesthesiology Clinics, 2009, 47, 121-135.	0.3	1
781	How to achieve renal protection in the light of ONTARGET?. Journal of Hypertension, 2009, 27, S15-S17.	0.3	7
782		0.0	0
783	Post-Hospitalization Care of Patients with Acute Coronary Syndrome. , 2009, , 173-208.		0
784	Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Yearbook of Cardiology, 2009, 2009, 33-36.	0.0	0
785	Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. Yearbook of Cardiology, 2009, 2009, 28-31.	0.0	0
786	The rationale for choosing telmisartan and ramipril in the ONTARGET programme. European Heart Journal Supplements, 2009, 11, F3-F8.	0.0	3
787	Pharmacological Treatment. , 2009, , 79-96.		0
789	Are the Pleiotropic Effects of Telmisartan Clinically Relevant?. Current Pharmaceutical Design, 2009, 15, 2815-2832.	0.9	24
790	Biological Actions and Metabolism of Currently Used Pharmacological Agents for the Treatment of Congestive Heart Failure. Current Drug Metabolism, 2009, 10, 206-219.	0.7	14
791	Irbesartan and Hydrochlorothiazide Association in the Treatment of Hypertension. Current Vascular Pharmacology, 2009, 7, 120-136.	0.8	6
792	Influence of blood pressure reduction on composite cardiovascular endpoints in clinical trials. Journal of Hypertension, 2010, 28, 1356-1365.	0.3	69

#	Article	IF	Citations
793	New Strategies and Drugs in the Treatment of Hypertension: Monotherapy or Combination?. Recent Patents on Cardiovascular Drug Discovery, 2010, 5, 69-81.	1.5	4
794	How should we manage heart failure developing in patients already treated with angiotensin-converting enzyme inhibitors and beta-blockers for hypertension, diabetes or coronary disease?. Journal of Hypertension, 2010, 28, 1595-1598.	0.3	12
795	Reduced cerebrovascular remodeling and functional impairment in spontaneously hypertensive rats following combined treatment with suboptimal doses of telmisartan and ramipril: is less really more?. Journal of Hypertension, 2010, 28, 1384-1389.	0.3	3
796	Dual blockade of the reninâ€“angiotensinâ€“aldosterone system in cardiac and renal disease. Current Opinion in Nephrology and Hypertension, 2010, 19, 140-152.	1.0	27
797	Current management of pediatric dilated cardiomyopathy. Current Opinion in Cardiology, 2010, 25, 80-87.	0.8	12
798	Effects of suboptimal doses of the AT1 receptor blocker, telmisartan, with the angiotensin-converting enzyme inhibitor, ramipril, on cerebral arterioles in spontaneously hypertensive rat. Journal of Hypertension, 2010, 28, 1566-1573.	0.3	24
799	How Is Combination Therapy With ACEI and ARB Applied in Patients With Acute Myocardial Infarction?. Circulation Journal, 2010, 74, 1071-1072.	0.7	0
800	Combined Renin-Angiotensin System-Inhibition Therapy. Circulation Journal, 2010, 74, 2288-2289.	0.7	0
801	New Approaches to Blockade of the Reninâ€“Angiotensinâ€“Aldosterone System: Evidence From Randomized Controlled Trials (RCTs) of Angiotensin-Converting Enzyme Inhibitors and Angiotensin IIâ€“Receptor Blockers â€” Questions Remain Unsolved. Journal of Pharmacological Sciences, 2010, 113, 292-295.	1.1	8
802	Olmesartan Inhibits Angiotensin IIâ€“Induced Migration of Vascular Smooth Muscle Cells Through Src and Mitogen-Activated Protein Kinase Pathways. Journal of Pharmacological Sciences, 2010, 113, 161-168.	1.1	25
803	Systolic Heart Failure. New England Journal of Medicine, 2010, 362, 228-238.	13.9	395
804	Managing hyponatremia in patients with heart failure. Journal of Hospital Medicine, 2010, 5, S33-9.	0.7	1
805	Renin Inhibitors in Chronic Heart Failure: The Aliskiren Observation of Heart Failure Treatment Study in Context. Clinical Cardiology, 2010, 33, 536-541.	0.7	13
806	Spironolactone Use in Heart Failure Patients With Endâ€Stage Renal Disease on Hemodialysis: Is It Safe?. Clinical Cardiology, 2010, 33, 604-608.	0.7	33
807	Comparing angiotensin II receptor blockers on benefits beyond blood pressure. Advances in Therapy, 2010, 27, 257-284.	1.3	17
808	Early molecular imaging of interstitial changes in patients after myocardial infarction: Comparison with delayed contrast-enhanced magnetic resonance imaging. Journal of Nuclear Cardiology, 2010, 17, 1065-1072.	1.4	45
809	Effect of the cholinesterase inhibitor donepezil on cardiac remodeling and autonomic balance in rats with heart failure. Journal of Physiological Sciences, 2010, 60, 67-74.	0.9	60
810	Myocardial Ischemia in Patients with Diastolic Dysfunction and Heart Failure. Current Cardiology Reports, 2010, 12, 216-222.	1.3	28

#	Article	IF	Citations
811	Have the Renin-Angiotensin-Aldosterone System Perturbations in Cardiovascular Disease Been Exhausted?. Current Cardiology Reports, 2010, 12, 450-463.	1.3	7
812	Use of Medications to Lower Urine Protein Level in Patients With Diabetic Kidney Disease. Current Diabetes Reports, 2010, 10, 257-260.	1.7	0
813	Diabetes and Drug-Associated Hyperkalemia: Effect of Potassium Monitoring. Journal of General Internal Medicine, 2010, 25, 326-333.	1.3	61
814	Anti-hypertensive drugs and left ventricular hypertrophy: a clinical update. Internal and Emergency Medicine, 2010, 5, 469-479.	1.0	14
815	Reninâ€“angiotensinâ€“aldosterone system (RAAS) pharmacogenomics: implications in heart failure management. Heart Failure Reviews, 2010, 15, 209-217.	1.7	9
816	Heart failure: epidemiology, investigation and management. Medicine, 2010, 38, 473-478.	0.2	1
817	Diagnosis and Treatment of Heart Disease: Are Women Different From Men?. Progress in Cardiovascular Diseases, 2010, 53, 227-236.	1.6	71
818	Combination therapy in hypertension: An update. Diabetology and Metabolic Syndrome, 2010, 2, 44.	1.2	64
819	Telmisartan in High-Risk Cardiovascular Patients. American Journal of Cardiology, 2010, 105, 36A-43A.	0.7	3
820	Circulatory therapeutics: use of antihypertensive agents and their effects on the vasculature. Journal of Cellular and Molecular Medicine, 2010, 14, 1018-29.	1.6	24
821	Angiotensin Receptor Blockers, Cancer, and Smoking. Journal of Clinical Hypertension, 2010, 12, 945-948.	1.0	2
825	Increasingly restrictive definitions of hyperkalemia outcomes in a database study: effect on incidence estimates. Pharmacoepidemiology and Drug Safety, 2010, 19, 19-25.	0.9	12
826	Reninâ€“angiotensinâ€“aldosterone system blockade for cardiovascular diseases: current status. British Journal of Pharmacology, 2010, 160, 1273-1292.	2.7	277
827	Do we need more than just powerful blood pressure reductions? New paradigms in end-organ protection. Vascular Health and Risk Management, 2010, 6, 479.	1.0	5
828	Update on the role of candesartan in the optimal management of hypertension and cardiovascular risk reduction. Integrated Blood Pressure Control, 2010, 3, 45.	0.4	3
829	Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination. Vascular Health and Risk Management, 2010, 6, 549.	1.0	35
830	Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly. Clinical Interventions in Aging, 2010, 5, 403.	1.3	19
831	Impact of telmisartan in modifying vascular risk. Integrated Blood Pressure Control, 2010, 3, 81.	0.4	1

#	Article	IF	Citations
832	Meta-Analysis of Combined Therapy with Angiotensin Receptor Antagonists versus ACE Inhibitors Alone in Patients with Heart Failure. PLoS ONE, 2010, 5, e9946.	1.1	43
833	Mineralocorticoid receptor, CYP11B2 mRNA expression, and atrial matrix remodelling in patients with atrial fibrillation. Acta Cardiologica, 2010, 65, 527-533.	0.3	9
834	Cardio classics revisited – focus on the role of candesartan. Vascular Health and Risk Management, 2010, 6, 1047.	1.0	2
835	AdiÃ§Ã£o de Bloqueador do receptor de angiotensina II na insuficiÃªncia cardÃaca descompensada. Arquivos Brasileiros De Cardiologia, 2010, 94, 235-238.	0.3	2
836	Aliskiren and valsartan combination therapy for the management of hypertension. Vascular Health and Risk Management, 2010, 6, 711.	1.0	14
837	COMPARISON OF NEW GENERIC AND ORIGINAL RAMIPRIL IN PATIENTS WITH ARTERIAL HYPERTENSION AND HIGH CARDIOVASCULAR RISK. Rational Pharmacotherapy in Cardiology, 2010, 6, 20-28.	0.3	2
838	Pharmacologic Interactions in the CICU. , 2010, , 516-531.		1
839	Comparison of once-daily versus twice-daily dosing of valsartan in patients with chronic stable heart failure. Vascular Health and Risk Management, 2010, , 449.	1.0	0
840	InsuficiÃªncia cardÃaca com fraÃ§Ã£o de ejeÃ§Ã£o normal. Arquivos Brasileiros De Cardiologia, 2010, 94, 652-60, 694-702.	0.3	10
841	Impact of â€˜â€˜Off-Labelâ€™â€™ Use of Ivabradine on Exercise Capacity, Gas Exchange, Functional Class, Quality of Life, and Neurohormonal Modulation in Patients With Ischemic Chronic Heart Failure. Journal of Cardiovascular Pharmacology and Therapeutics, 2010, 15, 349-355.	1.0	49
842	Cardiology: Treatment of Systolic Heart Failure in the Elderly: An Evidence-Based Review. Annals of Pharmacotherapy, 2010, 44, 1604-1614.	0.9	12
843	Hypertension Guidelines for Pharmacists: 2009 Update. Canadian Pharmacists Journal, 2010, 143, 20-27.	0.4	0
844	Compared with low-dose losartan, high-dose losartan decreases risk of death or hospital admission for heart failure in people with heart failure who are intolerant to ACE inhibitors. Evidence-Based Medicine, 2010, 15, 51-52.	0.6	0
845	Cardiovascular Risk Reduction with Renin-Angiotensin Aldosterone System Blockade. Nursing Research and Practice, 2010, 2010, 1-7.	0.4	2
846	Treatment of Chronic Heart Failure. , 2010, , 379-392.		1
847	Radionuclide Imaging of Angiotensin II Type 1 Receptor Upregulation After Myocardial Ischemiaâ€“Reperfusion Injury. Journal of Nuclear Medicine, 2010, 51, 1956-1961.	2.8	41
848	Potassium Homeostasis and Renin-Angiotensin-Aldosterone System Inhibitors. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 531-548.	2.2	196
849	Evidence for the efficacy of ARBs across the cardiovascular continuum. Current Medical Research and Opinion, 2010, 26, 1203-1218.	0.9	13

#	Article	IF	Citations
850	Is the effect of angiotensin receptor blockade in patients with heart failure modified by treatment with aspirin? The answer is not so clear!. European Journal of Heart Failure, 2010, 12, 639-641.	2.9	0
851	Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure â€“ Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure, 2010, 12, 738-745.	2.9	15
852	Understanding the risk of hyperkalaemia in heart failure: role of aldosterone antagonism. Postgraduate Medical Journal, 2010, 86, 136-142.	0.9	20
853	Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension. Journal of Human Hypertension, 2010, 24, 263-273.	1.0	53
855	The apelinergic system: a promising therapeutic target. Expert Opinion on Therapeutic Targets, 2010, 14, 633-645.	1.5	37
856	Novel strategies in diastolic heart failure. Heart, 2010, 96, 1147-1153.	1.2	18
857	HEAAL: the final chapter in the story of angiotensin receptor blockers in heart failureâ€"lessons learnt from a decade of trials. European Journal of Heart Failure, 2010, 12, 99-103.	2.9	5
858	Feasibility of combined treatment with enalapril and candesartan in advanced chronic kidney disease. Nephrology Dialysis Transplantation, 2010, 25, 842-847.	0.4	20
859	Arzneiverordnungs-Report 2010. , 2010, , .		41
860	From Evidence to Rationale: Cardiovascular Protection by Angiotensin II Receptor Blockers Compared with Angiotensin-Converting Enzyme Inhibitors. Cardiology, 2010, 117, 163-173.	0.6	11
861	Of fads, fashion, surrogate endpoints and dual RAS blockade. European Heart Journal, 2010, 31, 2205-2208.	1.0	31
862	Systolic Heart Failure. New England Journal of Medicine, 2010, 362, 1545-1546.	13.9	2
863	Discharge use of angiotensin receptor blockers provides comparable effects with angiotensin-converting enzyme inhibitors on outcomes in patients hospitalized for heart failure. Hypertension Research, 2010, 33, 197-202.	1.5	12
864	Have we fallen off target with concerns surrounding dual RAAS blockade?. Kidney International, 2010, 78, 539-545.	2.6	15
865	Heart failure in the elderly: advances and challenges. Expert Review of Cardiovascular Therapy, 2010, 8, 695-715.	0.6	22
866	Prevention, Diagnosis, and Treatment of Hypertensive Heart Disease. Cardiology Clinics, 2010, 28, 675-691.	0.9	32
867	Clinical Update on Nursing Home Medicine: 2010. Journal of the American Medical Directors Association, 2010, 11, 543-566.	1.2	6
868	Myocardial Contractile Inefficiency and Dyssynchrony in Heart Failure With Preserved Ejection Fraction and Narrow QRS Complex. Journal of the American Society of Echocardiography, 2010, 23, 201-206.	1.2	19

#	Article	IF	Citations
869	Effects of Telmisartan Added to Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Hemodialysis Patients With Chronic Heart Failure. Journal of the American College of Cardiology, 2010, 56, 1701-1708.	1.2	150
870	Treating Heart Failure on Dialysis. Journal of the American College of Cardiology, 2010, 56, 1709-1711.	1.2	4
871	Quantitative Evaluation of Drug or Device Effects on Ventricular Remodeling as Predictors of Therapeutic Effects on Mortality in Patients With Heart Failure and Reduced Ejection Fraction. Journal of the American College of Cardiology, 2010, 56, 392-406.	1.2	387
872	Digoxin therapy: A persisting interest despite contrary winds. Archives of Cardiovascular Diseases, 2010, 103, 281-284.	0.7	13
873	Optimal Antagonism of the Renin-Angiotensin-Aldosterone System. Drugs, 2010, 70, 1215-1230.	4.9	37
874	Is addition of angiotensin receptor blockade superior to increasing ACE inhibitor dose in patients with heart failure?. International Journal of Cardiology, 2010, 139, 309-312.	0.8	2
875	Low-dose angiotensin receptor blockers as an alternative to ACE-inhibitors increase the risk of appropriate ICD interventions in heart failure. International Journal of Cardiology, 2010, 145, 522-524.	0.8	2
876	Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the reninâ€“angiotensinâ€“aldosterone system: Antihypertensive effects and benefits beyond BP control. Life Sciences, 2010, 86, 289-299.	2.0	39
878	HFSA 2010 Comprehensive Heart Failure Practice Guideline. Journal of Cardiac Failure, 2010, 16, e1-e2.	0.7	1,086
880	Section 8: Disease Management, Advance Directives, and End-of-Life Care in Heart Failure Education and Counseling. Journal of Cardiac Failure, 2010, 16, e98-e114.	0.7	3
882	Does aspirin use adversely influence intermediate-term postdischarge outcomes for hospitalized patients who are treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers? Findings from Organized Program to Facilitate Life-Saving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). American Heart Journal, 2010, 159, 222-230.e2.	1.2	15
883	Chronic Cardiac Failure. , 2010, , 272-285.		1
884	Telmisartan: a review of its pharmacodynamic and pharmacokinetic properties. Expert Opinion on Drug Metabolism and Toxicology, 2010, 6, 863-871.	1.5	49
885	The evolution of angiotensin blockade in the management of cardiovascular disease. Canadian Journal of Cardiology, 2010, 26, 7E-13E.	0.8	10
886	Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncology, The, 2010, 11, 627-636.	5.1	415
887	Standards of Medical Care in Diabetesâ€”2010. Diabetes Care, 2010, 33, S11-S61.	4.3	2,863
888	Outpatient Management of Pediatric Heart Failure. Heart Failure Clinics, 2010, 6, 515-529.	1.0	12
890	Adjunctive Pharmacologic Therapies in Acute Myocardial Infarction. , 2010, , 145-182.		1

#	Article	IF	Citations
891	Renin-angiotensin-aldosterone system blockade in high-risk hypertensive patients: current approaches and future trends. Therapeutic Advances in Cardiovascular Disease, 2010, 4, 359-373.	1.0	8
892	Candesartan in the treatment of hypertension: what have we learnt in the last decade?. Expert Opinion on Drug Safety, 2011, 10, 957-968.	1.0	7
893	The Role of Direct Renin Inhibition in Clinical Practice. American Journal of Cardiovascular Drugs, 2011, 11, 303-315.	1.0	6
894	Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study. European Journal of Heart Failure, 2011, 13, 755-764.	2.9	19
895	CONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the reninâ€“angiotensinâ€“aldosterone system the cornerstone of therapy for systolic heart failure. European Journal of Heart Failure, 2011, 13, 929-936.	2.9	67
896	Chronic Heart Failure in Older Adults. Medical Clinics of North America, 2011, 95, 439-461.	1.1	15
897	Natural History of End-stage LV Dysfunction: Has It Improved from the Classic Franciosa and Cohn Graph?. Cardiology Clinics, 2011, 29, 485-495.	0.9	2
898	Left Ventricular Remodeling in Heart Failure. JACC: Cardiovascular Imaging, 2011, 4, 98-108.	2.3	604
899	Heart Failure (Part 2). European Geriatric Medicine, 2011, 2, 237-244.	1.2	0
900	ABC de la insuficiencia cardiaca. Seminarios De La Fundaciâˆšâ‰¥n EspaâˆšÂ±ola De Reumatologâˆšâ‰¤a, 2011, 12, 42-49.	0.1	1
901	Long-term clinical and economic outcomes associated with angiotensin II receptor blocker use in hypertensive patients. Current Medical Research and Opinion, 2011, 27, 1719-1731.	0.9	8
902	Telmisartan. Drugs, 2011, 71, 651-677.	4.9	14
903	Chronic Heart Failure. American Journal of Cardiovascular Drugs, 2011, 11, 153-171.	1.0	65
904	Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. New England Journal of Medicine, 2011, 364, 11-21.	13.9	2,491
907	Type 2 Diabetes, Pre-Diabetes, and the Metabolic Syndrome. , 2011, , .		11
910	Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. American Heart Journal, 2011, 162, 900-906.	1.2	143
911	Renin Angiotensin Aldosterone System Blockade: Little to No Rationale for ACE Inhibitor and ARB Combinations. American Journal of Medicine, 2011, 124, 15-19.	0.6	17
912	Unique â€œdelta lockâ€•structure of telmisartan is involved in its strongest binding affinity to angiotensin II type 1 receptor. Biochemical and Biophysical Research Communications, 2011, 404, 434-437.	1.0	34

#	Article	IF	Citations
913	Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324â€˜168 participants from randomised trials. Lancet Oncology, The, 2011, 12, 65-82.	5.1	332
914	Long-Term Survival of Routine Implantable Cardioverter/Defibrillator Recipients Appears to be Significantly Impaired with Concomitant Diuretics and Improved with Aldosterone Antagonists. Cardiovascular Therapeutics, 2011, 29, 243-250.	1.1	1
915	Republished technology and guidelines: The diagnosis and management of chronic heart failure: review following the publication of the NICE guidelines. Postgraduate Medical Journal, 2011, 87, 841-846.	0.9	2
916	The diagnosis and management of chronic heart failure: review following the publication of the NICE guidelines. Heart, 2011, 97, 411-416.	1.2	35
918	Tratamiento de la insuficiencia cardiaca. Medicine, 2011, 10, 6240-6248.	0.0	0
919	Medical therapy for chronic heart failure. Lancet, The, 2011, 378, 713-721.	6.3	73
920	Heart Failure as a Consequence of Dilated Cardiomyopathy. , 2011, , 372-394.		2
921	Cardiovascular outcomes with angiotensin II receptor blockers: clinical implications of recent trials. Vascular Health and Risk Management, 2011, 7, 391.	1.0	6
922	Angiotensin II type 1 receptor antagonists in the treatment of hypertension in elderly patients: focus on patient outcomes. Patient Related Outcome Measures, 2011, 2, 27.	0.7	6
923	HospitalizaÃ§Ã£o e mortalidade por insuficiÃªncia cardÃaca em hospitais pÃºblicos no municÃpio de SÃ£o Paulo. Arquivos Brasileiros De Cardiologia, 2011, 97, 402-407.	0.3	22
924	Critical review of cancer risk associated with angiotensin receptor blocker therapy. Vascular Health and Risk Management, 2011, 7, 741.	1.0	11
925	Molecular Basis for Heart Failure. , 2011, , 7-31.		1
926	A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors. Vascular Health and Risk Management, 2011, 7, 297.	1.0	20
927	Heart Failure in Special Populations. , 2011, , 716-727.		0
928	Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T). Vascular Health and Risk Management, 2011, 7, 85.	1.0	8
929	Polypharmacy in heart failure: A growing challenge. British Journal of Cardiac Nursing, 2011, 6, 214-220.	0.0	6
930	Differential clinical profile of candesartan compared to other angiotensin receptor blockers. Vascular Health and Risk Management, 2011, 7, 749.	1.0	29
931	Summary of AHRQ's Comparative Effectiveness Review of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Added to Standard Medical Therapy for Treating Stable Ischemic Heart Disease. Journal of Managed Care Pharmacy, 2011, 17, 1-15.	2.2	10

#	Article	IF	Citations
932	Telmisartan and cardioprotection. Vascular Health and Risk Management, 2011, 7, 677.	1.0	9
933	Effects of Olmesartan on the Renin-angiotensin-aldosterone System for Patients with Essential Hypertension after Cardiac Surgeryâ€"Investigation Using a Candesartan Change-over Studyâ€". Annals of Thoracic and Cardiovascular Surgery, 2011, 17, 487-493.	0.3	11
934	Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials. BMJ: British Medical Journal, 2011, 342, d2234-d2234.	2.4	121
935	Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer. , 2011, , CD008011.		23
936	Management of Chronic Heart Failure in Adults: Synopsis of the National Institute for Health and Clinical Excellence Guideline. Annals of Internal Medicine, 2011, 155, 252.	2.0	49
937	Protecting the kidneys in lupus nephritis. International Journal of Clinical Rheumatology, 2011, 6, 529-546.	0.3	11
938	Costarring Statins With ARBs. Circulation Journal, 2011, 75, 540-541.	0.7	0
939	Impact of recent landmark clinical trials on hypertension treatment. Clinical Investigation, 2011, 1, 1141-1154.	0.0	3
941	In hemodialysis patients with CHF, adding telmisartan to standard ACE inhibitors reduced CHD mortality and admissions. Annals of Internal Medicine, 2011, 154, JC5.	2.0	0
942	Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals. Journal of Hypertension, 2011, 29, 623-635.	0.3	171
943	Trends in coâ€prescribing of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in Ireland. British Journal of Clinical Pharmacology, 2011, 71, 458-466.	1.1	9
944	Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis. International Journal of Clinical Practice, 2011, 65, 253-263.	0.8	23
945	Easy money?: Health cost savings resulting from the switch from a branded drug to a low-cost generic drug in the same class. International Journal of Clinical Practice, 2011, 65, 242-244.	0.8	2
946	Pharmacologic Therapy for New York Heart Association Class IV Heart Failure. Congestive Heart Failure, 2011, 17, 213-219.	2.0	7
947	Value of Angiotensin Receptor Blocker Therapy in Diabetes. Journal of Clinical Hypertension, 2011, 13, 290-295.	1.0	6
948	Angiotensin-Converting Enzyme Inhibitors. Journal of Clinical Hypertension, 2011, 13, 667-675.	1.0	83
949	Reducing Cardiorenal Risk Through Combination Therapy With a Direct Renin Inhibitor. Journal of Clinical Hypertension, 2011, 13, 848-855.	1.0	4
950	Exercise Training in Congestive Heart Failure: Risks and Benefits. Progress in Cardiovascular Diseases, 2011, 53, 419-428.	1.6	56

#	Article	IF	Citations
951	Geographic Variation in Cardioprotective Antihypertensive Medication Usage in Dialysis Patients. American Journal of Kidney Diseases, 2011, 58, 73-83.	2.1	24
952	En la prÃ¡ctica clÃ¬nica, el tratamiento combinado con IECA y ARA-II aumenta el riesgo de insuficiencia renal, hiperpotasemia y mortalidad en pacientes mayores. FMC Formacion Medica Continuada En Atencion Primaria, 2011, 18, 459.	0.0	0
954	Hyperkalemia and Renal Function During Monotherapy and Dual Renin-Angiotensin Blockade in the Community Setting. Clinical Therapeutics, 2011, 33, 456-464.	1.1	14
955	Retrospective Analysis of Real-World Efficacy of Angiotensin Receptor Blockers Versus Other Classes of Antihypertensive Agents in Blood Pressure Management. Clinical Therapeutics, 2011, 33, 1190-1203.	1.1	15
956	Exploring the potential of telmisartan in chronic constriction injury-induced neuropathic pain in rats. European Journal of Pharmacology, 2011, 667, 215-221.	1.7	34
957	Irbesartan in Patients with Atrial Fibrillation. New England Journal of Medicine, 2011, 364, 928-938.	13.9	220
958	An overview of candesartan in clinical practice. Expert Review of Cardiovascular Therapy, 2011, 9, 975-982.	0.6	9
959	The vagus nerve and autonomic imbalance in heart failure: past, present, and future. Heart Failure Reviews, 2011, 16, 97-99.	1.7	11
960	Rationale for Combining a Direct Renin Inhibitor with other Renin- Angiotensin System Blockers. Focus on Aliskiren and Combinations. Cardiovascular Drugs and Therapy, 2011, 25, 87-97.	1.3	9
961	Effect of Aliskiren in Patients with Heart Failure According to Background Dose of ACE Inhibitor: A Retrospective Analysis of the Aliskiren Observation of Heart Failure Treatment (ALOFT) Trial. Cardiovascular Drugs and Therapy, 2011, 25, 315-321.	1.3	6
962	Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia, 2011, 54, 2978-2986.	2.9	211
963	Cognitive enhancement following acute losartan in normotensive young adults. Psychopharmacology, 2011, 217, 51-60.	1.5	29
964	Mineralocorticoid-receptor Antagonists in Heart Failure: A Tale of Serendipity and Success. Current Heart Failure Reports, 2011, 8, 87-90.	1.3	0
965	Elevation of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline: a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitors. Fibrogenesis and Tissue Repair, 2011, 4, 25.	3.4	23
966	Validity of claimsâ€based definitions of left ventricular systolic dysfunction in Medicare patients. Pharmacoepidemiology and Drug Safety, 2011, 20, 700-708.	0.9	53
968	Â blockers for heart failure with reduced ejection fraction. BMJ: British Medical Journal, 2011, 343, d5603-d5603.	2.4	6
969	Reflex systemic sympathoâ€neural response to brachial adenosine infusion in treated heart failure. European Journal of Heart Failure, 2011, 13, 475-481.	2.9	4
970	Cardiovascular consequences of poor compliance to antihypertensive therapy. Blood Pressure, 2011, 20, 196-203.	0.7	11

#	Article	IF	Citations
971	Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study. European Journal of Heart Failure, 2011, 13, 107-114.	2.9	113
972	Candesartan cilexetil: an update. Expert Opinion on Pharmacotherapy, 2011, 12, 1769-1780.	0.9	5
973	Strategies to improve blood pressure control and cardiovascular outcomes in hypertensive patients. South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care, 2011, 53, 525-532.	0.2	1
974	Rationale for the use of multiple blockers of the reninâ€“angiotensinâ€“aldosterone system in specific patient populations. Therapy: Open Access in Clinical Medicine, 2011, 8, 227-236.	0.2	3
975	Combining angiotensin-receptor blockers with angiotensin-converting-enzyme inhibitors. Cmaj, 2011, 183, E309-E311.	0.9	5
976	Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. European Heart Journal, 2011, 32, 1227-1234.	1.0	130
977	Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients. Kidney International, 2011, 80, 978-985.	2.6	61
978	Translational Success Stories: Angiotensin Receptor 1 Antagonists in Heart Failure. Circulation Research, 2011, 109, 437-452.	2.0	56
979	Azilsartan. Cardiology in Review, 2011, 19, 300-304.	0.6	18
980	Association of Candesartan vs Losartan With All-Cause Mortality in Patients With Heart Failure. JAMA - Journal of the American Medical Association, 2011, 305, 175.	3.8	59
981	Effects of an N-Type Calcium Antagonist on Angiotensin II-Renin Feedback. American Journal of Nephrology, 2011, 33, 168-175.	1.4	11
982	Can ACE Inhibitors and Angiotensin Receptor Blockers Be Detrimental in CKD Patients?. Nephron Clinical Practice, 2011, 118, c407-c419.	2.3	44
983	Standards of Medical Care in Diabetesâ€”2011. Diabetes Care, 2011, 34, S11-S61.	4.3	2,448
984	Effects of valsartan and amlodipine on cardiorenal protection in Japanese hypertensive patients: the Valsartan Amlodipine Randomized Trial. Hypertension Research, 2011, 34, 62-69.	1.5	37
985	Effects of telmisartan and losartan on cardiovascular protection in Japanese hypertensive patients. Hypertension Research, 2011, 34, 1179-1184.	1.5	21
986	Combination inhibition of the reninâ€“angiotensin system: is more better?. Kidney International, 2011, 80, 245-255.	2.6	15
987	Reninâ€“angiotensin system blockade and reduction of cardiovascular risk: future perspectives. Expert Review of Cardiovascular Therapy, 2011, 9, 1585-1591.	0.6	7
988	Associations of plasma renin with 10-year cardiovascular mortality, sudden cardiac death, and death due to heart failure. European Heart Journal, 2011, 32, 2642-2649.	1.0	56

#	Article	IF	Citations
989	What Is the Prognostic Significance of Pulmonary Hypertension in Heart Failure?. Circulation: Heart Failure, 2011, 4, 541-545.	1.6	33
990	Chronic Heart Failure: We Are Fighting the Battle, but Are We Winning the War?. Scientifica, 2012, 2012, 1-16.	0.6	7
991	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European Heart Journal, 2012, 33, 1787-1847.	1.0	5,233
992	Management Strategies in Atrial Fibrillation in Patients With Heart Failure. Cardiology in Review, 2012, 20, 288-296.	0.6	3
993	Which, if any, antihypertensive agents cause cancer?. Current Opinion in Cardiology, 2012, 27, 374-380.	0.8	23
994	Regression of ECG-LVH is Associated with Lower Risk of New-Onset Heart Failure and Mortality in Patients with Isolated Systolic Hypertension; The LIFE Study. American Journal of Hypertension, 2012, 25, 1101-1109.	1.0	26
995	Angiotensin Receptor Blockers in Clinical Practice â€" Implications of the ONTARGET Study. Journal of International Medical Research, 2012, 40, 10-17.	0.4	4
996	Angiotensin receptor blockers and outcomes in real-world older patients with heart failure and preserved ejection fraction: a propensity-matched inception cohort clinical effectiveness study. European Journal of Heart Failure, 2012, 14, 1179-1188.	2.9	41
997	Aliskiren, ALTITUDE, and the implications for ATMOSPHERE. European Journal of Heart Failure, 2012, 14, 341-343.	2.9	737
999	Myofibroblasts in the Infarct Area: Concepts and Challenges. Microscopy and Microanalysis, 2012, 18, 35-49.	0.2	76
1000	New Bundled World: Quality of Care and Readmission in Diabetes Patients. Journal of Diabetes Science and Technology, 2012, 6, 563-571.	1.3	24
1002	Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade Iâ€"II essential hypertension: a randomized, double-blind clinical study. Hypertension Research, 2012, 35, 552-558.	1.5	103
1003	Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. European Heart Journal, 2012, 33, 2782-2795.	1.0	148
1004	Hypertension in the elderly. World Journal of Cardiology, 2012, 4, 135.	0.5	173
1005	Cardiology in Family Practice. , 2012, , .		3
1006	The Role of ARBs Alone or with HCTZ in the Treatment of Hypertension and Prevention of Cardiovascular and Renal Complications. Postgraduate Medicine, 2012, 124, 40-52.	0.9	11
1007	Haemodynamic effects of aliskiren in decompensated severe heart failure. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2012, 13, 128-132.	1.0	4
1008	The role of angiotensin receptor blockers in reducing the risk of cardiovascular disease. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2012, 13, 317-327.	1.0	8

#	Article	IF	Citations
1009	2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: Executive Summary. Circulation, 2012, 126, 3097-3137.	1.6	1,188
1010	2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease. Circulation, 2012, 126, e354-471.	1.6	675
1011	Should all patients at high cardiovascular risk receive renin-angiotensin system blockers?. QJM - Monthly Journal of the Association of Physicians, 2012, 105, 11-27.	0.2	15
1012	The Control of Arterial Hypertension: Epidemiological and Economic Challenge. Current Hypertension Reviews, 2012, 8, 151-158.	0.5	0
1013	Combinations of Renin-Angiotensin-Aldosterone System Antagonists:True Advantages?. Current Pharmaceutical Design, 2012, 18, 952-957.	0.9	2
1014	Effects of ACE-Inhibitors and Angiotensin Receptor Blockers on Inflammation. Current Pharmaceutical Design, 2012, 18, 4385-4413.	0.9	97
1015	Long-term follow-up of 111 patients with angiotensin-converting enzyme inhibitor-related angioedema. Yearbook of Cardiology, 2012, 2012, 45-47.	0.0	0
1016	Treatment of CSA: A Letter to the Editor by N.S. Freedman and B.A. Phillips and Responses by S. Chowdhuri, et al., on the Task Force report on the Treatment of Adult CSA. Sleep, 2012, 35, 905-7; author reply 905-7.	0.6	0
1017	Inhibition of the reninâ€“angiotensinâ€“aldosterone system. Journal of Hypertension, 2012, 30, 647-654.	0.3	15
1019	Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324â€‰168 participants from randomised trials. Yearbook of Cardiology, 2012, 2012, 22-24.	0.0	0
1020	Diagnosis of Stable Ischemic Heart Disease: Summary of a Clinical Practice Guideline From the American College of Physicians/American College of Cardiology Foundation/American Heart Association/American Association for Thoracic Surgery/Preventive Cardiovascular Nurses Association/Society of Thoracic Surgeons. Annals of Internal Medicine, 2012, 157, 729.	2.0	78
1021	Management of Stable Ischemic Heart Disease: Summary of a Clinical Practice Guideline From the American College of Physicians/American College of Cardiology Foundation/American Heart Association/American Association for Thoracic Surgery/Preventive Cardiovascular Nurses Association/Society of Thoracic Surgeons. Annals of Internal Medicine, 2012, 157, 735.	2.0	51
1022	Effects of Valsartan, an Angiotensin II Receptor Blocker, on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction Who Receive an Angiotensin-Converting Enzyme Inhibitor. Circulation Journal, 2012, 76, 1442-1451.	0.7	18
1023	Contemporary Medical Management of Systolic Heart Failure. Circulation Journal, 2012, 76, 268-277.	0.7	24
1024	Serum Blood Urea Nitrogen and Plasma Brain Natriuretic Peptide and Low Diastolic Blood Pressure Predict Cardiovascular Morbidity and Mortality Following Discharge in Acute Decompensated Heart Failure Patients. Circulation Journal, 2012, 76, 2372-2379.	0.7	30
1025	Management of Hypertension in People with Diabetes Mellitus: Translating the 2012 Canadian Hypertension Education Program Recommendations into Practice. Canadian Journal of Diabetes, 2012, 36, 345-353.	0.4	4
1026	2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: Executive Summary. Journal of the American College of Cardiology, 2012, 60, 2564-2603.	1.2	191
1027	2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease. Journal of the American College of Cardiology, 2012, 60, e44-e164.	1.2	1,423

#	Article	IF	Citations
1028	Targeting Fibrosis for the Treatment of Heart Failure: A Role for Transforming Growth Factorâ€Î². Cardiovascular Therapeutics, 2012, 30, e30-40.	1.1	112
1029	Hyperkalemia Associated with Use of Angiotensinâ€Converting Enzyme Inhibitors and Angiotensin Receptor Blockers. Cardiovascular Therapeutics, 2012, 30, e156-66.	1.1	138
1030	What Have We Learned About Patients With Heart Failure and Preserved Ejection Fraction From DIG-PEF, CHARM-Preserved, and I-PRESERVE?. Journal of the American College of Cardiology, 2012, 60, 2349-2356.	1.2	157
1031	Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes. New England Journal of Medicine, 2012, 367, 2204-2213.	13.9	1,145
1032	Cochrane Review: Medical interventions for treating anthracyclineâ€induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer. Evidence-Based Child Health: A Cochrane Review Journal, 2012, 7, 1857-1902.	2.0	1
1034	Differential effects of late-life initiation of low-dose enalapril and losartan on diastolic function in senescent Fischer 344â€‰Ã—â€‰Brown Norway male rats. Age, 2012, 34, 831-843.	3.0	6
1035	Coronary care units continue to be effective at improving patient outcomes. Australian Critical Care, 2012, 25, 143-146.	0.6	2
1036	Hemodynamic and central blood pressure differences between carvedilol and valsartan added to lisinopril at rest and during exercise stress. Journal of the American Society of Hypertension, 2012, 6, 117-123.	2.3	13
1037	Differences in mean and variability of heart rate and ambulatory rate-pressure product when valsartan or carvedilol is added to lisinopril. Journal of the American Society of Hypertension, 2012, 6, 399-404.	2.3	8
1039	Effective Strategies to Improve the Management of Heart Failure. Primary Care - Clinics in Office Practice, 2012, 39, 393-413.	0.7	6
1040	Predicting adverse events during angiotensin receptor blocker treatment in heart failure: results from the HEAAL trial. European Journal of Heart Failure, 2012, 14, 1401-1409.	2.9	25
1041	Standards of Medical Care in Diabetesâ€”2012. Diabetes Care, 2012, 35, S11-S63.	4.3	1,956
1042	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. European Journal of Heart Failure, 2012, 14, 803-869.	2.9	2,307
1044	Medication prescribing errors pertaining to cardiovascular/antidiabetic medications: a prescription audit in primary care. Fundamental and Clinical Pharmacology, 2012, 26, 410-417.	1.0	10
1045	Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treatment of ischemic heart disease: Future research needs prioritization. American Heart Journal, 2012, 163, 777-782.e8.	1.2	14
1046	Meta-Analysis of Randomized Trials of Angioedema as an Adverse Event of Reninâ€“Angiotensin System Inhibitors. American Journal of Cardiology, 2012, 110, 383-391.	0.7	145
1047	Angiotensin receptor blockers for prevention of new-onset type 2 diabetes: A meta-analysis of 59,862 patients. International Journal of Cardiology, 2012, 155, 236-242.	0.8	26
1048	Update on Aldosterone Antagonists Use in Heart Failure With Reduced Left Ventricular Ejection Fraction Heart Failure Society of America Guidelines Committee. Journal of Cardiac Failure, 2012, 18, 265-281.	0.7	50

#	Article	IF	Citations
1049	Heart Failure in Hypertension. Drugs, 2012, 72, 1373-1398.	4.9	16
1050	Candesartan plus hydrochlorothiazide: an overview of its use and efficacy. Expert Opinion on Pharmacotherapy, 2012, 13, 2699-2709.	0.9	5
1051	Angiotensin receptor blockers for heart failure. The Cochrane Library, 2021, 2021, CD003040.	1.5	56
1052	Vasodilators Across the Heart Failure Spectrum. Journal of the American College of Cardiology, 2012, 59, 452-454.	1.2	1
1053	An ACE for My Sweet Heart. Journal of the American College of Cardiology, 2012, 59, 748-750.	1.2	1
1054	Association of Heart Rate and Outcomes in a Broad Spectrum of Patients With Chronic Heart Failure. Journal of the American College of Cardiology, 2012, 59, 1785-1795.	1.2	146
1055	Effect of Fixed-Dose Combined Isosorbide Dinitrate/Hydralazine in Elderly Patients in the African-American Heart Failure Trial. Journal of Cardiac Failure, 2012, 18, 600-606.	0.7	15
1056	Renal denervation in the treatment of resistant arterial hypertension and other perspectives. Cor Et Vasa, 2012, 54, e202-e208.	0.1	1
1057	ACE inhibitors or ARBs for diabetic nephropathy: The unrelenting debate. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2012, 6, 215-217.	1.8	7
1058	Renal Dysfunction in Heart Failure. Medical Clinics of North America, 2012, 96, 955-974.	1.1	28
1060	The evolving landscape of RAAS inhibition: from ACE inhibitors to ARBs, to DRIs andâ€‰beyond. Expert Review of Cardiovascular Therapy, 2012, 10, 713-725.	0.6	10
1061	GuÃa de prÃ¡ctica clÃnica de la ESC sobre diagnÃ³stico y tratamiento de la insuficiencia cardiaca aguda y crÃ³nica 2012. Revista Espanola De Cardiologia, 2012, 65, 938.e1-938.e59.	0.6	31
1062	The Epidemiology and Pathophysiology of Heart Failure. Medical Clinics of North America, 2012, 96, 881-890.	1.1	35
1063	Manual of Outpatient Cardiology. , 2012, , .		1
1064	Should we SHIFT our thinking about digoxin? Observations on ivabradine and heart rate reduction in heart failure. European Heart Journal, 2012, 33, 1137-1141.	1.0	66
1065	Effect of Switching from Telmisartan, Valsartan, Olmesartan, or Losartan to Candesartan on Morning Hypertension. Clinical and Experimental Hypertension, 2012, 34, 86-91.	0.5	12
1068	Managing the Kidney when the Heart is Failing. , 2012, , .		0
1069	Diabetic Nephropathy: Role of Aldosterone and Benefits of Therapy with Aldosterone Receptor Blocker. , 2012, , .		0

#	Article	IF	Citations
1071	THE COMPARATIVE STUDY OF EFFICACY AND TOLERABILITY OF GENERIC AND ORIGINAL VALSARTAN AS A MONOTHERAPY OR IN COMBINATION WITH HYDROCHLOROTHIAZIDE AND BISOPROLOL IN PATIENTS WITH ARTERIAL HYPERTENSION OF 1-2 DEGREE AND METABOLIC SYNDROME. Rational Pharmacotherapy in Cardiology, 2012, 8, 17-22.	0.3	1
1072	Angiotensin receptor blockers in preventing stroke: A systematic review and meta-analysis of randomized controlled trials. African Journal of Pharmacy and Pharmacology, 2012, 6, 3256-3264.	0.2	1
1073	Structural basis for telmisartan-mediated partial activation of PPAR gamma. Hypertension Research, 2012, 35, 715-719.	1.5	49
1074	Systolic heart failure in the elderly: optimizing medical management. Heart Failure Reviews, 2012, 17, 563-571.	1.7	14
1075	Renal dysfunction in acute and chronic heart failure: prevalence, incidence and prognosis. Heart Failure Reviews, 2012, 17, 133-149.	1.7	74
1076	The Neurohormonal Network in the RAAS Can Bend Before Breaking. Current Heart Failure Reports, 2012, 9, 81-91.	1.3	9
1078	Predictors of Depressed Left Ventricular Function in Patients Presenting With ST-Elevation Myocardial Infarction. American Journal of Cardiology, 2012, 109, 327-331.	0.7	9
1079	Efficacy and Tolerability of Fimasartan, a New Angiotensin Receptor Blocker, Compared With Losartan (50/100 mg): A 12-Week, Phase III, Multicenter, Prospective, Randomized, Double-Blind, Parallel-Group, Dose Escalation Clinical Trial With an Optional 12-Week Extension Phase in Adult Korean Patients With Mild-to-Moderate Hypertension. Clinical Therapeutics, 2012, 34, 552-568.e9.	1.1	53
1080	Is there benefit in optimising heart failure treatment in over-80 year-old patients? (HF-80 study): study protocol for a randomized controlled trial. Trials, 2012, 13, 25.	0.7	10
1081	Does achieving an intensive versus usual blood pressure level prevent stroke?. Annals of Neurology, 2012, 71, 133-140.	2.8	44
1082	Extended heart failure clinic follow-up in low-risk patients: a randomized clinical trial (NorthStar). European Heart Journal, 2013, 34, 432-442.	1.0	81
1083	Tratamiento de la insuficiencia cardiaca crÃ³nica. Medicine, 2013, 11, 2146-2156.	0.0	0
1084	2013 ACCF/AHA Guideline for the Management ofÂHeartÂFailure: Executive Summary. Journal of the American College of Cardiology, 2013, 62, 1495-1539.	1.2	276
1085	Dual renin-angiotensin system inhibition for prevention of renal and cardiovascular events: do the latest trials challenge existing evidence?. Cardiovascular Diabetology, 2013, 12, 108.	2.7	9
1086	Treatment for chronic heart failure in the elderly: current practice and problems. Heart Failure Reviews, 2013, 18, 529-551.	1.7	73
1087	Medication Management of Chronic Heart Failure in Older Adults. Drugs and Aging, 2013, 30, 765-782.	1.3	18
1088	A review of current therapies used in the treatment of congestive heart failure. Expert Review of Cardiovascular Therapy, 2013, 11, 1171-1178.	0.6	8
1089	Should We Measure Quality by the Dose?. Journal of the American College of Cardiology, 2013, 62, 1802-1803.	1.2	0

#	Article	IF	Citations
1090	Traditional Heart Failure Medications and Sudden Cardiac Death Prevention. Journal of Cardiovascular Pharmacology and Therapeutics, 2013, 18, 412-426.	1.0	20
1091	Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensinâ€converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGMâ€HF). European Journal of Heart Failure, 2013, 15, 1062-1073.	2.9	358
1092	2013 ACCF/AHA Guideline for the Management of Heart Failure. Circulation, 2013, 128, e240-327.	1.6	2,335
1093	Possibilities of influencing the myocardial remodeling. Cor Et Vasa, 2013, 55, e355-e363.	0.1	0
1094	Efficacy and safety of a 60-week treatment with candesartan in Japanese patients with mild to moderate chronic heart failure. Journal of Cardiology, 2013, 61, 267-274.	0.8	2
1095	RELAX-AHF: rising from the doldrums in acute heart failure. Lancet, The, 2013, 381, 5-6.	6.3	20
1096	American Association of Clinical Endocrinologistsâ€™ Comprehensive Diabetes Management Algorithm 2013 Consensus Statement. Endocrine Practice, 2013, 19, 1-48.	1.1	132
1097	Targeting Wnt Signaling to Improve Wound Healing After Myocardial Infarction. Methods in Molecular Biology, 2013, 1037, 355-380.	0.4	10
1098	Clinical Characteristics and Outcomes of Young and Very Young Adults With Heart Failure. Journal of the American College of Cardiology, 2013, 62, 1845-1854.	1.2	84
1099	Renal dysfunction, restrictive left ventricular filling pattern and mortality risk in patients admitted with heart failure: a 7-year follow-up study. BMC Nephrology, 2013, 14, 267.	0.8	4
1101	Reninâ€“Angiotensinâ€“Aldosterone System Inhibitors in Heart Failure. Clinical Pharmacology and Therapeutics, 2013, 94, 459-467.	2.3	44
1102	The potential role of valsartan + AHU377 (LCZ696) in the treatment of heart failure. Expert Opinion on Investigational Drugs, 2013, 22, 1041-1047.	1.9	23
1103	Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (Jâ€ÐHF). European Journal of Heart Failure, 2013, 15, 110-118.	2.9	278
1104	Pharmacologic Management of Hypertension. , 2013, , 474-489.		4
1105	Dual neurohormonal intervention in CV disease: angiotensin receptor and Neprilysin inhibition. Expert Opinion on Investigational Drugs, 2013, 22, 915-925.	1.9	23
1106	When Conventional Heart Failure Therapy is Not Enough: Angiotensin Receptor Blocker, Direct Renin Inhibitor, or Aldosterone Antagonist?. Congestive Heart Failure, 2013, 19, 107-115.	2.0	25
1107	Frontiers of Therapy for Patients With Heart Failure. American Journal of Medicine, 2013, 126, 6-12.e6.	0.6	14
1108	The past, present and future of reninâ€“angiotensin aldosterone system inhibition. International Journal of Cardiology, 2013, 167, 1677-1687.	0.8	97

#	Article	IF	Citations
1109	Strategies for Management of Acute Decompensated Heart Failure. , 2013, , 281-306.		0
1110	Heart Failure in the Lifetime of Musca Domestica (The Common Housefly). JACC: Heart Failure, 2013, 1, 178-180.	1.9	13
1111	Angiotensin II receptor blockers for patients with chronic heart failure: The next step forward. Journal of Cardiology, 2013, 61, 307-308.	0.8	0
1112	Antagonistas de los receptores de la angiotensina II en el tratamiento de la hipertensiÃ³n arterial, las enfermedades cardiovasculares y las renales. Realidad y futuro. Hipertension Y Riesgo Vascular, 2013, 30, 3-10.	0.3	0
1113	Age-Dependent Effect of Left Ventricular Ejection Fraction on Long-Term Mortality in Patients With Heart Failure (from the Heart Failure Survey in ISrael). American Journal of Cardiology, 2013, 112, 1901-1906.	0.7	4
1115	Supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trialâ€"Rationale and design. Journal of Cardiology, 2013, 62, 31-36.	0.8	15
1116	Cardiorenal Syndrome in Critical Care: The Acute Cardiorenal and Renocardiac Syndromes. Advances in Chronic Kidney Disease, 2013, 20, 56-66.	0.6	59
1117	An Open-Label Dose Escalation Study to Evaluate the Safety of Administration of Nonviral Stromal Cell-Derived Factor-1 Plasmid to Treat Symptomatic Ischemic Heart Failure. Circulation Research, 2013, 112, 816-825.	2.0	127
1118	Targeting the reninâ€"angiotensinâ€"aldosterone system in heart failure. Nature Reviews Cardiology, 2013, 10, 125-134.	6.1	78
1119	Devices in the management of advanced, chronic heart failure. Nature Reviews Cardiology, 2013, 10, 98-110.	6.1	56
1120	Aldosterone Antagonists: Evidenceâ€Based Yet Underutilized Effective Heart Failure Therapy. Congestive Heart Failure, 2013, 19, 105-106.	2.0	4
1121	Standards of Medical Care in Diabetesâ€"2013. Diabetes Care, 2013, 36, S11-S66.	4.3	3,076
1122	2013 ACCF/AHA Guideline for the Management of HeartÂFailure. Journal of the American College of Cardiology, 2013, 62, e147-e239.	1.2	7,017
1123	Treatment of Congestive Heart Failure. , 2013, , 347-360.		1
1124	Hypertension Therapy. , 2013, , 561-575.		0
1125	Comparative Effectiveness Research in Heart Failure Therapies. Heart Failure Clinics, 2013, 9, 79-92.	1.0	6
1126	Effect of Aliskiren on Postdischarge Mortality and Heart Failure Readmissions Among Patients Hospitalized for Heart Failure. JAMA - Journal of the American Medical Association, 2013, 309, 1125.	3.8	297
1127	Impact of Angiotensin II Receptor Blocker Therapy (Olmesartan or Valsartan) on Coronary Atherosclerotic Plaque Volume Measured by Intravascular Ultrasound in Patients With Stable Angina Pectoris. American Journal of Cardiology, 2013, 112, 363-368.	0.7	8

#	Article	IF	Citations
1128	Meta-analyses can misdirect decisions on treatment. Nature Reviews Nephrology, 2013, 9, 311-312.	4.1	4
1129	Is there benefit in dual reninâ€“ angiotensinâ€“aldosterone system blockade? No, yes and maybe: A guide for the perplexed. Diabetes and Vascular Disease Research, 2013, 10, 193-201.	0.9	13
1130	RAAS Inhibitors and Cardiovascular Protection in Large Scale Trials. Cardiovascular Drugs and Therapy, 2013, 27, 171-179.	1.3	71
1131	Is Dual Renin-Angiotensin-System Blockade Associated With Increased Risk of Stroke?. JACC: Heart Failure, 2013, 1, 454-457.	1.9	0
1132	Hypertension in elderly. Clinical Queries Nephrology, 2013, 2, 96-102.	0.2	1
1133	Methods used for the assessment of LV systolic function: common currency or tower of Babel?. Heart, 2013, 99, 1078-1086.	1.2	54
1134	Plasma Renin and Cardiovascular Risk: What Is the Evidence for an Association?. Cardiology, 2013, 125, 50-59.	0.6	9
1135	Heart Failure. Primary Care - Clinics in Office Practice, 2013, 40, 17-42.	0.7	5
1136	Pharmacological management of chronic heart failure: old drugs, new drugs and new indications. British Journal of Hospital Medicine (London, England: 2005), 2013, 74, C18-C22.	0.2	2
1137	Cancer in cardiovascular drug trials and vice versa: a personal perspective. European Heart Journal, 2013, 34, 1089-1094.	1.0	6
1138	Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial. European Heart Journal, 2013, 34, 3117-3127.	1.0	53
1139	Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. BMJ, The, 2013, 346, f360-f360.	3.0	185
1140	Angiotensin Receptor Blockers. , 2013, , 191-203.		0
1141	Aliskiren: review of efficacy and safety data with focus on past and recent clinical trials. Therapeutic Advances in Chronic Disease, 2013, 4, 232-241.	1.1	30
1142	Association of Spironolactone Use With All-Cause Mortality in Heart Failure. Circulation: Heart Failure, 2013, 6, 174-183.	1.6	38
1143	Impact of Race on Cumulative Exposure to Antihypertensive Medications in Dialysis. American Journal of Hypertension, 2013, 26, 234-242.	1.0	5
1144	Complete Reninâ€“Angiotensinâ€“Aldosterone System (RAAS) Blockade in High-Risk Patients. Hypertension, 2013, 62, 444-449.	1.3	9
1145	Pharmacologic Management of Heart Failure in the Ambulatory Setting. , 2013, , 241-269.		1

#	Article	IF	Citations
1146	Choice of anti-hypertensive agents in diabetic subjects. Diabetes and Vascular Disease Research, 2013, 10, 385-396.	0.9	17
1147	Interaction between baseline and early worsening of renal function and efficacy of renin-angiotensin-aldosterone system blockade in patients with heart failure: insights from the Val-HeFT study. European Journal of Heart Failure, 2013, 15, 1236-1244.	2.9	51
1148	Reninâ€“angiotensin system blockade in heart failure patients on longâ€term haemodialysis in Taiwan. European Journal of Heart Failure, 2013, 15, 1194-1202.	2.9	21
1149	Implementation of a pharmacist-managed heart failure medication titration clinic. American Journal of Health-System Pharmacy, 2013, 70, 1070-1076.	0.5	51
1150	Angiotensin II and Oxidative Stress in the Failing Heart. Antioxidants and Redox Signaling, 2013, 19, 1095-1109.	2.5	93
1151	Dual RAS blockadeâ€”unresolved controversy?. Nature Reviews Nephrology, 2013, 9, 640-640.	4.1	1
1152	Inhibition of Renin-Angiotensin System. Journal of Investigative Medicine, 2013, 61, 551-557.	0.7	18
1153	Olmesartan-based therapies. Journal of Hypertension, 2013, 31, S13-S17.	0.3	11
1154	Heart Failure in Hypertension. , 2013, , 262-269.		0
1155	Heart Failure in Women. , 2013, , 1055-1068.		0
1156	Management of heart failure. Medical Journal of Australia, 2013, 199, 334-339.	0.8	34
1157	Angiotensin receptor blockers as an alternative in heart failure. NursePrescribing, 2014, 12, 393-399.	0.1	0
1158	Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2014, 7, 169.	1.1	135
1159	Current Status of Heart Transplantation. , 2014, , 403-423.		0
1160	Clinical Relevance of Local Renin Angiotensin Systems. Frontiers in Endocrinology, 2014, 5, 113.	1.5	54
1161	Additive effects of cilnidipine, an L-/N-type calcium channel blocker, and an angiotensin II receptor blocker on reducing cardiorenal damage in Otsuka Long-Evans Tokushima Fatty rats with type 2 diabetes mellitus. Drug Design, Development and Therapy, 2014, 8, 799.	2.0	6
1162	Stage B: What is the Evidence for Treatment of Asymptomatic Left Ventricular Dysfunction?. Current Cardiology Reviews, 2014, 11, 18-22.	0.6	12
1165	Relationship between myocardial perfusion abnormalities and contractile impairment in anginal patients. Journal of Nuclear Cardiology, 2014, 21, 1181-1190.	1.4	4

#	Article	IF	Citations
1166	Tacrolimus-induced hypertension and nephrotoxicity in Fawn-Hooded rats are attenuated by dual inhibition of reninâ€“angiotensin system. Hypertension Research, 2014, 37, 724-732.	1.5	19
1167	Insuficiencia cardÃaca. FMC Formacion Medica Continuada En Atencion Primaria, 2014, 21, 9-36.	0.0	0
1168	Non-canonical signalling and roles of the vasoactive peptides angiotensins and kinins. Clinical Science, 2014, 126, 753-774.	1.8	14
1169	Multidrug and optimal heart failure therapy prescribing in older general practice populations: a clinical data linkage study. BMJ Open, 2014, 4, e003698.	0.8	9
1171	Relationships Between Biomarkers and Left Ventricular Filling Pressures at Rest and During Exercise in Patients After Myocardial Infarction. Journal of Cardiac Failure, 2014, 20, 959-967.	0.7	12
1172	Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to <scp>CHARM</scp>â€Preserved. European Journal of Heart Failure, 2014, 16, 33-40.	2.9	186
1173	Worsening renal function during reninâ€“angiotensinâ€“aldosterone system inhibitor initiation and longâ€term outcomes inÂpatients with left ventricular systolic dysfunction. European Journal of Heart Failure, 2014, 16, 41-48.	2.9	104
1174	Influence of Hospitalization for Cardiovascular Versus Noncardiovascular Reasons on Subsequent Mortality in Patients With Chronic Heart Failure Across the Spectrum of Ejection Fraction. Circulation: Heart Failure, 2014, 7, 895-902.	1.6	43
1175	Azilsartan, Aliskiren, and Combination Antihypertensives Utilizing Reninâ€“Angiotensinâ€“Aldosterone System Antagonists. American Journal of Therapeutics, 2014, 21, 419-435.	0.5	8
1176	Alpha-1 Adrenoceptorâ€“Angiotensin II Type 1 Receptor Cross-Talk and Its Relevance in Clinical Medicine. Cardiology in Review, 2014, 22, 51-55.	0.6	3
1177	Angiotensin Receptor Antagonists to Prevent Sudden Death in Heart Failure: Does the Dose Matter?. ISRN Cardiology, 2014, 2014, 1-7.	1.6	7
1178	Ranolazine Preserves and Improves Left Ventricular Ejection Fraction and Autonomic Measures When Added to Guideline-Driven Therapy in Chronic Heart Failure. Heart International, 2014, 9, heartint.500021.	0.4	25
1179	Complete inhibition of the reninâ€“angiotensinâ€“aldosterone system; where do we stand?. Current Opinion in Nephrology and Hypertension, 2014, 23, 449-455.	1.0	5
1180	â€œFere libenter homines id quod volunt credunt†Apprehension for the stroke reduction in the KYOTO HEART Study on the basis of meta-regression from the evidence. International Journal of Cardiology, 2014, 170, 258-260.	0.8	0
1181	Central nervous system circuits modified in heart failure: pathophysiology and therapeutic implications. Heart Failure Reviews, 2014, 19, 759-779.	1.7	15
1182	Novel Blockers of the Renin-Angiotensin-Aldosterone System in Chronic Heart Failure. Current Heart Failure Reports, 2014, 11, 31-39.	1.3	3
1183	Renal Denervation for Hypertension. Current Problems in Cardiology, 2014, 39, 35-51.	1.1	5
1184	Hypertension in Diabetes Mellitus. , 2014, , 119-134.		0

#	Article	IF	Citations
1186	Management of ACCF/AHA Stage C Heart Failure. Cardiology Clinics, 2014, 32, 73-93.	0.9	8
1187	The Renin-Angiotensin-Aldosterone System and Heart Failure. Cardiology Clinics, 2014, 32, 21-32.	0.9	139
1188	Baseline characteristics and treatment of patients in Prospective comparison of <scp>ARNI</scp> with <scp>ACEI</scp> to Determine Impact on Global Mortality and morbidity in Heart Failure trial (<scp>PARADIGMâ€HF</scp>). European Journal of Heart Failure, 2014, 16, 817-825.	2.9	148
1189	Comorbidities and Differential Diagnosis in Heart Failure with Preserved Ejection Fraction. Heart Failure Clinics, 2014, 10, 481-501.	1.0	33
1190	Combined Angiotensin Inhibition in Diabetic Nephropathy. New England Journal of Medicine, 2014, 370, 777-779.	13.9	10
1191	Renin-Angiotensin-Aldosterone System Inhibition. Primary Care - Clinics in Office Practice, 2014, 41, 765-778.	0.7	24
1192	Angioedema Related to Angiotensin Inhibitors. Journal of Pharmacy Practice, 2014, 27, 461-465.	0.5	13
1193	Implications of Kidney Disease in the Cardiac Patient. Interventional Cardiology Clinics, 2014, 3, 317-331.	0.2	0
1194	Telmisartan Reduces Mortality and Left Ventricular Hypertrophy With Sympathoinhibition in Rats with Hypertension and Heart Failure. American Journal of Hypertension, 2014, 27, 260-267.	1.0	21
1195	Management of oral chronic pharmacotherapy in patients hospitalized for acute decompensated heart failure. International Journal of Cardiology, 2014, 176, 321-326.	0.8	8
1196	Rhythm Control in Heart Failure Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2014, 64, 710-721.	1.2	71
1197	Chronic heart failure: epidemiology, investigation and management. Medicine, 2014, 42, 562-567.	0.2	10
1198	Time and Technology Will Tell. Heart Failure Clinics, 2014, 10, 543-557.	1.0	15
1199	Polypharmacy in Heart Failure. Heart Failure Clinics, 2014, 10, 577-590.	1.0	11
1200	Medical therapy versus implantable cardioverter -defibrillator in preventing sudden cardiac death in patients with left ventricular systolic dysfunction and heart failure: A meta-analysis of >35,000 patients. International Journal of Cardiology, 2014, 173, 197-203.	0.8	26
1201	Influence of Previous Heart Failure Hospitalization on Cardiovascular Events in Patients With Reduced and Preserved Ejection Fraction. Circulation: Heart Failure, 2014, 7, 590-595.	1.6	123
1202	Reninâ€“Angiotensin System Blocking Drugs. Journal of Cardiovascular Pharmacology and Therapeutics, 2014, 19, 14-33.	1.0	53
1203	Standards of Medical Care in Diabetesâ€”2014. Diabetes Care, 2014, 37, S14-S80.	4.3	3,893

#	Article	IF	Citations
1204	Pharmacotherapy to reduce arrhythmic mortality. Indian Heart Journal, 2014, 66, S113-S119.	0.2	2
1205	Renin-angiotensin system inhibitors and troponin elevation in spinal surgery. Journal of Clinical Neuroscience, 2014, 21, 1133-1140.	0.8	4
1206	Prevalence of Guideline-Directed Medical Therapy Among Patients Receiving Cardiac Resynchronization Therapy Defibrillator Implantation in the National Cardiovascular Data Registry During the Years 2006 to 2008. American Journal of Cardiology, 2014, 113, 2052-2056.	0.7	13
1207	Loop Diuretic Resistance in Heart Failure: Resistance Etiologyâ€“Based Strategies to Restoring Diuretic Efficacy. Journal of Cardiac Failure, 2014, 20, 611-622.	0.7	44
1208	Canadian Cardiovascular Society Guidelines for the Diagnosis and Management of Stable Ischemic HeartÂDisease. Canadian Journal of Cardiology, 2014, 30, 837-849.	0.8	132
1209	Modulation of the Renin-Angiotensin-Aldosterone System in Heart Failure. Current Atherosclerosis Reports, 2014, 16, 403.	2.0	15
1210	Routine Echocardiography Screening for Asymptomatic Left Ventricular Dysfunction in Childhood Cancer Survivors: A Model-Based Estimation of the Clinical and Economic Effects. Annals of Internal Medicine, 2014, 160, 661.	2.0	83
1211	Antihypertensive Medication Exposure and Cardiovascular Outcomes in Hemodialysis Patients. American Journal of Nephrology, 2014, 40, 113-122.	1.4	6
1212	Inclusion of older people in interventional clinical trials. Clinical Investigation, 2014, 4, 87-99.	0.0	4
1213	Medicines management in the community: An HF specialist nurse prescriber's experience. British Journal of Cardiac Nursing, 2014, 9, 444-451.	0.0	0
1214	Insights Into the Activation and Inhibition of Angiotensin II Type 1 Receptor in the Mechanically Loaded Heart. Circulation Journal, 2014, 78, 1283-1289.	0.7	29
1215	Both processes and readmissions matter for heart failure: How can we align them?. American Heart Journal, 2015, 170, 968-970.	1.2	0
1216	Efficacy and safety of supramaximal titrated inhibition of reninâ€angiotensinâ€aldosterone system in idiopathic dilated cardiomyopathy. ESC Heart Failure, 2015, 2, 129-138.	1.4	15
1217	Current Challenges in the Management of Heart Failure. Circulation Journal, 2015, 79, 948-953.	0.7	25
1218	Increased B-type-natriuretic peptide promotes myocardial cell apoptosis via the B-type-natriuretic peptide/long non-coding RNA LSINCT5/caspase-1/interleukin 1Î² signaling pathway. Molecular Medicine Reports, 2015, 12, 6761-6767.	1.1	26
1219	The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. Clinical Science, 2015, 130, 57-77.	1.8	208
1220	Update of treatment in chronic heart failure. Medicina ClÃnica (English Edition), 2015, 145, 545-550.	0.1	1
1221	2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-segment Elevation. Revista Espanola De Cardiologia (English Ed), 2015, 68, 1125.	0.4	57

#	Article	IF	Citations
1222	Factors associated with 30-day readmission of patients with heart failure from a Japanese administrative database. BMC Cardiovascular Disorders, 2015, 15, 134.	0.7	32
1223	Effects of an evidence-based medicine workshop on Japanese pharmacy studentsâ€™ awareness regarding the importance of reading current clinical literature. Journal of Pharmaceutical Health Care and Sciences, 2015, 1, 23.	0.4	6
1224	Neprilysin Inhibition in Heart Failure with Reduced Ejection Fraction: A Clinical Review. Pharmacotherapy, 2015, 35, 823-837.	1.2	23
1225	Predicting outcome in acute heart failure, does it matter?. Acta Cardiologica, 2015, 70, 653-663.	0.3	5
1226	Geographic differences in heart failure trials. European Journal of Heart Failure, 2015, 17, 893-905.	2.9	64
1227	A Novel Angiotensin Type I Receptor Antagonist, Fimasartan, Prevents Doxorubicin-induced Cardiotoxicity in Rats. Journal of Korean Medical Science, 2015, 30, 559.	1.1	32
1228	Beta-Blockers and Nitrates: Pharmacotherapy and Indications. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2015, 13, 25-30.	0.4	9
1229	Hitting the Mark: Blood Pressure Targets and Agents in Those With Prevalent Cardiovascular Disease and Heart Failure. Advances in Chronic Kidney Disease, 2015, 22, 140-144.	0.6	2
1230	Comparing Sodium Intake Strategies in Heart Failure. Circulation: Heart Failure, 2015, 8, 636-645.	1.6	21
1232	Association between reninâ€“angiotensin system antagonist use and mortality in heart failure with severe renal insufficiency: a prospective propensity score-matched cohort study. European Heart Journal, 2015, 36, 2318-2326.	1.0	83
1233	Sudden Cardiac Death in Coronary Artery Disease. Cardiovascular Medicine, 2015, , 621-656.	0.0	0
1234	Dual Inhibitors: RAAS Blockers/Combination Therapies: What Do All These Trials Mean?. , 2015, , 57-68.		0
1235	Drugs Targeting RAAS in the Treatment of Hypertension and Other Cardiovascular Diseases. , 2015, , 751-806.		2
1236	Synergistic effects of cardiac resynchronization therapy and drug up-titration in heart failure: is this enough?. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 189-190.	1.4	1
1237	Clinical characteristics, precipitating factors, management and outcome of patients with prior stroke hospitalised with heart failure: an observational report from the Middle East. BMJ Open, 2015, 5, e007148-e007148.	0.8	12
1238	Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Terms of Major Cardiovascular Disease Outcomes in Elderly Patients. Medicine (United) Tj ETQq1 1 0.784314 rgBT /Overlock		
1239	Comparative associations between angiotensin converting enzyme inhibitors, angiotensin receptor blockers and their combination, and outcomes in patients with heart failure and reduced ejection fraction. International Journal of Cardiology, 2015, 199, 415-423.	0.8	7
1240	8. Cardiovascular Disease and Risk Management. Diabetes Care, 2015, 38, S49-S57.	4.3	224

#	Article	IF	Citations
1241	The Comparative Efficacy and Safety of the Angiotensin Receptor Blockers in the Management of Hypertension and Other Cardiovascular Diseases. Drug Safety, 2015, 38, 33-54.	1.4	115
1242	Novel RAAS agonists and antagonists: clinical applications and controversies. Nature Reviews Endocrinology, 2015, 11, 242-252.	4.3	126
1243	LCZ696: too good to be true?. European Heart Journal, 2015, 36, 410-412.	1.0	10
1244	Secondary Prevention After Coronary Artery Bypass Graft Surgery. Circulation, 2015, 131, 927-964.	1.6	313
1245	Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. European Heart Journal, 2015, 36, 915-923.	1.0	51
1246	Too much is too much: evidence against dual RAAS inhibition in hypertensives with heart failure symptoms. European Heart Journal, 2015, 36, 899-901.	1.0	2
1247	Pharmacologic Options for the Management of Systolic Heart Failure: Examining Underlying Mechanisms. Canadian Journal of Cardiology, 2015, 31, 1282-1292.	0.8	10
1249	Cardio-renal protection through reninâ€“angiotensinâ€“aldosterone system inhibition: current knowledge and new perspectives. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 132-133.	1.4	3
1250	Contemporary Drug Development in Heart Failure. Circulation: Heart Failure, 2015, 8, 826-831.	1.6	34
1251	Falling Cardiovascular Mortality in HeartÂFailure With Reduced Ejection Fraction and Implications for Clinical Trials. JACC: Heart Failure, 2015, 3, 603-614.	1.9	36
1252	Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure. Annals of Pharmacotherapy, 2015, 49, 1237-1251.	0.9	17
1253	LCZ696: The Next Step in Improving RAS Inhibition?. Current Hypertension Reports, 2015, 17, 37.	1.5	7
1254	Treatment of hypertension in patients with coronary artery disease. Journal of the American Society of Hypertension, 2015, 9, 453-498.	2.3	47
1255	Current Management of Heart Failure. Medical Clinics of North America, 2015, 99, 863-876.	1.1	3
1256	Medical Treatment of Heart Failure and Coronary Heart Disease. Cardiovascular Medicine, 2015, , 533-560.	0.0	0
1257	Cardiac Energy Metabolic Alterations in Pressure Overloadâ€“Induced Left and Right Heart Failure (2013) Tj ETQq1 1 0.784314 rgBT	0.8	45
1258	Ivabradine on Aortic Stiffness in Patients with Heart Failure. Journal of Investigative Medicine, 2015, 63, 620-625.	0.7	8
1259	Treatment of Hypertension in Patients With Coronary Artery Disease. Hypertension, 2015, 65, 1372-1407.	1.3	97

#	Article	IF	Citations
1260	"Frailty, Thy Name Is Woman": Syndrome of Women With Heart Failure With Preserved Ejection Fraction. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, S48-S51.	0.9	12
1261	Drug therapies in older adults (part 2). Clinical Medicine, 2015, 15, 155-159.	0.8	5
1262	Treatment of Hypertension in PatientsÂWith Coronary Artery Disease. Journal of the American College of Cardiology, 2015, 65, 1998-2038.	1.2	120
1263	Treatment of Hypertension in Patients With Coronary Artery Disease. Circulation, 2015, 131, e435-70.	1.6	163
1264	Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation. Circulation, 2015, 131, 1486-1494.	1.6	92
1265	Meta-Analysis of Large-Scale Randomized Trials to Determine the Effectiveness of Inhibition of the Renin-Angiotensin Aldosterone System in Heart Failure. American Journal of Cardiology, 2015, 116, 155-161.	0.7	33
1266	An update of the blockade of the renin angiotensin aldosterone system in clinical practice. Expert Opinion on Pharmacotherapy, 2015, 16, 2283-2292.	0.9	26
1267	Gaps and Resemblances in Current Heart Failure Guidelines. Heart Failure Clinics, 2015, 11, 529-541.	1.0	1
1268	Difficulty accessing data from randomised trials of drugs for heart failure: a call for action. BMJ, The, 2015, 351, h5002.	3.0	11
1269	The association of chronic kidney disease with the use of renin-angiotensin system inhibitors after acute myocardial infarction. American Heart Journal, 2015, 170, 735-743.	1.2	4
1270	Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for hypertension: are they equivalent?. Journal of the American Society of Hypertension, 2015, 9, 582-583.	2.3	1
1271	Coronary artery disease in the military patient. Journal of the Royal Army Medical Corps, 2015, 161, 211-222.	0.8	10
1273	Containing the Cost of Heart Failure Management. Cardiac Electrophysiology Clinics, 2015, 7, 577-584.	0.7	6
1274	Improving outcomes in heart failure: a personal perspective. European Heart Journal, 2015, 36, 3467-3470.	1.0	41
1275	Comparison of metoprolol succinate versus carvedilol in time to cardiovascular admission in a Veterans Affairs healthcare system: An observational study. American Journal of Health-System Pharmacy, 2015, 72, S183-S190.	0.5	2
1277	Understanding Heart Failure. Cardiac Electrophysiology Clinics, 2015, 7, 557-575.	0.7	20
1278	Biomarkers of activation of renin-angiotensin-aldosterone system in heart failure: how useful, how feasible?. Clinica Chimica Acta, 2015, 443, 85-93.	0.5	22
1279	International Geographic Variation in Event Rates in Trials of Heart Failure With Preserved and Reduced Ejection Fraction. Circulation, 2015, 131, 43-53.	1.6	75

#	Article	IF	Citations
1280	Dual Renin-Angiotensin-Aldosterone Blockade: Promises and Pitfalls. Current Hypertension Reports, 2015, 17, 511.	1.5	5
1281	Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program. European Heart Journal, 2015, 36, 669-675.	1.0	62
1283	Cardiac Drug Therapy. Contemporary Cardiology, 2015, , .	0.0	4
1284	The effect of a repeated immunoadsorption in patients with dilated cardiomyopathy after recurrence of severe heart failure symptoms. Journal of Clinical Apheresis, 2015, 30, 217-223.	0.7	14
1285	SERCA2a Gene Therapy for Heart Failure. , 2016, , 389-400.		0
1286	Should Angiotensin Receptor Neprilysin Inhibitors Replace Angiotensin-converting Enzyme Inhibitors in Heart Failure With a Reduced Ejection Fraction?. Cardiac Failure Review, 2016, 2, 47.	1.2	5
1287	Pharmacologic Approach to Heart Failure in Children. Current Cardiology Reviews, 2016, 12, 117-120.	0.6	7
1288	Heart Failure: Diagnosis, Management and Utilization. Journal of Clinical Medicine, 2016, 5, 62.	1.0	249
1289	The Mechanism of Action of LCZ696. Cardiac Failure Review, 2016, 2, 40.	1.2	38
1290	Foundations of Pharmacotherapy for Heart Failure With Reduced Ejection Fraction. Journal of Cardiovascular Nursing, 2016, 31, 101-113.	0.6	3
1291	Calibrating the impact of dual RAAS blockade on the heart and the kidney - balancing risks and benefits. International Journal of Clinical Practice, 2016, 70, 537-553.	0.8	8
1292	Long-term use of secondary prevention medications for heart failure in Western Australia: a protocol for a population-based cohort study. BMJ Open, 2016, 6, e014397.	0.8	8
1293	Inverse agonism: the classic concept of GPCRs revisited [Review]. Endocrine Journal, 2016, 63, 507-514.	0.7	28
1294	Sacubitril/Valsartan (LCZ696) in Heart Failure. Handbook of Experimental Pharmacology, 2016, 243, 133-165.	0.9	31
1295	Candesartan cilexetil prevents diet-induced insulin resistance via peroxisome proliferator-activated receptor-Î³ activation in an obese rat model. Experimental and Therapeutic Medicine, 2016, 12, 272-278.	0.8	5
1296	Heart failure: an historical perspective. European Heart Journal Supplements, 2016, 18, G3-G10.	0.0	19
1297	Angiotensin II Receptor Blockers and Cancer Risk. Medicine (United States), 2016, 95, e3600.	0.4	28
1299	Contemporary Pharmacological Treatment of Heart Failure. , 2016, , 207-227.		0

#	Article	IF	Citations
1300	Analysis of recurrent events with an associated informative dropout time: Application of the joint frailty model. Statistics in Medicine, 2016, 35, 2195-2205.	0.8	41
1301	2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation, 2016, 134, e282-93.	1.6	494
1302	Update in Hypertension Therapy. Medical Clinics of North America, 2016, 100, 665-693.	1.1	7
1303	The role of pharmacotherapy in the prevention of sudden cardiac death in patients with heart failure. Heart Failure Reviews, 2016, 21, 415-431.	1.7	6
1304	A Randomized, Double-blind, Candesartan-controlled, Parallel Group Comparison Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Patients with Mild to Moderate Essential Hypertension. Clinical Therapeutics, 2016, 38, 1485-1497.	1.1	11
1305	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2016, 37, 2129-2200.	1.0	13,008
1306	Mechanisms of Vascular Smooth Muscle Contraction and the Basis for Pharmacologic Treatment of Smooth Muscle Disorders. Pharmacological Reviews, 2016, 68, 476-532.	7.1	365
1307	Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure. New England Journal of Medicine, 2016, 374, 1521-1532.	13.9	204
1308	Challenges to Data Monitoring Committees When Regulatory Authorities Intervene. New England Journal of Medicine, 2016, 374, 1580-1584.	13.9	17
1309	Administration of antioxidant peptide SS-31 attenuates transverse aortic constriction-induced pulmonary arterial hypertension in mice. Acta Pharmacologica Sinica, 2016, 37, 589-603.	2.8	36
1310	Pharmacological interventions into the reninâ€“angiotensin system with ACE inhibitors and angiotensin II receptor antagonists: effects beyond blood pressure lowering. Therapeutic Advances in Cardiovascular Disease, 2016, 10, 151-161.	1.0	19
1311	Love of Angiotensin-Converting Enzyme Inhibitors in the Time of Cholera. JACC: Heart Failure, 2016, 4, 403-408.	1.9	18
1312	Impact of substitution among generic drugs on persistence and adherence: A retrospective claims data study from 2 Local Healthcare Units in the Lombardy Region of Italy. Atherosclerosis Supplements, 2016, 21, 1-8.	1.2	19
1313	Cardiac remodelling and RAS inhibition. Therapeutic Advances in Cardiovascular Disease, 2016, 10, 162-171.	1.0	96
1314	Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Prothrombotic Processes and Myocardial Infarction Risk. American Journal of Cardiovascular Drugs, 2016, 16, 399-406.	1.0	14
1315	Hypertension and Stroke. , 2016, , .		3
1316	A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension. Lancet, The, 2016, 388, 2665-2712.	6.3	670
1317	Hyperkalemia in Heart Failure. Journal of the American College of Cardiology, 2016, 68, 1575-1589.	1.2	86

#	Article	IF	Citations
1318	Current treatment of heart failure with reduction of left ventricular ejection fraction. Expert Review of Clinical Pharmacology, 2016, 9, 1619-1631.	1.3	6
1319	Heart Failure: a Major Cardiovascular Complication of Diabetes Mellitus. Current Diabetes Reports, 2016, 16, 116.	1.7	40
1320	Reframing the association and significance of coâ€morbidities in heart failure. European Journal of Heart Failure, 2016, 18, 744-758.	2.9	169
1321	Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure. ESC Heart Failure, 2016, 3, 177-188.	1.4	90
1322	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2016, 18, 891-975.	2.9	5,272
1323	Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm. British Journal of Pharmacology, 2016, 173, 1911-1924.	2.7	14
1324	Should We STOP Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Advanced Kidney Disease?. Nephron, 2016, 133, 147-158.	0.9	8,212
1325	Aliskiren, Enalapril, or Both in Heart Failure. New England Journal of Medicine, 2016, 375, 701-702.	13.9	4
1326	Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer. The Cochrane Library, 2016, 2016, CD008011.	1.5	34
1327	Î²-Arrestin mediates the Frankâ€“Starling mechanism of cardiac contractility. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 14426-14431.	3.3	46
1328	What constitutes optimal neurohumoral antagonism in chronic heart failure?. Heart, 2016, 102, 1922-1932.	1.2	3
1329	Influence of Left Ventricular Ejection Fraction on the Effects of Supplemental Use of Angiotensin Receptor Blocker Olmesartan in Hypertensive Patients With Heart Failure. Circulation Journal, 2016, 80, 2155-2164.	0.7	11
1330	Tailoring Therapies in Advanced Heart Failure. Heart Failure Clinics, 2016, 12, 375-384.	1.0	3
1332	Short-Term Angiotensin Subtype 1 Receptor Blockade Does Not Alter the Circulatory Responses to Sympathetic Nervous System Modulation in Healthy Volunteers Before and During Sevoflurane Anesthesia: Results of a Pilot Study. Journal of Cardiothoracic and Vascular Anesthesia, 2016, 30, 1479-1484.	0.6	1
1333	Cardiovascular Risk Assessment, Summary of Guidelines for the Management of Hypertension and a Critical Appraisal of the 2014 Expert Panel of the National Institutes of Health Report. , 2016, , 131-150.		0
1334	How robust are clinical trials in heart failure?. European Heart Journal, 2017, 38, ehw427.	1.0	49
1335	Trends in Antihypertensive Medication Use Among US Patients With Resistant Hypertension, 2008 to 2014. Hypertension, 2016, 68, 1349-1354.	1.3	38
1336	Systems Pharmacology Dissection of the Integrated Treatment for Cardiovascular and Gastrointestinal Disorders by Traditional Chinese Medicine. Scientific Reports, 2016, 6, 32400.	1.6	48

#	Article	IF	Citations
1337	Digoxin in Heart Failure with a Reduced Ejection Fraction: A Risk Factor or a Risk Marker?. Cardiology, 2016, 134, 311-319.	0.6	633
1338	Renin-Angiotensin System Inhibition and Lower 30-Day All-Cause Readmission in Medicare Beneficiaries with Heart Failure. American Journal of Medicine, 2016, 129, 1067-1073.	0.6	42
1340	Mega clinical trials which have shaped the RAS intervention clinical practice. Therapeutic Advances in Cardiovascular Disease, 2016, 10, 133-150.	1.0	39
1341	The Established Therapies: HF-PEF and HF-REF. , 2016, , 1-27.		0
1342	Effect of single and dual renin-angiotensin blockade on stroke in patients with and without diabetes in VALIANT. European Stroke Journal, 2016, 1, 93-100.	2.7	1
1343	Cost-effectiveness of screening strategies to detect heart failure in patients with type 2 diabetes. Cardiovascular Diabetology, 2016, 15, 48.	2.7	10
1344	Clinical Update: Cardiovascular Disease in Diabetes Mellitus. Circulation, 2016, 133, 2459-2502.	1.6	766
1345	Neprilysin Inhibition as a PARADIGM Shift in Heart Failure Therapy. Current Heart Failure Reports, 2016, 13, 172-180.	1.3	6
1346	A Review of New Pharmacologic Treatments for Patients With Chronic Heart Failure With Reduced Ejection Fraction. Journal of Clinical Pharmacology, 2016, 56, 936-947.	1.0	6
1347	Angiotensin IIâ€"Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer. JAMA Oncology, 2016, 2, 1030.	3.4	160
1348	Dipeptidyl peptidaseâ€4 inhibition improves cardiac function in experimental myocardial infarction: Role of stromal cellâ€derived factorâ€1 l±. Journal of Diabetes, 2016, 8, 63-75.	0.8	28
1349	Medical Therapy Leads to Favorable Remodeling in Left Ventricular Non-compaction Cardiomyopathy: Dilated Phenotype. Pediatric Cardiology, 2016, 37, 674-677.	0.6	17
1350	Heart failure â€" what the general physician needs to know. Clinical Medicine, 2016, 16, 25-33.	0.8	1
1351	Heart Failure. Nursing Clinics of North America, 2016, 51, 13-27.	0.7	2
1352	8. Cardiovascular Disease and Risk Management. Diabetes Care, 2016, 39, S60-S71.	4.3	237
1353	Reninâ€"angiotensinâ€"aldosterone system blockers for heart failure with reduced ejection fraction or left ventricular dysfunction: Network meta-analysis. International Journal of Cardiology, 2016, 205, 65-71.	0.8	23
1354	Potential New Agents for the Management of Hyperkalemia. American Journal of Cardiovascular Drugs, 2016, 16, 19-31.	1.0	16
1355	Pulse pressure is not an independent predictor of outcome in type 2 diabetes patients with chronic kidney disease and anemiaâ€"the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT). Journal of Human Hypertension, 2016, 30, 46-52.	1.0	13

#	Article	IF	Citations
1356	The renin-angiotensin-aldosterone system in heart failure for the non-specialist: the past, the present and the future. Postgraduate Medical Journal, 2017, 93, 29-37.	0.9	48
1358	Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study. Journal of Cardiology, 2017, 70, 225-231.	0.8	36
1359	Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction. Circulation: Heart Failure, 2017, 10, .	1.6	178
1360	Drug Therapy for Stable Angina Pectoris. Drugs, 2017, 77, 265-284.	4.9	32
1362	Comparing six antihypertensive medication classes for preventing newâ€onset diabetes mellitus among hypertensive patients: a network metaâ€analysis. Journal of Cellular and Molecular Medicine, 2017, 21, 1742-1750.	1.6	15
1363	Novel Cardiac Intracrine Mechanisms Based on Ang-(1-12)/Chymase Axis Require a Revision of Therapeutic Approaches in Human Heart Disease. Current Hypertension Reports, 2017, 19, 16.	1.5	35
1364	Potential Expanded Indications for Neprilysin Inhibitors. Current Heart Failure Reports, 2017, 14, 134-145.	1.3	26
1365	Current and emerging pharmacologic options for the management of patients with chronic and acute decompensated heart failure. Expert Review of Clinical Pharmacology, 2017, 10, 517-534.	1.3	4
1366	The effectiveness and safety of angiotensin-converting enzyme inhibition or receptor blockade in vascular diseases in patients with hemodialysis. Medicine (United States), 2017, 96, e6525.	0.4	1
1367	Impact of an antimicrobial stewardship programme on antibiotic usage and resistance in a tertiary hospital in China. Journal of Clinical Pharmacy and Therapeutics, 2017, 42, 579-584.	0.7	15
1368	Heart Failure Guidelines on Pharmacotherapy. Handbook of Experimental Pharmacology, 2017, 243, 109-129.	0.9	8
1369	2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation, 2017, 136, e137-e161.	1.6	2,130
1370	Race/Ethnic Differences in Outcomes Among Hospitalized Medicare Patients With Heart Failure and Preserved EjectionÂFraction. JACC: Heart Failure, 2017, 5, 483-493.	1.9	41
1371	Progress in the Presence of Failure: Updates in Chronic Systolic Heart Failure Management. Current Treatment Options in Cardiovascular Medicine, 2017, 19, 50.	0.4	3
1372	Serelaxin in the Treatment of Acute Heart Failure in the Emergency Department. Current Emergency and Hospital Medicine Reports, 2017, 5, 68-75.	0.6	0
1374	Heart Failure Complicating Acute Myocardial Infarction. Heart Failure Clinics, 2017, 13, 513-525.	1.0	4
1375	Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease. Pharmacological Research, 2017, 125, 57-71.	3.1	96
1376	Treatment of Heart Failure with Abnormal Left Ventricular Systolic Function in Older Adults. Heart Failure Clinics, 2017, 13, 467-483.	1.0	3

#	Article	IF	Citations
1377	The Combination of Beta Blockers and Renin-Angiotensin System Blockers Improves Survival in Incident Hemodialysis Patients: A Propensity-Matched Study. Kidney International Reports, 2017, 2, 665-675.	0.4	4
1378	The evolution of heart failure with reduced ejection fraction pharmacotherapy: What do we have and where are we going?. , 2017, 178, 67-82.		2
1379	Implantable cardioverter defibrillators for primary prevention of death in left ventricular dysfunction with and without ischaemic heart disease: a meta-analysis of 8567 patients in the 11 trials. European Heart Journal, 2017, 38, 1738-1746.	1.0	74
1380	Association Between Use of Long-Acting Nitrates and Outcomes in Heart Failure With Preserved Ejection FractionCLINICAL PERSPECTIVE. Circulation: Heart Failure, 2017, 10, e003534.	1.6	14
1381	Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. European Heart Journal, 2017, 38, 1132-1143.	1.0	160
1382	Drugs to prevent sudden cardiac death. International Journal of Cardiology, 2017, 237, 22-24.	0.8	7
1383	Current Pharmacological Therapies in Heart Failure Patients. High Blood Pressure and Cardiovascular Prevention, 2017, 24, 107-114.	1.0	21
1384	9. Cardiovascular Disease and Risk Management. Diabetes Care, 2017, 40, S75-S87.	4.3	203
1385	Brain and heart magnetic resonance imaging/spectroscopy in duchenne muscular dystrophy. European Journal of Clinical Investigation, 2017, 47, e12842.	1.7	4
1386	Renal Sympathetic Denervation ProtectsÂthe Failing Heart Via Inhibition ofÂNeprilysinÂActivity in the Kidney. Journal of the American College of Cardiology, 2017, 70, 2139-2153.	1.2	69
1387	Unbreakable? An analysis of the fragility of randomized trials that support diabetes treatment guidelines. Diabetes Research and Clinical Practice, 2017, 134, 91-105.	1.1	32
1388	Oedemaâ€fibrosis in Duchenne Muscular Dystrophy: Role of cardiovascular magnetic resonance imaging. European Journal of Clinical Investigation, 2017, 47, e12843.	1.7	14
1389	The potential role and rationale for treatment of heart failure with sodiumâ€“glucose coâ€transporter 2 inhibitors. European Journal of Heart Failure, 2017, 19, 1390-1400.	2.9	139
1390	Seventeen-Year Nationwide Trends in Antihypertensive Drug Use in Denmark. American Journal of Cardiology, 2017, 120, 2193-2200.	0.7	19
1391	2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. Canadian Journal of Cardiology, 2017, 33, 1342-1433.	0.8	503
1392	Long-term management of end-stage heart failure. Bailliere's Best Practice and Research in Clinical Anaesthesiology, 2017, 31, 153-166.	1.7	22
1393	Elevated Admission Potassium Levels and 1-Year and 10-Year Mortality Among Patients With Heart Failure. American Journal of the Medical Sciences, 2017, 354, 268-277.	0.4	7
1394	Dose of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure. Circulation: Heart Failure, 2017, 10, .	1.6	47

#	Article	IF	Citations
1395	2017 Lucian Award. Circulation Research, 2017, 121, 1312-1315.	2.0	1
1396	Interactive Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers or Their Combination on Survival of Hemodialysis Patients. American Journal of Nephrology, 2017, 46, 439-447.	1.4	6
1397	Effect of renin-angiotensin system inhibitors on mortality in heart failure with preserved ejection fraction: a meta-analysis of observational cohort and randomized controlled studies. Heart Failure Reviews, 2017, 22, 775-782.	1.7	27
1398	Declining Risk of Sudden Death in Heart Failure. New England Journal of Medicine, 2017, 377, 41-51.	13.9	355
1399	Treatment of Hyperkalemia in Heart Failure. Current Heart Failure Reports, 2017, 14, 266-274.	1.3	16
1400	Angiotensin-converting enzyme inhibitors and receptor blockers in heart failure and chronic kidney disease â€“ Demystifying controversies. Indian Heart Journal, 2017, 69, 371-374.	0.2	17
1401	Understanding Heart Failure. Heart Failure Clinics, 2017, 13, 1-19.	1.0	45
1402	Non-withdrawal of beta blockers in acute decompensated chronic and de novo heart failure with reduced ejection fraction in a prospective multicentre study of patients with acute heart failure in the Middle East. BMJ Open, 2017, 7, e014915.	0.8	12
1403	Identification of the difference in the pathogenesis in heart failure arising from different etiologies using a microarray dataset. Clinics, 2017, 72, 600-608.	0.6	7
1405	Losartan Attenuates Scar Formation in Filtering Bleb After Trabeculectomy. , 2017, 58, 1478.		19
1406	Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials. BMC Cardiovascular Disorders, 2017, 17, 257.	0.7	48
1407	Korean Guidelines for Diagnosis and Management of Chronic Heart Failure. Korean Circulation Journal, 2017, 47, 555.	0.7	56
1408	Management of advanced adult congenital heart disease. SA Heart Journal, 2017, 14, .	0.0	0
1409	Survival and Heart Failure Hospitalization in Patients With Cardiac Resynchronization Therapy With or Without a Defibrillator for Primary Prevention in Japanã€€â€• Analysis of the Japan Cardiac Device Treatment Registry Database â€•. Circulation Journal, 2017, 81, 1798-1806.	0.7	16
1410	Neurohormonal Blockade in Heart Failure. Cardiac Failure Review, 2017, 03, 19.	1.2	53
1411	Dilated Cardiomyopathy and Cardioskeletal Involvement. , 2017, , 85-111.		0
1412	The heart failure burden of type 2 diabetes mellitusâ€”a review of pathophysiology and interventions. Heart Failure Reviews, 2018, 23, 303-323.	1.7	41
1413	Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 853-872.	2.9	434

#	Article	IF	Citations
1414	Hyperkalemia in the Hypertensive Patient. Current Cardiology Reports, 2018, 20, 12.	1.3	7
1415	Drug therapies in chronic heart failure: a focus on reduced ejection fraction. Clinical Medicine, 2018, 18, 138-145.	0.8	11
1416	Was the Enalapril Dose Too Low in the PARADIGM-HF Trial?. Cardiology in Review, 2018, 26, 196-200.	0.6	5
1417	Clinical tolerability of generic versus brand beta blockers in heart failure with reduced left ventricular ejection fraction: a retrospective cohort from heart failure clinic. Journal of Drug Assessment, 2018, 7, 8-13.	1.1	2
1418	Reninâ€“angiotensin system inhibitionâ€”it's been a long but fruitful journey. European Journal of Heart Failure, 2018, 20, 687-688.	2.9	0
1419	Chronic Management of Patients with Left Ventricular Assist Devices. , 2018, , 145-159.		0
1420	Representation of black patients in randomized clinical trials of heart failure with reduced ejection fraction. American Heart Journal, 2018, 197, 43-52.	1.2	27
1421	A prospective study of the impact of AGTR1 A1166C on the effects of candesartan in patients with heart failure. Pharmacogenomics, 2018, 19, 599-612.	0.6	10
1423	Analysing registries in heart failure: The case of angiotensin receptor blockers in Asians with heart failure with reduced ejection fraction. International Journal of Cardiology, 2018, 257, 224-225.	0.8	0
1424	Angiotensin-Converting Enzyme Inhibitors in Hypertension. Journal of the American College of Cardiology, 2018, 71, 1474-1482.	1.2	215
1425	Combination Therapy of Renin Angiotensin System Inhibitors and Î²-Blockers in Patients with Heart Failure. Advances in Experimental Medicine and Biology, 2018, 1067, 17-30.	0.8	7
1426	Dual RAAS Blockade with Aliskiren in Patients with Severely Impaired Chronic Kidney Disease. Experimental and Clinical Endocrinology and Diabetes, 2018, 126, 39-52.	0.6	2
1427	2017 EACTS Guidelines on perioperative medication in adult cardiac surgery. European Journal of Cardio-thoracic Surgery, 2018, 53, 5-33.	0.6	292
1428	2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Heart Rhythm, 2018, 15, e73-e189.	0.3	262
1429	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Circulation, 2018, 138, e272-e391.	1.6	468
1430	Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the <scp>ATMOSPHERE</scp> trial. European Journal of Heart Failure, 2018, 20, 136-147.	2.9	18
1432	Mechanical Circulatory Support for Advanced Heart Failure. , 2018, , .		1
1433	Contribution of cardiac and extraâ€cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure. European Journal of Heart Failure, 2018, 20, 504-510.	2.9	52

#	Article	IF	Citations
1434	Cardiac Involvement in Duchenne Muscular Dystrophy and Related Dystrophinopathies. Methods in Molecular Biology, 2018, 1687, 31-42.	0.4	41
1435	Impact of systolic blood pressure on the safety and tolerability of initiating and upâ€titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study. European Journal of Heart Failure, 2018, 20, 491-500.	2.9	59
1437	OBSOLETE: Neurohormonal Blockade. , 2018, , .		0
1438	Association of Renin-Angiotensin Inhibitor Treatment With Mortality and Heart Failure Readmission in Patients With Transcatheter Aortic Valve Replacement. JAMA - Journal of the American Medical Association, 2018, 320, 2231.	3.8	72
1439	Sacubitril/Valsartan. Heart Failure Clinics, 2018, 14, 479-491.	1.0	1
1440	PHARMACOTHERAPY OF HEART FAILURE. Asian Journal of Pharmaceutical and Clinical Research, 2018, 11, 78.	0.3	2
1441	Management of advanced heart failure: a review. Expert Review of Cardiovascular Therapy, 2018, 16, 775-794.	0.6	6
1442	Association between reninâ€“angiotensin system inhibitor use and mortality/morbidity in elderly patients with heart failure with reduced ejection fraction: a prospective propensity score-matched cohort study. European Heart Journal, 2018, 39, 4257-4265.	1.0	38
1443	Kidney Function, ACE-Inhibitor/Angiotensin Receptor Blocker Use, and Survival Following Hospitalization for Heart Failure: A Cohort Study. Canadian Journal of Kidney Health and Disease, 2018, 5, 205435811880483.	0.6	3
1445	Heart Failure: Influence of Drug Interventions on Vessels. , 2018, , 575-588.		0
1446	Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. The Cochrane Library, 2018, 6, CD012721.	1.5	56
1448	Pharmacologic Management of Cancer Therapeutics-Induced Cardiomyopathy in Adult Cancer Survivors. Current Heart Failure Reports, 2018, 15, 270-279.	1.3	0
1449	Drug Adherence in Hypertension and Cardiovascular Protection. Updates in Hypertension and Cardiovascular Protection, 2018, , .	0.1	5
1450	Prognostic benefit of acute heart failure associated with atherosclerosis: the importance of prehospital medication in patients with severely decompensated acute heart failure. Heart and Vessels, 2018, 33, 1496-1504.	0.5	0
1451	The Reninâ€“Angiotensin System and the Heart. , 2018, , 43-55.		2
1452	Reninâ€“Angiotensin Blockade. , 2018, , 57-75.		0
1453	Renin Angiotensin Aldosterone System Blockers. , 2018, , 230-241.		1
1454	Quality of health economic evaluations for the ACC/AHA stable ischemic heart disease practice guideline: A systematic review. American Heart Journal, 2018, 204, 17-33.	1.2	7

#	Article	IF	Citations
1455	National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Guidelines for the Prevention, Detection, and Management of Heart Failure in Australia 2018. Heart Lung and Circulation, 2018, 27, 1123-1208.	0.2	262
1456	Atrial resynchronization therapy in patients with atrial fibrillation and heart failure with and without systolic left ventricular dysfunction: a pilot study. Journal of Interventional Cardiac Electrophysiology, 2018, 53, 9-17.	0.6	2
1457	Use of Fixed-Dose Combinations in Hypertension and Cardiovascular Disease Prevention. Updates in Hypertension and Cardiovascular Protection, 2018, , 225-235.	0.1	0
1458	Reninâ€“angiotensinâ€“aldosterone inhibition improves right ventricular function: a meta-analysis. Heart Asia, 2018, 10, e010999.	1.1	7
1459	Mechanisms and treatment of heart failure in diabetes. Practical Diabetes, 2018, 35, 117.	0.1	0
1460	Identifying Pathophysiological Mechanisms in Heart Failure WithÂReduced Versus Preserved EjectionÂFraction. Journal of the American College of Cardiology, 2018, 72, 1081-1090.	1.2	199
1461	Neurohormonal Blockade. , 2018, , 459-476.		0
1462	Hyporeninemic Hypoaldosteronism. , 2018, , 703-712.		1
1463	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Journal of the American College of Cardiology, 2018, 72, e91-e220.	1.2	991
1464	Molecular and Cellular Mechanisms in Heart Failure. , 2018, , 3-19.		9
1465	Effect of renin-angiotensin system blockade in patients with severe renal insufficiency and heart failure. International Journal of Cardiology, 2018, 266, 180-186.	0.8	6
1467	Angiotensin receptor-neprilysin inhibitors: A new paradigm in heart failure with reduced ejection fraction. International Journal of Cardiology, 2019, 281, 179-185.	0.8	9
1468	Benefitâ€“risk review of different drug classes used in chronic heart failure. Expert Opinion on Drug Safety, 2019, 18, 37-49.	1.0	10
1469	Assessing Treatment Effects That Capture Disease Burden in Serious Chronic Diseases. Therapeutic Innovation and Regulatory Science, 2019, 53, 387-397.	0.8	5
1470	Heart Failure with Reduced Ejection Fraction. , 2019, , 383-395.		0
1471	Hypertension and Heart Failure. Heart Failure Clinics, 2019, 15, 531-541.	1.0	124
1472	Phase 3 DREAM-HF Trial of Mesenchymal Precursor Cells in Chronic Heart Failure. Circulation Research, 2019, 125, 265-281.	2.0	54
1473	Molecular Imaging Targets in Heart Failure and Left Ventricular Remodeling. , 2019, , 405-435.		0

#	Article	IF	Citations
1474	From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and HeartÂFailure (Part 2/5). Journal of the American College of Cardiology, 2019, 74, 683-698.	1.2	22
1475	Quality of life and outcomes in heart failure patients with ejection fractions in different ranges. PLoS ONE, 2019, 14, e0218983.	1.1	20
1476	Renin Activity in Heart Failure with Reduced Systolic Functionâ€"New Insights. International Journal of Molecular Sciences, 2019, 20, 3182.	1.8	31
1477	Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure. Pharmacological Reviews, 2019, 71, 539-570.	7.1	235
1478	Cardiac CT, PET & MR. , 2019, , .		2
1479	Angiotensin receptor blockers as an alternative to angiotensin converting enzyme inhibitors. British Journal of Cardiac Nursing, 2019, 14, 1-12.	0.0	1
1480	Renin-Angiotensin System Blockers and Acute Kidney Injury. , 2019, , 1357-1361.e2.		0
1481	Epidemiology of hyperkalemia in chronic kidney disease. Nefrologia, 2019, 39, 277-286.	0.2	22
1482	Stable Angina Medical Therapy Management Guidelines: A Critical Review of Guidelines from the European Society of Cardiology and National Institute for Health and Care Excellence. European Cardiology Review, 2019, 14, 18-22.	0.7	26
1483	Evaluation of acute myocardial infarction patients with mid-range ejection fraction after emergency percutaneous coronary intervention. Postgraduate Medical Journal, 2019, 95, 355-360.	0.9	2
1484	Targeted Mono-Therapy for Newly Diagnosed Dilated Cardiomyopathy. Journal of Cardiac Failure, 2019, 25, 686-689.	0.7	1
1485	Hyperkalemia in Real-World Patients Under Continuous Medical Care in Japan. Kidney International Reports, 2019, 4, 1248-1260.	0.4	47
1486	Heart Failure With Preserved Ejection Fraction In Perspective. Circulation Research, 2019, 124, 1598-1617.	2.0	500
1487	Dilated cardiomyopathy. Nature Reviews Disease Primers, 2019, 5, 32.	18.1	347
1488	Cost-Utility Analysis of Sacubitril/Valsartan Use Compared With Standard Care in Chronic Heart Failure Patients With Reduced Ejection Fraction in South Korea. Clinical Therapeutics, 2019, 41, 1066-1079.	1.1	23
1489	Changes in the function of angiotensin II type 1 receptor due to cholesterol depletion from cell membrane. Biochemical and Biophysical Research Communications, 2019, 514, 791-797.	1.0	3
1490	â€œReal Worldâ€•Eligibility for Sacubitril/Valsartan in Unselected Heart Failure Patients: Data from the Swedish Heart Failure Registry. Cardiovascular Drugs and Therapy, 2019, 33, 315-322.	1.3	19
1491	Causes and impact on survival of underuse of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in heart failure. Internal and Emergency Medicine, 2019, 14, 1083-1090.	1.0	5

#	Article	IF	Citations
1492	EpidemiologÃa de la hiperpotasemia en la enfermedad renal crÃ³nica. Nefrologia, 2019, 39, 277-286.	0.2	27
1493	Update on heart failure management and future directions. Korean Journal of Internal Medicine, 2019, 34, 11-43.	0.7	84
1494	Pharmacotherapy in Heart Failure (I): Renin-Angiotensin-Aldosterone System (incl. ARNI), Diuretics, Digoxin and Statins. Cardiovascular Medicine, 2019, , 105-120.	0.0	0
1495	The reninâ€angiotensinâ€aldosterone system and its suppression. Journal of Veterinary Internal Medicine, 2019, 33, 363-382.	0.6	251
1496	Hyperkalaemia: aetiology, epidemiology, and clinical significance. European Heart Journal Supplements, 2019, 21, A6-A11.	0.0	23
1497	Left Ventricular Size and Ejection Fraction. Heart Failure Clinics, 2019, 15, 147-158.	1.0	5
1499	Determinants of prolonged hospitalization in patients who underwent trans-femoral transcatheter aortic valve implantation. Postepy W Kardiologii Interwencyjnej, 2019, 15, 431-438.	0.1	2
1500	Treatment of Patients with Heart failure and Type 2 Diabetes: a review of the literature. Italian Journal of Medicine, 2019, 13, 205-224.	0.2	0
1501	Tailoring treatment of hyperkalemia. Nephrology Dialysis Transplantation, 2019, 34, iii62-iii68.	0.4	3
1502	JCS 2017/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failureã€€â€• Digest Version â€•. Circulation Journal, 2019, 83, 2084-2184.	0.7	446
1503	Effects of blood pressure-lowering drugs in heart failure. Journal of Hypertension, 2019, 37, 1757-1767.	0.3	7
1504	Effects of dual blockade in heart failure and renal dysfunction: Systematic review and meta-analysis. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2019, 20, 147032031988265.	1.0	2
1505	Evaluation of a guideline directed medical therapy titration program in patients with heart failure with reduced ejection fraction. IJC Heart and Vasculature, 2019, 22, 1-5.	0.6	19
1506	Adjunctive Pharmacologic Therapies in Acute Myocardial Infarction. , 2019, , 117-138.e7.		2
1507	Cardiorenal Syndrome Type 1. , 2019, , 216-222.e3.		0
1508	Pharmacologic Interactions. , 2019, , 432-445.e7.		0
1509	Heart Failure Postdischarge Clinic: A Pharmacist-led Approach to Reduce Readmissions. Current Problems in Cardiology, 2019, 44, 100407.	1.1	15
1510	Diabetic cardiomyopathy. Heart, 2019, 105, 337-345.	1.2	60

#	Article	IF	Citations
1511	Medication dosing for heart failure with reduced ejection fraction â€" opportunities and challenges. European Journal of Heart Failure, 2019, 21, 286-296.	2.9	57
1512	Contemporary Management of Heart Failure in the Elderly. Drugs and Aging, 2019, 36, 137-146.	1.3	8
1513	Early therapeutic effects of adaptive servo-ventilation on cardiac sympathetic nervous function in patients with heart failure evaluated using a combination of 11C-HED PET and 123I-MIBG SPECT. Journal of Nuclear Cardiology, 2019, 26, 1079-1089.	1.4	9
1514	Impact of renin-angiotensin system blockade on the prognosis of acute coronary syndrome based on left ventricular ejection fraction. Revista Espanola De Cardiologia (English Ed), 2020, 73, 114-122.	0.4	6
1515	Efecto negativo del bloqueo del sistema renina-angiotensina sobre la progresiÃ³n de la enfermedad renal crÃ³nica avanzada: Â¿una cuestiÃ³n de ajuste de dosis?. Nefrologia, 2020, 40, 38-45.	0.2	2
1516	Contemporary Medical Therapy for Heart Failure Patients with Reduced Ejection Fraction. , 2020, , 520-548.		0
1517	The renin-angiotensin-aldosterone system: a crossroad from arterial hypertension to heart failure. Heart Failure Reviews, 2020, 25, 31-42.	1.7	52
1518	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal, 2020, 41, 255-323.	1.0	2,811
1519	Heart Failure With Mid-range Ejection Fraction. Current Heart Failure Reports, 2020, 17, 1-8.	1.3	24
1520	Absence of left bundle branch block and blood urea nitrogen predict improvement in left ventricular ejection fraction in patients with cardiomyopathy and wearable cardioverter defibrillators. Clinical Cardiology, 2020, 43, 260-266.	0.7	2
1521	Effects of dual inhibition of reninâ€"angiotensinâ€"aldosterone system on cardiovascular and renal outcomes: balancing the risks and the benefits. Internal and Emergency Medicine, 2020, 15, 373-379.	1.0	3
1522	Computational issues in fitting joint frailty models for recurrent events with an associated terminal event. Computer Methods and Programs in Biomedicine, 2020, 188, 105259.	2.6	9
1523	Sudden death in heart failure: do we understand what we observe?. European Heart Journal, 2020, 41, 1985-1987.	1.0	3
1524	Medical Therapies for Heart Failure With Preserved Ejection Fraction. Hypertension, 2020, 75, 23-32.	1.3	61
1525	Should Angiotensin-Converting Enzyme Inhibitors ever Be Used for the Management of Hypertension?. Current Cardiology Reports, 2020, 22, 95.	1.3	22
1526	Guideline-directed medical therapy in heart failure patients: impact of focused care provided by a heart failure clinic in comparison to general cardiology out-patient department. Egyptian Heart Journal, 2020, 72, 53.	0.4	5
1527	Heart Failure With Reduced Ejection Fraction. JAMA - Journal of the American Medical Association, 2020, 324, 488.	3.8	391
1528	Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME. Journal of Hypertension, 2020, 38, 1829-1840.	0.3	15

#	Article	IF	Citations
1529	Cost-Effectiveness of the International Late Effects of Childhood Cancer Guideline Harmonization Group Screening Guidelines to Prevent Heart Failure in Survivors of Childhood Cancer. Journal of Clinical Oncology, 2020, 38, 3851-3862.	0.8	25
1530	Severe acute respiratory syndrome coronavirus 2 and renin-angiotensin system blockers: A review and pooled analysis. Archives of Cardiovascular Diseases, 2020, 113, 797-810.	0.7	7
1531	Cancer Mortality in Trials of Heart Failure With Reduced Ejection Fraction: A Systematic Review and Metaâ€Analysis. Journal of the American Heart Association, 2020, 9, e016309.	1.6	23
1532	Targeting Ca2 + Handling Proteins for the Treatment of Heart Failure and Arrhythmias. Frontiers in Physiology, 2020, 11, 1068.	1.3	16
1533	Cardiovascular Outcomes with Sacubitril-Valsartan in Heart Failure: Emerging Clinical Data . Therapeutics and Clinical Risk Management, 2020, Volume 16, 715-726.	0.9	10
1534	Efficacy and Safety Outcome of Angiotensin Receptor-Neprilysin Inhibitors (ARNIs) in Patients with Heart Failure and Preserved Ejection Fraction (HFpEF): Preliminary Results . Research Reports in Clinical Cardiology, 0, Volume 11, 39-47.	0.2	1
1535	Impact of left ventricular ejection fraction on the effect of renin-angiotensin system blockers after an episode of acute heart failure: From the KCHF Registry. PLoS ONE, 2020, 15, e0239100.	1.1	4
1536	Diabetic cardiomyopathy. Revista Clínica Espanõla, 2022, 222, 100-111.	0.3	11
1538	Ejection fraction in heart failure revisited-Âwhere does the evidence start?. European Heart Journal, 2020, 41, 2363-2365.	1.0	20
1539	Efficacy and safety of sodiumâ€“glucose coâ€transporter 2 inhibition according to left ventricular ejection fraction in DAPAâ€HF. European Journal of Heart Failure, 2020, 22, 1247-1258.	2.9	29
1540	Postponement of Death by Pharmacological Heart Failure Treatment: A Meta-Analysis of Randomized Clinical Trials. American Journal of Medicine, 2020, 133, e280-e289.	0.6	3
1541	Dual RAAS inhibition and cardiorenal disease: is enough really enough?. Internal and Emergency Medicine, 2020, 15, 361-363.	1.0	0
1542	A Modern History RAAS Inhibition and Beta Blockade for Heart Failure to Underscore the Non-equivalency of ACEIs and ARBs. Cardiovascular Drugs and Therapy, 2020, 34, 215-221.	1.3	6
1543	Management and outcomes of heart failure patients with CKD: experience from an interâ€disciplinary clinic. ESC Heart Failure, 2020, 7, 3225-3230.	1.4	14
1544	Pharmacological interventions for heart failure in people with chronic kidney disease. The Cochrane Library, 2020, 2020, CD012466.	1.5	7
1545	Detrimental effect of renin-angiotensin blockade on progression of chronic kidney disease at later stages: A matter of dosage adjustment?. Nefrologia, 2020, 40, 38-45.	0.2	1
1546	Pharmacological management of atrial fibrillation in patients with heart failure with reduced ejection fraction: review of current knowledge and future directions. Expert Review of Cardiovascular Therapy, 2020, 18, 85-101.	0.6	2
1547	MiocardiopatÃa diabÃ©tica. Revista Clinica Espanola, 2022, 222, 100-111.	0.2	11

#	Article	IF	Citations
1548	Adherence-adjustment in placebo-controlled randomized trials: An application to the candesartan in heart failure randomized trial. Contemporary Clinical Trials, 2020, 90, 105937.	0.8	9
1549	Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future. Clinical Research in Cardiology, 2020, 109, 1079-1098.	1.5	74
1550	Impact of Patient and Model of Care Factors on Titration and Tolerability of Sacubitril/Valsartan: An Early Australian Real-World Experience. Heart Lung and Circulation, 2020, 29, 1688-1695.	0.2	5
1551	Assessing the risk of angiotensin receptor blockers on major cardiovascular events: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovascular Disorders, 2020, 20, 188.	0.7	2
1552	Megaâ€trials in heart failure: effects of dilution in examination of new therapies. European Journal of Heart Failure, 2020, 22, 1698-1707.	2.9	11
1553	Implantable Cardioverterâ€“Defibrillators in Trials of Drug Therapy for Heart Failure: AÂSystematic Review and Metaâ€Analysis. Journal of the American Heart Association, 2020, 9, e015177.	1.6	9
1554	Practice Guidelines for the Diagnosis and Management of Systolic Heart Failure in Low- and Middle-Income Countries. Global Heart, 2013, 8, 141.	0.9	4
1555	Sodiumâ€“glucose cotransporterÂ2 inhibitors represent a paradigm shift in the prevention of heart failure in typeÂ2 diabetes patients. Journal of Diabetes Investigation, 2021, 12, 6-20.	1.1	17
1556	Population Pharmacokinetics of Candesartan in Patients with Chronic Heart Failure. Clinical and Translational Science, 2021, 14, 194-203.	1.5	3
1557	Epidemiology of acutely decompensated systolic heart failure over the 2003â€“2013 decade in Douala General Hospital, Cameroon. ESC Heart Failure, 2021, 8, 481-488.	1.4	4
1558	Management of hyperkalemia during treatment with mineralocorticoid receptor blockers: findings from esaxerenone. Hypertension Research, 2021, 44, 371-385.	1.5	23
1559	Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling. ESC Heart Failure, 2021, 8, 129-138.	1.4	9
1560	Diagnosis, prevention, and treatment of cardiovascular diseases in people with type 2 diabetes and prediabetes: a consensus statement jointly from the Japanese Circulation Society and the Japan Diabetes Society. Diabetology International, 2021, 12, 1-51.	0.7	6
1561	Reorganization of heart failure management and improved outcome â€“ the 4D HF Project. Scandinavian Cardiovascular Journal, 2021, 55, 1-8.	0.4	6
1562	Using Tissue Doppler and Speckle Tracking Echocardiography to Assess if Ivabradine Improves Right Ventricular Function. Cureus, 2021, 13, e12920.	0.2	1
1564	Effects of angiotensin II receptor blockers on serum levels of epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids in patients admitted to a cardiovascular center. European Journal of Clinical Pharmacology, 2021, 77, 887-894.	0.8	0
1565	Clinical Characteristics of De Novo Heart Failure and Acute Decompensated Chronic Heart Failure: Are They Distinctive Phenotypes That Contribute to Different Outcomes?. Cardiac Failure Review, 2020, 7, e02.	1.2	11
1566	Patient factors associated with titration of medical therapy in patients with heart failure with reduced ejection fraction: data from the QUALIFY international registry. ESC Heart Failure, 2021, 8, 861-871.	1.4	20

#	Article	IF	Citations
1567	Association between antihypertensive treatment and adverse events: systematic review and meta-analysis. BMJ, The, 2021, 372, n189.	3.0	58
1568	The Role of the Renin-Angiotensin-Aldosterone System in Cardiovascular Disease: Pathogenetic Insights and Clinical Implications. , 0, , .		0
1569	Updates in pharmacotherapy of heart failure with reduced ejection fraction. Annals of Translational Medicine, 2021, 9, 516-516.	0.7	5
1570	Dynamic changes in cardiovascular and systemic parameters prior to sudden cardiac death in heart failure with reduced ejection fraction: a <scp>PARADIGMâ€HF</scp> analysis. European Journal of Heart Failure, 2021, 23, 1346-1356.	2.9	11
1571	Human cell receptors: potential drug targets to combat COVID-19. Amino Acids, 2021, 53, 813-842.	1.2	21
1573	Combining sodium-glucose cotransporter 2 inhibitors and angiotensin receptor-neprilysin inhibitors in heart failure patients with reduced ejection fraction and diabetes mellitus: A multi-institutional study. International Journal of Cardiology, 2021, 330, 91-97.	0.8	10
1574	Representation of Black patients in heart failure clinical trials. Current Opinion in Cardiology, 2021, 36, 329-334.	0.8	5
1575	Pharmacological Management of Heart Failure: A Century of Expert Opinions in Cecil Textbook of Medicine. American Journal of Therapeutics, 2021, 28, e292-e298.	0.5	4
1576	Optimizing sodium-glucose co-transporter 2 inhibitor use in patients with heart failure with reduced ejection fraction: A collaborative clinical practice statement. American Journal of Preventive Cardiology, 2021, 6, 100183.	1.3	4
1577	Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the <scp>VICTORIA</scp> (<scp>Vericiguat</scp> Global Study in) Tj ETQq1 1 0.784314 rgBT /Overlock	2.9	58
1578	Recent advances in pharmacological treatment of heart failure. European Journal of Clinical Investigation, 2021, 51, e13624.	1.7	19
1579	Prognostic relevance of elevated plasma osmolality on admission in acute decompensated heart failure with preserved ejection fraction: insights from PURSUIT-HFpEF registry. BMC Cardiovascular Disorders, 2021, 21, 281.	0.7	3
1580	Sodiumâ€“glucose coâ€transporter 2 inhibitors in heart failure with preserved ejection fraction: reasons for optimism. European Journal of Heart Failure, 2021, 23, 1250-1255.	2.9	17
1581	Myocardial Tissue Characterization in Heart Failure with Preserved Ejection Fraction: From Histopathology and Cardiac Magnetic Resonance Findings to Therapeutic Targets. International Journal of Molecular Sciences, 2021, 22, 7650.	1.8	17
1582	Efficiency Comparison of Analysis Methods for Recurrent Event and Time-to-First Event Endpoints in the Presence of Terminal Eventsâ€”Application to Clinical Trials in Chronic Heart Failure. Statistics in Biopharmaceutical Research, 2023, 15, 268-279.	0.6	9
1583	Empagliflozin Improves Cardiovascular and Renal Outcomes in HeartÂFailure Irrespective of Systolic Blood Pressure. Journal of the American College of Cardiology, 2021, 78, 1337-1348.	1.2	52
1584	Impact of renin-angiotensin-aldosterone system inhibition on morbidity and mortality during long-term continuous-flow left ventricular assist device support: An IMACS report. Journal of Heart and Lung Transplantation, 2021, 40, 1605-1613.	0.3	5
1586	Impact of insulin therapy on the mortality of acute heart failure patients with diabetes mellitus. Cardiovascular Diabetology, 2021, 20, 180.	2.7	13

#	Article	IF	Citations
1588	Days alive out of hospital in heart failure: Insights from the PARADIGM-HF and CHARM trials. American Heart Journal, 2021, 241, 108-119.	1.2	10
1589	Effects of Holding Beta-Blockers on the Vital Signs of Heart Failure Patients. Cardiology Research, 2021, 12, 2-9.	0.5	1
1590	Hypertension and Its Relation to Heart Failure With a Preserved Ejection Fraction. , 2021, , 258-267.		0
1591	Angioedema with sacubitril/valsartan: Trial-level meta-analysis of over 14,000 patients and real-world evidence to date. International Journal of Cardiology, 2021, 323, 188-191.	0.8	7
1592	Pharmacological Treatment for Chronic Heart Failure: A Specialist Nurse Perspective. , 0, , 163-183.		3
1593	Heart Disease in the Elderly. , 2013, , 669-686.		3
1594	Aging and Remodeling of the RAS and RAAS and Related Pathways: Implications for Heart Failure Therapy. , 2014, , 259-289.		6
1595	Heart Failure in the Older Hypertensive Patient. , 2005, , 197-228.		1
1596	Echocardiographic Assessment of Ventricular Systolic Function. , 2007, , 89-117.		5
1597	Renin-Angiotensin System. , 2009, , 121-147.		2
1598	Cardiovascular Risk Assessment and Summary of Guidelines for the Management of Hypertension. , 2011, , 97-113.		1
1600	AT1 Receptor Antagonists: Pharmacology. Handbook of Experimental Pharmacology, 2004, , 417-451.	0.9	3
1601	Consensus document: management of heart failure in type 2 diabetes mellitus. Heart Failure Reviews, 2021, 26, 1037-1062.	1.7	3
1602	Treatment of Hypertension in the Patient with Cardiovascular Disease * *Abbreviations: ACEI, angiotensin converting enzyme inhibitor; ACS, acute coronary syndromes; AF, atrial fibrillation; MI, myocardial infarction; ARB, angiotensin II type 1 receptor blocker; BB, beta-adrenergic receptor blocker; BP, blood pressure; CCB, calcium channel blocker; CVD, cardiovascular disease; CHD, coronary heart disease; DM, diabetes mellitus; DBP, diastolic blood pressure; ESRD, end-stage renal disease; HF, heart failure;. , 2007, , 625-646.		4
1603	Management of Heart Failure Patients with Reduced Ejection Fraction. , 2012, , 543-577.		12
1604	Pharmakologie des kardiovaskulÃren Systems - das Herz. , 2013, , 381-435.		1
1606	Antihypertensive drugs and the risk of cancer: a critical review of available evidence and perspective. Journal of Hypertension, 2020, 38, 1005-1015.	0.3	8
1607	Angiotensin Receptor Blockers: Role in Hypertension Management, Cardiovascular Risk Reduction, and Nephropathy. Southern Medical Journal, 2009, 102, S1-S12.	0.3	14

#	Article	IF	Citations
1608	Transcatheter Mitral Valve Repair in Patients with Heart Failure: A Meta-Analysis. Cardiology, 2021, 146, 42-48.	0.6	2
1609	The one-two punch: knocking out angiotensin II in the heart. Journal of Clinical Investigation, 2010, 120, 1028-1031.	3.9	8
1610	Prediction of sudden death in elderly patients with heart failure. Journal of Geriatric Cardiology, 2018, 15, 185-192.	0.2	11
1611	Diagnosis, Prevention, and Treatment of Cardiovascular Diseases in People With Type 2 Diabetes and Prediabetesâ€€â€• A Consensus Statement Jointly From the Japanese Circulation Society and the Japan Diabetes Society â€•. Circulation Journal, 2020, 85, 82-125.	0.7	16
1612	Standards of Medical Care in Diabetes 2014. Majmaah Journal of Health Sciences, 2014, 2, 64-64.	0.1	1
1613	Recent Patient Characteristics and Medications at Admission and Discharge in Hospitalized Patients With Heart Failure. Journal of Clinical Medicine Research, 2016, 8, 97-104.	0.6	3
1614	The Change in Body Weight During Hospitalization Predicts Mortality in Patients With Acute Decompensated Heart Failure. Journal of Clinical Medicine Research, 2017, 9, 200-206.	0.6	5
1615	The impact of heart rate on patients diagnosed with heart failure with mid-range ejection fraction. Anatolian Journal of Cardiology, 2018, 21, 68-74.	0.5	5
1616	Normal Reference Intervals for Cardiac Dimensions and Function for Use in Echocardiographic Practice: A Guideline from the British Society of Echocardiography. Echo Research and Practice, 2020, 7, G1-G18.	0.6	89
1617	Expert Comment: Is Medication Titration in Heart Failure too Complex?. Cardiac Failure Review, 2017, 03, 25.	1.2	25
1618	The Limitations of Symptom-based Heart Failure Management. Cardiac Failure Review, 2019, 5, 74-77.	1.2	10
1619	Use of Reninâ€“Angiotensinâ€“Aldosterone System Inhibitors in Older Patients with Heart Failure and Reduced Ejection Fraction. Cardiac Failure Review, 2019, 5, 70-73.	1.2	7
1620	Heart Failure With Mid-range or Recovered Ejection Fraction: Differential Determinants of Transition. Cardiac Failure Review, 2020, 6, e28.	1.2	7
1621	Recent Warnings about Antihypertensive Drugs and Cancer Risk: Where Do They Come From?. European Cardiology Review, 2020, 15, e21.	0.7	8
1622	2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology, 2020, 25, 4083.	0.4	229
1623	2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology, 2020, 25, 4083.	0.4	32
1625	I Diretriz Latino-Americana para o DiagnÃ³stico e Tratamento da Cardiopatia ChagÃ¡sica. Arquivos Brasileiros De Cardiologia, 2011, 97, 01-48.	0.3	70
1626	Combined RAAS and NEP Inhibition. International Cardiovascular Forum Journal, 0, 17, .	1.1	1

#	Article	IF	Citations
1628	Aliskiren for heart failure: a systematic review and meta-analysis of randomized controlled trials. Oncotarget, 2017, 8, 88189-88198.	0.8	5
1629	Neuromodulation Therapy in Heart Failure: Combined Use of Drugs and Devices. Journal of Innovations in Cardiac Rhythm Management, 2020, 11, 4151-4159.	0.2	6
1630	Candesartan in heart failure. Clinical Interventions in Aging, 2006, 1, 357-366.	1.3	14
1631	Valsartan in the treatment of heart attack survivors. Vascular Health and Risk Management, 2006, 2, 125-138.	1.0	25
1632	Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy. Vascular Health and Risk Management, 2008, 4, 223-234.	1.0	11
1633	Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction. Current Topics in Medicinal Chemistry, 2019, 19, 1818-1849.	1.0	22
1634	Contemporary Pharmacologic Management of Heart Failure with Reduced Ejection Fraction: A Review. Current Cardiology Reviews, 2020, 16, 55-64.	0.6	7
1635	A Practical Guide for the Treatment of Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF). Current Cardiology Reviews, 2014, 11, 23-32.	0.6	20
1636	Management of Cardiac Involvement in NeuroMuscular Diseases: Review. Open Cardiovascular Medicine Journal, 2008, 2, 93-96.	0.6	15
1637	Telmisartan lowers albuminuria in type 2 diabetic patients treated with angiotensin enzyme inhibitors. Advances in Medical Sciences, 2009, 54, 37-40.	0.9	6
1638	Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. Health Technology Assessment, 2009, 13, 1-207, iii.	1.3	365
1639	The Dilemma of Dual Renin-Angiotensin System Blockade in Chronic Kidney Disease: Why Beneficial in Animal Experiments But Not in the Clinic?. Physiological Research, 2017, 66, 181-192.	0.4	9
1640	Are patients in heart failure trials representative of primary care populations? A systematic review. BJGP Open, 2018, 2, bjgpopen18X101337.	0.9	6
1641	Advances in systolic heart failure. F1000 Medicine Reports, 2010, 2, .	2.9	3
1642	Angiotensin Receptor-Neprilysin Inhibition (ARNI) in Heart Failure. International Journal of Heart Failure, 2020, 2, 73.	0.9	15
1643	Fimasartan, an angiotensin II receptor antagonist, ameliorates an in vivo zebrafish model of heart failure. Korean Journal of Internal Medicine, 2020, 35, 1400-1410.	0.7	14
1644	Treatment of Heart Failure with Reduced Ejection Fraction: Current Update. Korean Journal of Medicine, 2015, 88, 127.	0.1	5
1645	Effect of telmisartan on vascular endothelium in hypertensive and type 2 diabetic hypertensive patients. Turkish Journal of Medical Sciences, 0, , .	0.4	4

#	Article	IF	Citations
1646	Recent Advances in Pharmacotherapy for Heart Failure: Future Directions. Trends in Medical Research, 2007, 2, 61-71.	0.2	7
1647	Angiotensin-receptor blockers in heart failure: evidence from the CHARM trial.. Cleveland Clinic Journal of Medicine, 2004, 71, 665-673.	0.6	8
1648	Heart failure in women is different than in men; should treatment be different?. Cleveland Clinic Journal of Medicine, 2007, 74, 423-424.	0.6	9
1649	The ABCs of managing systolic heart failure: Past, present, and future. Cleveland Clinic Journal of Medicine, 2016, 83, 753-765.	0.6	7
1650	Atrial Fibrillation in Heart Failure Patients with Preserved or Reduced Ejection Fraction. Prognostic significance of Rhythm control strategy with Catheter Ablation. Journal of Atrial Fibrillation, 2019, 11, 2128.	0.5	14
1651	The heart failure in Internal Medicine in Tuscany: the SMIT Study. Italian Journal of Medicine, 2015, 9, 349.	0.2	7
1652	Empagliflozin: Not just a glorified diuretic. Indian Journal of Endocrinology and Metabolism, 2016, 20, 154.	0.2	4
1653	The Renin-Angiotensin-Aldosterone System in Renal and Cardiovascular Disease and the Effects of its Pharmacological Blockade. Journal of Diabetes & Metabolism, 2012, 03, .	0.2	13
1654	Renal sympathetic denervation suppresses ventricular substrate remodelling in a canine high-rate pacing model. EuroIntervention, 2014, 10, 392-399.	1.4	23
1655	Overview of resistant hypertension: A glimpse of the cardiologistâ€™s current standpoint. World Journal of Cardiology, 2012, 4, 275.	0.5	3
1656	Update of treatment of heart failure with reduction of left ventricular ejection fraction. Archives of Medical Sciences Atherosclerotic Diseases, 2016, 1, 106-116.	0.5	8
1657	Emerging strategies to preserve renal function. Journal of Nephrology, 2011, 24, 133-141.	0.9	11
1659	Short-term add-on therapy with angiotensin receptor blocker for end-stage inotrope-dependent heart failure patients: B-type natriuretic peptide reduction in a randomized clinical trial. Clinics, 2014, 69, 308-313.	0.6	2
1660	2019 Focused Update of the Guidelines of the Taiwan Society of Cardiology for the Diagnosis and Treatment of Heart Failure. Acta Cardiologica Sinica, 2019, 35, 244-283.	0.1	50
1661	Critical Questions about PARADIGM-HF and the Future. Acta Cardiologica Sinica, 2016, 32, 387-96.	0.1	17
1662	Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Chronic Heart Failure. Annals of Internal Medicine, 2005, 142, 386.	2.0	6
1663	Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers for ischemic heart disease. Annals of Internal Medicine, 2009, 151, 861-71.	2.0	41
1664	Role of reninâ€“angiotensinâ€“aldosterone system inhibitors in heart failure and chronic kidney disease. Drugs in Context, 2020, 9, 1-9.	1.0	7

#	Article	IF	Citations
1665	Drug Layering in HeartÂFailure. JACC: Heart Failure, 2021, 9, 775-783.	1.9	32
1666	MedikamentÃ¶se Therapie der Herzinsuffizienz. Pharma-Kritik (discontinued), 2003, 25, .	0.0	1
1667	Inhibitors of the RAS: Evidence-Based Medicine. Handbook of Experimental Pharmacology, 2004, , 545-592.	0.9	0
1668	Drugs Blocking the Renin-Angiotensin-Aldosterone System. , 2004, , 227-241.		0
1669	Clinical Pharmacology of Angiotensin II Receptor Antagonists. Handbook of Experimental Pharmacology, 2004, , 453-484.	0.9	0
1670	Combined Blockade of the Renin Angiotensin System with ACE Inhibitors and AT1 Receptor Antagonists. Handbook of Experimental Pharmacology, 2004, , 485-516.	0.9	0
1671	Title is missing!. Japanese Journal of Clinical Pharmacology and Therapeutics, 2004, 35, 37-38.	0.1	0
1672	ACE-Hemmer und Angiotensinrezeptorantagonisten. , 2004, , 179-206.		0
1675	é«˜è¡€åœ§ç”ç©¶ãŒé€²æ©(å¾ªç'°å™¨å¦ 2003å¹´ãŒé€²æ©). Journal of JCS Cardiologists, 2004, 12, 113-117.	0.1	0
1676	Heart Failure. Critical Pathways in Cardiology, 2004, 3, 194-204.	0.2	12
1678	Inhibition of the Renin-Angiotensin-Aldosterone System. , 2005, , 195-212.		0
1679	Paralyzing the Renin-Angiotensin System to Retard the Progression of Diabetic Nephropathy: A bench-to-bedside review. Qatar Medical Journal, 2005, 2005, .	0.2	0
1683	Renin-angiotensin-aldosterone system (RAAS) blockade in peripheral arterial diseases. , 2005, , 65-74.		0
1685	Comparison of Antihypertensive Effects of an Angiotensin-Converting Enzyme Inhibitor, a Calcium Antagonist and a Diuretic in Patients With Hypertension Not Controlled by Angiotensin Receptor Blocker Monotherapy. Yearbook of Cardiology, 2006, 2006, 78-80.	0.0	0
1686	Vasodilators in the Management of Heart Failure. Fundamental and Clinical Cardiology, 2006, , 99-112.	0.0	0
1687	Prognosis Assessment and End of Life Issues. Fundamental and Clinical Cardiology, 2006, , 531-546.	0.0	0
1688	Angiotensin II antagonists in acute and post-acute myocardial infarction. , 2006, , 1-12.		0
1689	The antidiabetic effect of angiotensin II receptor antagonists. , 2006, , 85-98.		0

#	Article	IF	Citations
1690	Angiotensin receptor blockers for chronic heart failure. , 2006, , 127-171.		0
1691	Update in the Approach to and Management of Heart Failure. Southern Medical Journal, 2006, 99, 1346-1355.	0.3	6
1693	Heart Failure in Hypertension. , 2007, , 340-350.		0
1694	The Heart and the Kidney. , 2007, , 2819-2837.		0
1695	Strategies for Management of Decompensated Heart Failure. , 2007, , 385-409.		2
1696	Pharmacologic Management of Heart Failure in the Ambulatory Setting. , 2007, , 331-362.		0
1698	The Medical Management of Heart Failure. , 2007, , 1397-1416.		0
1701	Medicamenteuze behandeling van chronisch hartfalen. , 2007, , 123-137.		0
1702	ACE Inhibition in Heart Failure and Ischaemic Heart Disease. , 2007, , 21-54.		0
1703	Pharmacologic Treatment of Hypertension. , 2007, , 578-599.		0
1705	Clinical Evidence Review: Best Practice Heart Failure. , 2007, 11, 55-64.		2
1706	Diagnosis and Treatment of Congestive Heart Failure. , 2008, , 119-131.		0
1708	Traitement de l'insuffisance cardiaque. , 2008, , 101-125.		1
1709	Is the combination of enalapril and losartan irrational?. Indian Journal of Pharmacology, 2008, 40, 91.	0.4	0
1710	ACE-Hemmer und Angiotensinrezeptorantagonisten. , 2008, , 201-229.		0
1711	Systemic Hypertension in the Elderly. Fundamental and Clinical Cardiology, 2008, , 137-158.	0.0	0
1712	Diagnostic algorithm and therapeutic options in chronic heart failure: updated review of clinical practice guidelines. Polish Archives of Internal Medicine, 2008, 118, 489-500.	0.3	1
1713	Inhibitors of Angiotensin-Converting Enzyme, Angiotensin II Receptor, Aldosterone, and Renin. , 2009, , 112-159.		0

#	Article	IF	Citations
1714	Inhibiting the Renin Angiotensin Aldosterone System in Patients with Heart Failure and Myocardial Infarction. , 2009, , 93-102.		1
1716	Hemmstoffe des Renin-Angiotensin-Systems. , 2009, , 203-235.		0
1718	CMS and Type 2 Diabetes Mellitus: Bound Together by the Renin Angiotensin Aldosterone System. , 2009, , 187-206.		0
1719	Effect of renin-angiotensin system inhibitors in diabetic dialysis patients with chronic heart failure. Nihon Toseki Igakkai Zasshi, 2009, 42, 151-157.	0.2	0
1720	Heart failure guidelines in North America and Europe: agreement or disagreement?. European Journal of Heart Failure, Supplement, 2009, 8, i11-i14.	0.2	0
1721	Consider Â blockers for patients with heart failure. BMJ: British Medical Journal, 2009, 338, b1728-b1728.	2.4	2
1722	Perspectives of using angiotensin receptor antagonists. Systemic Hypertension, 2009, 6, 38-43.	0.1	0
1723	Modulating the levels of circulating BNP by therapeutic approaches for heart failure. Cor Et Vasa, 2009, 51, 419-424.	0.1	0
1724	Medical Therapy for Heart Failure. , 2010, , 29-68.		0
1725	Evidence based optimization of medical therapy in Chronic Heart Failure. University Heart Journal, 2009, 5, 32-35.	0.0	0
1731	Valsartan and Amlodipine: Safety and Efficacy in Stroke Prevention. Clinical Medicine Reviews in Vascular Health, 0, 2, 151-161.	3.0	0
1732	Congestive Heart Failure: Stable Chronic Heart Failure Patients. , 2010, , 187-205.		0
1733	Hemmstoffe des Renin-Angiotensin-Systems. , 2010, , 219-252.		0
1736	Advances in management. BMJ: British Medical Journal, 2010, 341, c4280-c4280.	2.4	3
1737	Risk Reduction in the Diabetic Patient. , 2011, , 281-315.		1
1738	Recurrent Stroke Prevention II: Angiotensin Receptor Blockersâ€"The LIFE, MOSES, PRoFESS, and Other Trials. , 2011, , 159-171.		0
1739	Medicamenteuze behandeling van chronisch hartfalen. , 2011, , 117-126.		0
1740	NHG-Standaard Hartfalen. , 2011, , 459-496.		4

#	Article	IF	Citations
1741	Aldosterone blockade. , 2011, , 253-257.		0
1742	Antagonism of the Renin-Angiotensin-Aldosterone System in Heart Failure. , 2011, , 659-673.		0
1744	Management of the postcoronary patient. , 2011, , 650-659.		0
1745	Hemmstoffe des Renin-Angiotensin-Systems. , 2011, , 225-260.		0
1746	ACE-inhibitors and angiotensin receptor blockers. , 2011, , 247-252.		0
1747	Cardiovascular Pharmacology. , 2011, , 235-295.		2
1748	Heart Failure as a Consequence of Congenital Heart Disease. , 2011, , 455-464.		0
1755	Hyperkalemia Risk and Treatment of Heart Failure. , 2012, , 81-99.		0
1756	Hyperkalemia Risk and Treatment of Heart Failure. , 2012, , 23-41.		0
1757	Changes in Kidney Function Following Heart Failure Treatment: Focus on Reninâ€“Angiotensin System Blockade. , 2012, , 11-22.		0
1759	Dual Blockade of the Reninâ€“Angiotensinâ€“Aldosterone System: Benefits Versus Adverse Outcomes. , 2012, , 453-465.		0
1760	Hemmstoffe des Renin-Angiotensin-Systems. , 2012, , 225-262.		0
1762	Changes in Kidney Function Following Heart Failure Treatment: Focus on Reninâ€“Angiotensin System Blockade. , 2012, , 39-50.		0
1763	Clinical Epidemiology: Principles Revisited in an Approach to Study Heart Failure. , 0, , .		0
1764	Pregnancy in a Patient With Cancer and Heart Failure: Challenges and Complexities. Journal of the Advanced Practitioner in Oncology, 2012, 3, 85-93.	0.2	1
1769	Management of arrhythmias in heart failure. What a practicing physician should know in the current times. Cardiology Journal, 2012, 19, 567-577.	0.5	1
1771	Specificity of the Cardiocerebral-Event Reductions in the Kyoto Heart and Jikei Heart Study. International Journal of Cardiovascular Research, 2013, 03, .	0.1	0
1772	Endogenous Cardiac Stem Cell Therapy for Ischemic Heart Failure. Journal of Clinical & Experimental Cardiology, 2013, 01, .	0.0	0

#	Article	IF	Citations
1774	Algorithm for Treatment of Advanced Heart Failure. , 2013, , 9-34.		0
1775	Hemmstoffe des Renin-Angiotensin-Systems. , 2013, , 217-256.		0
1777	Chronic and End-Stage Heart Failure. , 2014, , 255-270.		0
1779	Hemmstoffe des Renin- Angiotensin-Systems. , 2014, , 259-300.		0
1780	Pharmacological Treatment of Patients with Chronic Systolic Heart Failure. European Cardiology Review, 2014, 9, 43.	0.7	1
1781	What is the Logic behind Treating Some Heart Failure Patients without ACE Inhibitors and Beta-Blockers?. Journal of Pharmacogenomics & Pharmacoproteomics, 2014, 05, .	0.2	0
1782	Medical Management of Coronary Artery Disease. , 2014, , 1-17.		0
1783	The Recent Trends in the Use of Angiotensin II Receptor Blockers. Journal of the Nihon University Medical Association, 2014, 73, 8-11.	0.0	1
1787	End Stage Heart Failure: An Emerging Menace. Cardiovascular Journal, 2011, 1, 129-131.	0.0	0
1792	Medical Management of Coronary Artery Disease. , 2015, , 2369-2382.		0
1793	Medicatie bij hartfalen. , 2015, , 53-83.		0
1794	2015 Guidelines on Treatment of Hypertension in Patients With Coronary Artery Disease. Journal of Cardiology and Therapy, 2015, 2, 418-421.	0.1	0
1795	Hemmstoffe des Renin-Angiotensin-Systems. , 2015, , 267-309.		1
1796	Evolution of Heart Failure-related Hospital Admissions and Mortality Rates: a 12-Year Analysis. International Journal of Cardiovascular Sciences, 2015, 28, .	0.0	0
1797	Renin-angiotensin system blockade in the treatment of heart failure and the role of valsartan in this treatment. Anatolian Journal of Cardiology, 2015, 14, 1-8.	0.4	1
1798	1. Clinical Pharmacology in Heart Failure. Japanese Journal of Clinical Pharmacology and Therapeutics, 2015, 46, 83-88.	0.1	1
1799	The Prevalence of Extra-cranial Carotid Artery Disease in Chronic Heart Failure. Cardiology and Angiology, 2015, 3, 17-26.	0.0	1
1800	Heart Failure in South Asian Population. , 2015, , 305-317.		0

#	Article	IF	Citations
1801	ÐŸÐžÐIÐ'ÐÐ¯Ð›Ð¬ÐÐ¯Ð™ ÐÐÐ›IÐ— Ð—ÐÐ¡Ð¢ÐžÐ¡Ð£Ð'ÐÐÐ¯ ÐIÐ—ÐÐ¯Ð¥ Ð¡Ð¥ÐžÐ•Ðœ Ð›IÐšÐ£Ð'ÐÐÐ¯ Ð¥Ð'ÐžÐÐ¯Ð¥ IÐ— ÐŸÐžÐ		
1803	Renin angiotensin system blockers-associated angioedema in the Thai population: analysis from Thai National Pharmacovigilance Database. Asian Pacific Journal of Allergy and Immunology, 2015, 33, 227-35.	0.2	2
1804	Treatment of Hypertension in Patients with Polymorbidity: Sartans. LÃ¬ki UkraÃ¯ni, 2015, .	0.0	0
1805	New therapy approach in heart failure with preserved ejection fraction based on new pathophysiological concept. Srce I Krvni Sudovi, 2016, 35, 53-59.	0.1	0
1808	Congestive Heart Failure: Stable Chronic Heart Failure Patients. , 2017, , 207-226.		1
1809	Inhibition of the Renin-Angiotensin-Aldosterone System. , 2017, , 85-96.		0
1810	Mechanical Circulatory Support as a Bridge to Heart Transplantation. , 2017, , 639-663.		0
1812	Medical Treatment of Heart Failure with Reduced Ejection Fraction â€“ Prognostic Indication. International Cardiovascular Forum Journal, 0, 10, .	1.1	0
1813	CANDESARTAN IN CARDIOLOGY PRACTICE. Meditsinskiy Sovet, 2017, , 12-16.	0.1	0
1814	CANDESARTAN IN CARDIOLOGY PRACTICE. Meditsinskiy Sovet, 2017, , 12-16.	0.1	1
1816	Acute and Chronic Heart Failure. , 2018, , 237-252.		0
1817	Pharmacoeconomic analysis of the use of ramipril and candesartan in patients with arterial hypertension. ScienceRise: Pharmaceutical Science, 2018, .	0.1	0
1818	2018 KHRS Guidelines for Catheter Ablation of Ventricular Arrhythmias â€“ Part1. International Journal of Arrhythmia, 2018, 19, 36-62.	0.3	1
1819	Study of Effect of Methanolic Extract of Thevetia Peruviana Leaves on Doxorubicin Induced Cardio Toxicity in Wistar Rats. American Journal of PharmTech Research, 2018, 8, 88-98.	0.2	0
1820	Fixed combinations in modern hypertension treatment algorithms. Cardiovascular Therapy and Prevention (Russian Federation), 2018, 17, 86-94.	0.4	1
1821	Angiotensin Receptor Blockers as an Alternative to Angiotensin-Converting Enzyme Inhibitors in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention. Journal of Korean Medical Science, 2019, 34, e289.	1.1	7
1823	Analysis of lipid-lowering therapy in hypertensive patients. Hypertension, 2019, .	0.2	1
1824	The modern paradigm of pathophysiology, prevention and treatment of heart failure in type 2 diabetes mellitus. Russian Journal of Cardiology, 2019, , 98-111.	0.4	6

#	Article	IF	Citations
1825	Prevalence and prognostic value of monoclonal gammopathy in heart failure patients with preserved ejection fraction: A prospective study. Cardiology Journal, 2020, , .	0.5	1
1826	EURASIAN ASSOCIATION OF CARDIOLOGY (EAC)/ NATIONAL SOCIETY OF HEART FAILURE AND MYOCARDIAL DISEASE (NSHFMD) GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF CHRONIC HEART FAILURE (2020). Eurasian Heart Journal, 2020, , 6-76.	0.2	6
1827	Pharmacologic Support of theÂFailing Heart. , 2020, , 597-605.		0
1829	Literature Analysis on Clinical Efficacy of Huangkui Capsule in Treating Diabetic Nephropathy. Traditional Chinese Medicine, 2020, 09, 56-64.	0.1	1
1830	Recent Guideline for the Management of Hypertension in Patients with Diabetes. Journal of Korean Diabetes, 2020, 21, 27-35.	0.1	0
1831	Advanced Heart Failure Management and Selection for Advanced Therapies. Advances in Medical Technologies and Clinical Practice Book Series, 0, , 216-235.	0.3	0
1832	New Evidence about the Beneficial Effects of Angiotensin-Receptor Blockers on the Heart and the Kidney. , 2007, , 433-440.		0
1833	Regulationsmechanismen des Renin-Angiotensin-Systems im kardiovaskulÃren System. , 2006, , 377-407.		0
1837	Use of Angiotensin Receptor Blockers in the Elderly. , 2005, , 349-367.		1
1838	Combination Drug Therapy in the Elderly. , 2005, , 399-425.		0
1839	Treatment of Congestive Heart Failure. , 2005, , 371-390.		0
1840	Heart Disease in the Elderly. , 2005, , 705-727.		0
1841	Diabetic Renal and Related Heart Disease. , 2006, , 437-451.		0
1842	Heart Failure Controversies. , 2007, , 241-248.		0
1843	ACE Inhibitor Controversies. , 2007, , 63-66.		0
1845	Treatment of Diastolic Heart Failure. , 2008, , 223-239.		0
1849	Chronic and End-Stage Heart Failure. , 2021, , 517-533.		0
1850	Heart attack patients with complications. Treat with valsartan, captopril, or both?. Canadian Family Physician, 2004, 50, 1093-5.	0.1	0

#	Article	IF	Citations
1851	Valsartan in the treatment of heart failure or left ventricular dysfunction after myocardial infarction. Vascular Health and Risk Management, 2007, 3, 425-30.	1.0	18
1852	Cardiovascular high-risk patients--treat to protect, but whom?. Medscape Journal of Medicine, 2008, 10 Suppl, S2.	0.6	3
1853	No HOPE without proof: do ARBs meet the standard for cardiovascular protection?. Medscape Journal of Medicine, 2008, 10 Suppl, S6.	0.6	3
1854	Cardiac and vascular protection: the potential of ONTARGET. Medscape Journal of Medicine, 2008, 10 Suppl, S7.	0.6	1
1855	Clinical trial update: focus on the ONTARGET study. Vascular Health and Risk Management, 2007, 3, 901-8.	1.0	4
1856	Results of the ONTARGET and TRANSCEND studies: an update and discussion. Vascular Health and Risk Management, 2009, 5, 21-9.	1.0	17
1857	Apoptosis after reperfused myocardial infarction: Role of angiotensin II. Experimental and Clinical Cardiology, 2004, 9, 219-28.	1.3	4
1858	Comparison of once-daily versus twice-daily dosing of valsartan in patients with chronic stable heart failure. Vascular Health and Risk Management, 2010, 6, 449-55.	1.0	6
1859	Targeting success in heart failure: evidence-based management. Canadian Family Physician, 2010, 56, 1313-7.	0.1	2
1860	Congestive heart failure in Indians: how do we improve diagnosis & management?. Indian Journal of Medical Research, 2010, 132, 549-60.	0.4	8
1861	Use of Angiotensin receptor blockers in cardiovascular protection: current evidence and future directions. P and T, 2011, 36, 22-40.	1.0	39
1862	Clinical evidence review: best practice heart failure. , 2007, 11, 55-64.		0
1863	Heart failure with preserved ejection fraction. Journal of Geriatric Cardiology, 2013, 10, 369-76.	0.2	16
1864	Renin inhibitors in diabetes and hypertension: an update. EXCLI Journal, 2014, 13, 1111-9.	0.5	3
1865	Treatment Considerations for a Dual Epidemic of Atrial Fibrillation and Heart Failure. Journal of Atrial Fibrillation, 2013, 6, 740.	0.5	3
1866	Effect of angiotensin II type 1 receptor antagonist valsartan on cardiac remodeling and left ventricular function in patients with acute ST-elevation myocardial infarction. Journal of Medicine and Life, 2008, 1, 323-33.	0.4	3
1867	Heart Failure in Older Adults: A Geriatrician Call for Action. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2018, 35, S23-S29.	0.6	0
1868	Antisense oligonucleotides for the treatment of cardiomyopathy in Duchenne muscular dystrophy. American Journal of Translational Research (discontinued), 2019, 11, 1202-1218.	0.0	19

#	Article	IF	Citations
1869	Mechanism and prevention strategy of a bidirectional relationship between heart failure and cancer (Review). Experimental and Therapeutic Medicine, 2021, 22, 1463.	0.8	1
1870	Standards of Medical Care in Diabetesâ€“2006. Diabetes Care, 2006, 29, s4-s42.	4.3	702
1872	Hypertension and Diabetes. , 2022, , 263-291.		2
1874	Contemporary Drug Treatment of Advanced Heart Failure with Reduced Ejection Fraction. Drugs, 2022, 82, 375-405.	4.9	7
1875	Sacubitril/valsartan, sodiumâ€glucose cotransporter 2 inhibitors and vericiguat for congestive heart failure therapy. Basic and Clinical Pharmacology and Toxicology, 2022, 130, 425-438.	1.2	5
1876	The use of angiotensin II receptor blocker is associated with greater recovery of cardiac function than angiotensinâ€converting enzyme inhibitor in dilated cardiomyopathy. ESC Heart Failure, 2022, 9, 1175-1185.	1.4	4
1877	An updated systematic review on heart failure treatments for patients with renal impairment: the tide is not turning. Heart Failure Reviews, 2022, 27, 1761-1777.	1.7	3
1878	Clinical trials report. The sweet secret of dark chocolate. Current Hypertension Reports, 2004, 6, 45-6.	1.5	0
1879	Valsartan in acute myocardial infarction trial. Current Cardiology Reports, 2004, 6, 159-60.	1.3	2
1880	Diuretics should continue to be one of the preferred initial therapies in the management of hypertension: the argument for. Journal of Clinical Hypertension, 2005, 7, 111-6; quiz 121-2.	1.0	3
1881	Medical Management of Patients With Heart Failure and Reduced Ejection Fraction. Korean Circulation Journal, 2022, 52, 173.	0.7	9
1882	Capillaries as a Therapeutic Target for Heart Failure. Journal of Atherosclerosis and Thrombosis, 2022, 29, 971-988.	0.9	4
1883	Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease. Circulation, 2022, 145, 693-712.	1.6	57
1884	Association between dosing and combination use of medications and outcomes in heart failure with reduced ejection fraction: data from the <scp>S</scp>wedish Heart Failure Registry. European Journal of Heart Failure, 2022, 24, 871-884.	2.9	33
1885	Therapeutic targets for cardiac fibrosis: from old school to next-gen. Journal of Clinical Investigation, 2022, 132, .	3.9	53
1886	Diabetic Heart Failure with Preserved Left Ventricular Ejection Fraction: Review of Current Pharmacotherapy. Journal of Diabetes Research, 2022, 2022, 1-10.	1.0	1
1887	Optimal effectiveness of heart failure management â€" an umbrella review of meta-analyses examining the effectiveness of interventions to reduce (re)hospitalizations in heart failure. Heart Failure Reviews, 2022, 27, 1683-1748.	1.7	8
1888	Angiotensin Converting Enzyme Inhibitors versus Receptor Blockers in Patients with Ventricular Tachyarrhythmias. Journal of Clinical Medicine, 2022, 11, 1460.	1.0	1

#	Article	IF	Citations
1889	Pharmacological treatment options for heart failure with reduced ejection fraction: A 2022 update. Expert Opinion on Pharmacotherapy, 2022, 23, 673-680.	0.9	3
1890	Global disparities in prescription of guideline-recommended drugs for heart failure with reduced ejection fraction. European Heart Journal, 2022, 43, 2224-2234.	1.0	22
1891	Re-print: Ranolazine may be the Best and Safest Pharmacologic Therapy for Congestive Heart Failure, and Safe, Effective for Ventricular and Atrial Arrhythmias. Clinical Cardiology and Cardiovascular Interventions, 2020, 3, 01-13.	0.1	0
1892	Treatment of Heart Failure with reduced Ejection Fraction in 2022: The Essential Pillars. , 2022, 2, 15-23.		0
1893	State of the Art Treatment for Chronic Heart Failure. , 0, , 27-44.		0
1895	Standard Medical Therapy of Heart Failure. , 0, , 21-43.		0
1899	Dual RAAS Blockade in CKD: Does the Hype have Teeth?. Kidney360, 0, , 10.34067/KID.0000912022.	0.9	1
1900	20 Years of Real-World Data to Estimate the Prevalence of Heart Failure and Its Subtypes in an Unselected Population of Integrated Care Units. Journal of Cardiovascular Development and Disease, 2022, 9, 149.	0.8	7
1901	Inhibitors of the renin-angiotensin-aldosterone system. , 2013, , 119-168.		8
1902	Which therapy for which condition?. , 2013, , 463-541.		1
1905	Pharmacogenomic study of heart failure and candesartan response from the CHARM programme. ESC Heart Failure, 2022, 9, 2997-3008.	1.4	3
1906	Hyperkalaemia in Heart Failure: Consequences for Outcome and Sequencing of Therapy. Current Heart Failure Reports, 2022, 19, 191-199.	1.3	2
1907	Polypharmacy in Older Heart Failure Patients: a Multidisciplinary Approach. Current Heart Failure Reports, 2022, 19, 290-302.	1.3	11
1908	Insights into foundational therapies for heart failure with reduced ejection fraction. Clinical Cardiology, 2022, 45, .	0.7	7
1909	Cardiovascular Research in FriedreichÂAtaxia. JACC Basic To Translational Science, 2022, 7, 1267-1283.	1.9	11
1912	Use of guidelineâ€recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence and persistence. European Journal of Heart Failure, 2022, 24, 2185-2195.	2.9	23
1913	Functional and Metabolic Imaging in Heart Failure with Preserved Ejection Fraction: Promises, Challenges, and Clinical Utility. Cardiovascular Drugs and Therapy, 2023, 37, 379-399.	1.3	2
1914	Role of sex on the efficacy of pharmacological and non-pharmacological treatment of heart failure with reduced ejection fraction: A systematic review. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	2

#	Article	IF	Citations
1915	Retrospective Evaluation of In-Hospital and Thirty-Month Mortality Parameters in Cases of Acute Coronary Syndrome. , 0, , .		0
1916	Management of heart failure with reduced ejection fraction. Heart, 0, , heartjnl-2020-318811.	1.2	4
1917	Polypharmacy among older individuals with heart failure: trends between 2000 and 2017 in the province of Quebec, Canada. Therapeutic Advances in Cardiovascular Disease, 2022, 16, 175394472211139.	1.0	3
1918	Edema formation in congestive heart failure and the underlying mechanisms. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	11
1919	Death without Previous Hospital Readmission in Patients with Heart Failure with Reduced Ejection Fractionâ€"A New Endpoint from Old Clinical Trials. Journal of Clinical Medicine, 2022, 11, 5518.	1.0	0
1920	Hyperkalaemia as a cause of undertreatment with mineralocorticoid receptor antagonists in heart failure. ESC Heart Failure, 2023, 10, 66-79.	1.4	6
1921	Impact of Socioeconomic Status on Mortality and Readmission in Patients With Heart Failure With Reduced Ejection Fraction: The ARIC Study. Journal of the American Heart Association, 2022, 11, .	1.6	10
1922	Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure. JAMA Cardiology, 2022, 7, 1148.	3.0	15
1923	Reviewing the Modern Therapeutical Options and the Outcomes of Sacubitril/Valsartan in Heart Failure. International Journal of Molecular Sciences, 2022, 23, 11336.	1.8	3
1924	Targets and management of hypertension in heart failure: focusing on the stages of heart failure. Journal of Clinical Hypertension, 2022, 24, 1218-1225.	1.0	1
1926	Optimization of Drug Therapy for Heart Failure With Reduced Ejection Fraction Based on Gender. Current Heart Failure Reports, 2022, 19, 467-475.	1.3	2
1927	Heart Failure and Diabetes Mellitus: Dangerous Liaisons. International Journal of Heart Failure, 2022, 4, 163.	0.9	7
1928	ÕŠÕ¡Õ°ÕºÕ¡Õ¶Õ¾Õ¡Õ®, Õ´Õ«Õ»Õ«Õ¶ Ö‡ Õ«Õ»Õ¡Õ® Õ¡Ö€Õ¿Õ¡Õ´Õ²Õ´Õ¡Õ¶ Ö†Ö€Õ¡Õ¯ÖÕ«Õ¡ÕµÕ¸Õ¾ Ö„Ö€Õ¸Õ¶Õ«Õ¯Õ¡Õ¯Õ¡Õ		
1930	Meta-Analysis on Drug and Device Therapy of New York Heart Association Functional Class IV Heart Failure With Reduced Ejection Fraction. American Journal of Cardiology, 2023, 188, 52-60.	0.7	1
1931	Exploring the cardiac ECM during fibrosis: A new era with next-gen proteomics. Frontiers in Molecular Biosciences, 0, 9, .	1.6	8
1932	Mechanisms of current therapeutic strategies for heart failure: more questions than answers?. Cardiovascular Research, 2023, 118, 3467-3481.	1.8	4
1933	Incident stroke events in clinical trials of antihypertensive drugs in cardiovascular disease patients: A network meta-analysis of randomized controlled trials. Current Problems in Cardiology, 2022, , 101551.	1.1	1
1934	Reflecting on the advancements of HFrEF therapies over the last two decades and predicting what is yet to come. European Heart Journal Supplements, 2022, 24, L2-L9.	0.0	0

#	Article	IF	Citations
1935	The four pillars of HFrEF therapy: is it time to treat heart failure regardless of ejection fraction?. European Heart Journal Supplements, 2022, 24, L10-L19.	0.0	6
1936	Reninâ€“Angiotensinâ€“Aldosterone System as an Old New Target in Heart Failure Therapy. , 2023, , 307-330.		1
1937	Evaluation and Management of Patients with Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement. Diabetes and Metabolism Journal, 2023, 47, 10-26.	1.8	4
1938	Evaluation and Management of Patients With Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement. International Journal of Heart Failure, 2023, 5, 1.	0.9	2
1939	Longâ€term mortality and cardiovascular events of seven angiotensin receptor blockers in hypertensive patients: Analysis of a national realâ€world database: A retrospective cohort study. Health Science Reports, 2023, 6, .	0.6	2
1940	Heart failure and diabetes: Clinical significance and epidemiology of this twoâ€way association. Diabetes, Obesity and Metabolism, 2023, 25, 3-14.	2.2	4
1941	Plasma renin activity variation following admission predicts patient outcome in acute decompensated heart failure with reduced and mildly reduced ejection fraction. Heliyon, 2023, 9, e13181.	1.4	0
1942	The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure. ESC Heart Failure, 2023, 10, 1314-1325.	1.4	3
1943	Comparison of Investigator-Reported and Centrally Adjudicated HeartÂFailureÂOutcomes in the EMPEROR-Reduced Trial. JACC: Heart Failure, 2023, 11, 407-417.	1.9	3
1944	The interaction between physical frailty and prognostic impact of heart failure medication in elderly patients. ESC Heart Failure, 2023, 10, 1698-1705.	1.4	4
1945	Randomised controlled trials of antihypertensive therapy: does exclusion of orthostatic hypotension alter treatment effect? A systematic review and meta-analysis. Age and Ageing, 2023, 52, .	0.7	1
1946	Practical Pharmacological Treatment of Heart Failure: Does Ejection Fraction Matter Anymore?. Journal of Cardiovascular Development and Disease, 2023, 10, 114.	0.8	0
1947	Heart failure with reduced ejection fraction and atrial fibrillation: a Subâ€Saharan African perspective. ESC Heart Failure, 2023, 10, 1580-1596.	1.4	3
1948	The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure Management: The Continuing Challenge of Clinical Outcome Endpoints in Heart Failure Trials. Pharmaceutics, 2023, 15, 1092.	2.0	1
1949	Renin-Angiotensin Inhibition and Outcomes in HFrEF and Advanced Kidney Disease. American Journal of Medicine, 2023, 136, 677-686.	0.6	2
1950	Hallmarks of cardiovascular ageing. Nature Reviews Cardiology, 2023, 20, 754-777.	6.1	28
1955	Diagnosis and Management of Heart FailureÂin Children. , 2023, , 1-39.		0
1977	Reversibility of Cardiac Remodeling in Hypertensive Patients with Heart Failure. Updates in Hypertension and Cardiovascular Protection, 2023, , 357-370.	0.1	0

#	Article	IF	Citations